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Abstract 
Polymeric nanogels - also referred to as hydrogel nanoparticles, macromolecular 
micelles or polymeric nanoparticles - are emerging as promising drug carriers for 
therapeutic applications. These nanostructures hold versatility and properties suitable for 
the delivery of bioactive molecules, namely biopharmaceuticals. The polymer and the 
production methodology used are fundamental options. These systems may be obtained 
by incorporation of targeting moieties, detectable probes and/or degradable bonds 
allowing a controlled release in the physiologic environment which lead to smart systems 
reactive to physiologic stimuli, etc. A particular challenge in this field is the development 
of preparation procedures avoiding the use of organic solvents or surfactants. 
Dextrin is a very promising biomaterial, available in medical grade and accepted by the 
United States Food and Drug Administration for application in humans. It is a polymer 
composed of α-(1-4) D-glucose units. In this work, dextrin was modified with long alkyl 
chains to produce an amphiphilic molecule. Dextrin-VA-SC16 (dexC16) has a hydrophilic 
dextrin backbone with grafted acrylate groups (VA), substituted with hydrophobic 1-
hexadecanethiol (SC16). A versatile synthetic method was developed allowing control of 
the dextrin degree of substitution with the hydrophobic chains. Upon dispersion in water, 
dexC16 self-assembles through association of the hydrophobic alkyl chains, originating 
nanoparticles. The hydrophobic chains, randomly distributed along the polymer 
backbone, promote the formation of hydrophobic domains within the nanoparticles. 
Colloidally stable nanoparticles were obtained. An average diameter of about 20 nm was 
determined by dynamic light scattering, atomic force microscopy and transmission 
electron microscopy. The critical micelle concentration, around 0.001 g/dL, was 
determined using pyrene as a fluorescent probe, and confirmed by dynamic light 
scattering. The influence of the degree of substitution on nanoparticles size, colloidal 
stability, density, aggregation number and nanoparticle weight was studied. The more 
substituted polymer forms more densely packed hydrophobic domains, such that the 
colloidal stability (in water or phosphate buffered saline solution) of nanoparticles is 
increased. Size distribution was also evaluated at different pH, urea concentration and 
ionic strength conditions. The nanoparticles have a slightly higher size when prepared in 
buffer (irrespective of the pH) or in the presence of a salt or urea (irrespective of the 
concentration). 
The uptake of nanoparticles by cells of the mononuclear phagocytic system limits its 
use as colloidal drug carriers, reducing the blood circulation time and the ability to reach 
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biological targets. The interaction between dextrin nanoparticles and murine bone 
marrow-derived macrophages was evaluated in vitro by confocal laser scanning 
microscopy and fluorescence activated cell sorting. Fluorescein-labelled nanoparticles 
were used to assess the phagocytic uptake and blood clearance after intravenous 
injection. Cytotoxicity and nitric oxide production were studied, using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay and the Griess 
method, respectively. The results show that the nanoparticles are not cytotoxic and do 
not stimulate the production of nitric oxide by macrophages, in the range of 
concentrations studied. Nanoparticles are phagocytosed by macrophages and are 
detected inside the cells, concentrated in cellular organelles. The blood clearance study 
showed that the blood removal of the nanoparticles occurs with a more pronounced rate 
in the first 3 h after administration, about 30% of the material remaining in systemic 
circulation at this stage. The tissue distribution, after intravenous injection in Wistar rats, 
was evaluated using functionalized nanoparticles with a 1,4,7,10-
tetraazacyclododecanetetraacetic acid (DOTA) metal chelator and subsequently labelled 
with the γ-emitting 153Sm3+ radioisotope. The blood clearance rate and organ 
biodistribution of radioactively labelled nanoparticles was analysed, using materials both 
with and without poly(ethylene glycol) surface coating. The dexC16 nanoparticles display a 
characteristic biodistribution profile, being mainly taken up by the organs of the 
mononuclear phagocyte system - liver and spleen. The blood circulation time extends to 
several hours – as observed using the fluorescein-labelled nanoparticles, although the 
concentration is halved in about 1 hour. The functionalization of the nanoparticles with 
PEG 5,000 in this formulation improves their circulation time in the bloodstream and 
reduces the accumulation in the liver and spleen. 
In order to explore the ability of dextrin nanoparticles as a drug carrier, curcumin was 
used as a model hydrophobic drug. Curcumin is a natural polyphenol with anti-oxidative, 
anti-inflammatory and anti-cancer properties. However, its therapeutical potential is 
substantially hindered by the rather low water solubility and bioavailability. Dextrin 
nanoparticles were tested as a curcumin carrier, allowing its dispersion in water, 
improving stability, and controlling release profile. Incorporation of curcumin into 
nanoparticles did not compromise its cytotoxicity in HeLa cell line.  
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Resumo 
Nanogéis poliméricos - também designados hidrogéis nanoparticulados, micelas 
macromoleculares ou nanopartículas poliméricas - têm-se revelado transportadores 
promissores de fármacos para aplicações terapêuticas. Estas nano-estruturas possuem 
versatilidade e propriedades adequadas para a libertação de moléculas bioactivas, 
nomeadamente biofármacos. A escolha do polímero e da metodologia de obtenção das 
nanopartículas é fundamental. Estes sistemas podem incorporar sondas para o seu 
direccionamento ou detecção e/ou ligações lábeis em ambiente fisiológico 
proporcionando uma degradação controlada constituindo assim sistemas inteligentes 
reactivos a estímulos fisiológicos. Um dos principais desafios neste campo é o 
desenvolvimento de procedimentos de preparação que não recorram a solventes 
orgânicos ou surfactantes. 
O dextrino é um biomaterial, disponível em grau médico e autorizado pela United 
States Food and Drug Administration para aplicações em humanos. Trata-se de um 
polímero composto por unidades de glucose ligadas por ligações α-(1-4). Neste trabalho, 
o dextrino foi modificado com cadeias alquílicas longas obtendo-se assim uma molécula 
anfifílica. O dextrino-VA-SC16 (dexC16) tem uma cadeia hidrofílica de dextrino com grupos 
acrilato enxertados (VA), por sua vez substituídos com a molécula hidrofóbica 1-
hexadecanetiol (SC16). Foi desenvolvido um método de síntese versátil que permite o 
controlo do grau de substituição do dextrino com cadeias hidrofóbicas. Ao ser disperso 
em água, o dexC16 auto-organiza-se através da associação das cadeias alquílicas 
hidrofóbicas, originando nanopartículas. As cadeias hidrofóbicas, aleatoriamente 
distribuídas na cadeia polimérica, promovem a formação de domínios hidrofóbicos no 
interior das nanopartículas. Foram assim obtidas nanopartículas coloidalmente estáveis, 
com um diâmetro médio aproximado de 20 nm, confirmado por difracção dinâmica da luz 
e miscroscopia de força atómica e de transmissão de electrões. A concentração micelar 
crítica, igual a aproximadamente 0.001 g/dL, foi determinada usando pireno como sonda 
fluorescente e foi confirmada por difracção dinâmica da luz. Foi caracterizada a 
influência do grau de substituição no tamanho das nanopartículas, na estabilidade 
colloidal, densidade, número de agregação e peso das nanopartículas. O polímero com 
maior grau de substituição origina domínios hidrofóbicos mais densos, aumentando a 
estabilidade coloidal (em água ou solução PBS) das nanopartículas. A distribuição de 
tamanhos das nanopartículas foi também avaliada em diferentes condições de pH, 
concentração de ureia e força iónica. As nanopartículas apresentam um ligeiro aumento 
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de tamanho quando preparadas em tampão (independentemente do pH) ou na presença 
de sal ou ureia (independentemente da concentração). 
A internalização das nanopartículas pelas células do sistema mononuclear fagocitário 
limita o seu uso como transportador coloidal de fármacos, uma vez que reduz o tempo 
de circulação no sangue e a possibilidade de atingirem os alvos biológicos. A interacção 
entre as nanopartículas de dextrino e macrófagos extraídos da medula óssea de ratinho 
foi avaliada in vitro por microscopia confocal e por citometria de fluxo. Nanopartículas 
marcadas com fluoresceína foram usadas para avaliar a internalização por fagocitose e a 
eliminação do sangue após injecção intravenosa. A citotoxicidade e a produção de óxido 
nitrico foram estudadas, usando o ensaio de MTT e o método de Griess, 
respectivamente. Os resultados mostram que as nanopartículas não são citotóxicas e 
não estimulam a produção de óxido nitrico pelos macrófagos, na gama de concentrações 
estudada. As nanopartículas são fagocitadas pelos macrófagos e foram detectadas no 
interior das células, concentradas em organelos celulares. O estudo da eliminação das 
nanopartículas do sangue mostrou que a sua remoção da corrente sanguinea ocorre de 
forma mais pronunciada nas 3 horas que seguem a administração, após o que cerca de 
30% do material permanece em circulação. A distribuição nos tecidos, após injecção 
intravenosa em ratos Wistar, foi avaliada usando nanopartículas funcionalizadas com um 
agente complexante do tipo DOTA e posteriormente marcadas com o radioisótopo γ-
emissor 153Sm3+. A eliminação do sangue e a biodistribuição das nanopartículas 
marcadas radioactivamente foi analisada usando materiais cobertos e não-cobertos com 
polietilenoglicol. As nanopartículas de dexC16 apresentam um perfil de biodistribuição 
característico sendo principalmente internalizadas pelos órgãos do sistema mononuclear 
fagocitário – fígado e baço. O tempo de circulação no sangue extende-se até algumas 
horas, apesar de a concentração ser reduzida para metade em cerca de 1 hora. A 
funcionalização das nanopartículas com polietilenoglicol 5000 aumenta o tempo de 
circulação no sangue e reduz a acumulação no fígado e no baço.  
Com o objectivo de explorar o potencial das nanopartículas de dextrino como 
transportador de fármacos, a curcumina foi usada como um fármaco hidrofóbico modelo. 
A curcumina é um polifenol natural com propriedades anti-oxidativas, anti-inflamatórias e 
anti-cancerígenas. No entanto, o seu potencial terapêutico é comprometido pela reduzida 
solubilidade em água e biodisponibilidade. As nanopartículas de dextrino foram testadas 
como transportadores de curcumina permitindo a sua dispersão em água, melhoria da 
estabilidade e controlo do perfil de libertação. A incorporação da curcumina nas 
nanopartículas não comprometeu a sua citotoxicidade na linha celular HeLa. 
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Motivation and Main Goals 
The development of biomaterials using natural polymers is an important and 
promissing field of research. The new technologies of tissue engineering, controlled drug 
delivery and regenerative medicine draw the need for new biomaterials - biocompatible, 
processable and degradable. Dextrin, a glucose polymer – unexpensive, available in 
medical grade and in large amounts - has been basically ignored as an option for these 
applications. However, its properties make it, in our view, a serious candidate for the 
production of biomaterials. As compared to starch, dextrin is much more soluble. Having 
a very low molecular weight, it may be easily excreted – it is also degradable in vivo – 
therefore it will not accumulate in the tissues, having excellent resorbability/excretability. 
The good solubility improves its potencial for modification, exploiting the reactivity of the 
hydroxyl groups.  
In this work, the production of nanogels made of dextrin was successfully exploited. 
The chemical reactivity of dextrin was further improved through grafting of acrylic groups. 
Other parallel ongoing projects include the development of dextrin injectable hydrogels. 
Thus, different applications of dextrin in the biomedical field are being exploited. Self-
assembled nanogels are promissing nanobiotechnological tools with potencial application 
in the drug delivery and diagnostics.  Exploiting the natural ability of biomolecules to self-
organize is a biomimetic approach being developed in several laboratories world wide. 
Much remains to be done in this field. This work attempts to develop new self-assembled 
nanogels, and the characterization of its properties, namely regarding the interaction with 
biological systems (cells and organisms) and unveiling aspects of the structural 
organization of these materials. 
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1. General Introduction: Self-assembled 
hydrogel nanoparticles for drug delivery 
applications 
 
Adapted from Materials (2010) 3, 1420-1460 
anotechnology is the source of exciting progresses in the drug delivery 
field, offering suitable means for site-specific and time-controlled delivery 
of small molecular weight drugs, proteins, peptides, oligosaccharides, vaccines and 
nucleic acids (Dubernet, et al., 2002, Jain, et al., 2009, Moghimi, et al., 2001, Panyam, et 
al., 2003a, Sun, et al., 2008). Overall, drug delivery is the method of administering a 
bioactive compound to achieve a therapeutic effect, in humans or animals. Drug delivery 
systems are formulations that modify the drug release profile and the ability to cross 
biological barriers, the biodistribution and pharmacokinetics, improving its efficacy and 
safety, as well as the patient compliance. Nanoformulations for drug delivery include 
numerous architectural designs in terms of size, shape, and materials. Several types of 
nanoparticles have been tested as potential drug delivery systems, including hydrogel 
nanoparticles (also known as polymeric nanogels or macromolecular micelles), 
dendrimers (Nanjwade, et al., 2009), nanospheres (Arias, et al., 2007), nanocapsules and 
liposomes (Iinuma, et al., 2002). Each kind of formulation has characteristic drug loading 
capacity, particle and drug stability, drug release rates, and targeting ability. This review 
highlights the use of self-assembled hydrogel nanoparticles for drug delivery applications. 
Hydrogels are polymeric networks with three-dimensional configuration that absorb large 
quantities of water or biological fluids. Their water affinity is attributed to the presence of 
hydrophilic groups - such as ether, amine, hydroxyl, sulfate and carboxyl - in the polymer 
chains. Hydrogels can be formulated as macroscopic networks, or confined to smaller 
dimensions. When their size is in the submicron range, they are known as nanogels 
N 
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(Vinogradov, et al., 2004). Nanogels, or hydrogel nanoparticles, have gained 
considerable attention as one of the most promising nanoparticulate drug delivery 
systems, owing to their unique properties that combine the characteristics of hydrogel 
systems (e.g., rather high water content) with a very small size (nanosize). Hydrogel 
nanoparticles are outstanding drug delivery systems: 
1. The particle size and surface properties can be manipulated to avoid rapid 
clearance by phagocytic cells, allowing both passive and active drug targeting; 
2. Controlled and sustained drug release at the target site, improving the therapeutic 
efficacy and reducing side effects. Drug loading is relatively high and may be achieved 
without chemical reactions; this is an important factor for preserving the drug activity; 
3. Ability to reach the smallest capillary vessels, due to their tiny volume, and to 
penetrate the tissues either through the paracellular or the transcellular pathways; 
4. Potential for administration through various routes, including oral, pulmonary, nasal, 
parenteral, intra-ocular etc. 
Self-assembled hydrogel nanoparticles in this context refer to nanogels formed from 
amphiphilic or polyionic polymers. The main properties of nanoparticles, the method and 
materials for their production, and the main applications will be reviewed. 
 
 
1.1 Materials, properties, methods 
1.1.1 Materials 
A wide range of materials may be used for nanogels preparation. Biodegradability is 
essential to avoid organ accumulation, potentially leading to toxicity and other 
undesirable side effects (Peracchia, et al., 1999, Plard, et al., 1999). Hydrogel 
nanoparticles are made either from natural or synthetic polymers. The former possess a 
high variety of functional groups, which allow chemical and biochemical modification, 
resulting in many kinds of biopolymer-based materials. Among these, polysaccharides 
are the more often used. Polysaccharides are naturally occurring carbohydrate-based 
polymers, formed of repeating units (monosaccharides) joined together by glycosidic 
bonds. They may be obtained from algal (alginate), plant (cellulose, starch) and animal 
(chitosan) sources, exhibit quite variable structures and properties, different reactive 
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groups, a wide range of molecular weights and variable chemical composition. 
Polysaccharides can be divided into non-polyelectrolytes (dextran, dextrin, pullulan) and 
polyelectrolyte. Polyelectrolyte polysaccharides may be further divided into positively 
(chitosan) and negatively (heparin, hyaluronic acid) charged. Polysaccharides are highly 
stable, safe, non-toxic, hydrophilic and biodegradable. They are, in addition, abundant 
natural resources and may be processed at low cost.  
Among the more often used synthetic polymers, block copolymers consist of two or 
more segments of simple polymers (blocks) joined in some arrangement. Block 
copolymers are further classified by the number of blocks each molecule contains: two, 
three, or more blocks correspond to diblocks, triblocks, or multiblocks, respectively. 
Biodegradable and biocompatible poly(D,L lactic acid) (PLA), poly(glycolic acid) (PGA) 
and their copolymer poly(D,L-lactic-co-glycolic acid) (PLGA) have been extensively used 
in controlled drug delivery and have been approved by the United States Food and Drug 
Administration (Hans, et al., 2002). 
1.1.2 Properties 
The ability of nanodelivery systems to overcome physiological barriers is determined 
by properties such as particle size, surface charge and hydrophobicity. Physiological 
barriers are biological structures or physiologic mechanisms that hinder nanoparticles 
from reaching their targets, therefore compromising the therapeutic efficacy. 
Nanoparticulate systems able to overcome these biological barriers should be capable of: 
efficient extravazation through the vasculature, prolonged vascular circulation time, 
improved cellular uptake and endosomal escape. 
The endothelial wall in the vasculature presents reduced permeability and constitutes 
the primary barrier for nanoparticles. The nanosize may facilitate the penetration of 
nanoparticles across the endothelium. It is well known that extravazation of nanoparticles 
into the brain, across the blood-brain barrier, represents a particular difficult challenge for 
nanomedicine. Small drugs may diffuse through the capillary walls into the tissues. 
Otherwise, nanoparticles transport occurs through compromised endothelial barrier or 
mediated by specific transport systems. Tumor tissues have an increased capillary 
permeability, which allows a high rate of nanoparticles accumulation, based on the 
“enhanced permeability and retention” (EPR) effect (Matsumura, et al., 1986). 
Nanoparticles circulating in the bloodstream are normally able to penetrate the tissues 
through a paracellular path only at restricted sites, where the capillaries have open 
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fenestrations, as in the sinus endothelium of the liver, in the tumor neovasculature 
(Brannon-Peppas, et al., 2004) or when the endothelial barrier is altered by inflammatory 
processes (e.g., rheumatoid arthritis, infections) (Moghimi, et al., 2005).  
Surface charge is important as it determines the stability of nanoparticles, hence its 
propensity to aggregate in the bloodstream or interact with the cell membranes. The zeta 
potential is commonly used to characterize and measure the surface charge: the larger 
the absolute value of the zeta potential, the larger the charge on the surface. In a sense, 
the zeta potential represents an index for particle stability. For charged particles, as the 
zeta potential increases the repulsive interactions becomes larger, leading to stable 
particles, likely to have a more uniform size distribution. A nanosuspension stabilized by 
electrostatic repulsion must have a minimum zeta potential of ±30 mV (Muller, et al., 
2001). This stability is important in preventing aggregation (Hornig, et al., 2009). When a 
surface modifier like PEG is added, the negative zeta potential is lowered, although 
increasing the nanoparticles stability due to steric effects and hydration forces (Vila, et al., 
2002).  
Long circulation time increases the odds for the nanoparticles to reach their target. 
The Mononuclear Phagocyte System (MPS) efficiently eliminates nanoparticles from the 
bloodstream, unless they are modeled to escape recognition. Opsonization is the process 
whereby a foreign organism or particle becomes covered with opsonins, thereby making 
it “visible” to phagocytic cells. This process typically occurs in the bloodstream and can 
take anywhere from a matter of seconds to many days to complete. Binding of opsonins 
onto the nanoparticle surface acts as a bridge between nanoparticles and phagocytes. 
Minimizing protein binding is the key point for developing long circulating time 
formulations. Together, these two processes – opsonization and phagocytosis - constitute 
the main blood clearance mechanism for particles larger than the renal threshold limit. 
There are no absolute rules or methods available to completely block opsonization, but 
research over the last 30 years yielded useful trends and methods to increase the blood 
circulation half-life and the effectiveness of “stealth” devices. For instance, it is well 
established that hydrophilic polymers provide steric stabilization and confers “stealth” 
invisibility for the body´s natural defense system (Storm, et al., 1995). As a general rule, 
the opsonization of hydrophobic particles, as compared to hydrophilic ones, has been 
shown to occur quicker, due the enhanced adsorption of blood serum proteins (Luttmann, 
et al., 2006). A correlation between surface charge and opsonization has also been 
demonstrated in vitro; neutral particles performing better than charged ones (Roser, et 
al., 1998). Therefore, a widely used method to slowdown opsonization relies on the use 
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of shielding groups which can block electrostatic and hydrophobic interactions that help 
opsonins binding the nanoparticle surfaces. These groups are typically long hydrophilic 
polymer chains and non-ionic surfactants. Examples of effective shielding groups include 
polysaccharides, polyacrylamide, poly(vinyl alcohol), poly(N-vinyl-2-pyrrolidone), 
poly(ethylene glycol) (PEG), and PEG-containing copolymers such as poloxamers, 
poloxamines, polysorbates, and PEG copolymers (Owens, et al., 2006, Storm, et al., 
1995). Among the polymers tested to date, the most effective and most used are PEG 
and PEG-containing copolymers, typically very flexible, highly hydrophilic and not 
charged, altogether properties lessening the protein binding. 
The high mobility of nanoparticles in the smallest capillaries allows for efficient uptake 
and selective drug accumulation at target sites (Panyam, et al., 2003b). Indeed, cell 
uptake of nanoparticles is relatively high, when compared to microparticles (> 1 µm) 
(Akagia, et al., 2007). Specific cell internalization can be improved by surface decoration 
with targeting ligands (peptide, sugar molecule, antibody, vitamins), which are recognized 
by target cells/tissues. The release of bioactive molecules into the cytoplasm or nucleous 
compartments can be a challenging problem. Internalized particles are initially within 
endosomes but are trafficked rapidly to lysosomes, where they are degraded 
enzymatically, preventing their action. To avoid lysosomal trafficking, smart polymers with 
specific chemical groups have been designed.  
Although nanogels are indeed rather promising, it must be stressed that their 
development as products for clinical applications still requires further knowledge on its 
physico-chemical properties, knowledge on the interaction with cells and tissues, 
nanotoxicology and safety. Generally, nanoparticles that have a mean diameter of 
approximately 100 nm, bearing a neutral and hydrophilic surface, exhibit prolonged blood 
circulation and an increased level of tumor delivery (Brannon-Peppas, et al., 2004).  
1.1.3 Methods 
The self-assembly process, defined as the autonomous organization of components 
into structurally well-defined aggregates, is characterized by numerous beneficial 
attributes; it is cost-effective, versatile and facile; the process occurs towards the 
system’s thermodynamic minima, resulting in stable and robust structures. Molecular self-
assembly is characterized by diffusion followed by specific association of molecules 
through non-covalent interactions, including electrostatic and/or hydrophobic associations 
(Figure 1.1). Individually, such interactions are weak, but dominate the structural and 
General Introduction | Chapter 1 
Gonçalves, C. | 2010 6 
conformational behavior of the assembly due to the large number of interactions involved 
(Zhang, 2002). While oppositely charged polysaccharides associate readily as a result of 
electrostatic attractions (Rinaudo, 2006), interactions among neutral polysaccharides 
tend to be weaker, or nonexistent, a modification with chemical entities able to trigger 
assembly being necessary. A convenient strategy consists on linking hydrophobic grafts 
to e.g., a highly water-soluble polysaccharide, inducing the formation of nanoparticles via 
hydrophobic interactions. This kind of amphiphilic polymers can be constructed by three 
routes: hydrophobic chains grafted to a hydrophilic backbone, hydrophilic chains grafted 
to a hydrophobic backbone (grafted polymers) or with alternating hydrophilic and 
hydrophobic segments (block polymers). Upon contact with an aqueous environment, 
amphiphilic polymers spontaneously form self-aggregated nanoparticles, via intra- or 
intermolecular associations between the hydrophobic moieties, primarily to minimize the 
interfacial free energy. The important feature, from the physicochemical point of view, is 
that the molecule is able to orient itself to expose the hydrophilic regions to the polar 
environment (normally the aqueous medium) and the hydrophobic segments aggregates 
in the internal core of the material. The concentration above which the polymeric chains 
aggregate is called the critical micelle concentration or the critical aggregate 
concentration. Several strategies for the preparation of nanoparticles have been used, 
including direct dissolution, solvent evaporation/film formation, dialysis, emulsion, and co-
solvent evaporation.  
 
(a) (b) 
: hydrophobic group 
: hydrophilic polymer
 
Figure 1.1. Schematic representation of intermolecular interactions driving self-assembly 
processes (a) electrostatic interactions or (b) hydrophobic association. 
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The commercialization of nanodevices obtained using these technologies is limited 
due to the employment of potentially toxic organic solvents and surfactants, often not 
acceptable, at least for parenteral administration. For example, polymer based 
nanoparticles may be prepared by the well-known solvent evaporation method, in which 
the droplets of a nanoemulsion are composed of a volatile organic solvent in which the 
polymer is solubilized (Soppimath, et al., 2001). Traces of solvent are very difficult to 
eliminate, even using very sophisticated and time consuming methods such as 
ultradialysis, ultracentrifugation or ultrafiltration. In general, the currently available 
nanotechnologies are not able to meet the severe requirements enacted by the public 
health agencies for medicines. Therefore, there is an urgent need to develop new 
concepts and ideas to overcome these technological issues by proposing preparation 
procedures avoiding the use of organic solvents and surfactants. In this view, direct 
dissolution in pure water is the most suitable strategy to obtain nanogels (Gonçalves, et 
al., 2007). 
 
 
1.2 Drug loading, targeting and release 
1.2.1 Drug loading 
Nanogels are widely used as carriers of therapeutic agents. A successful nanodelivery 
system should have a high drug-loading capacity, thereby reducing the required amount 
of carrier. Therapeutic agents can either be physically entrapped into the polymeric matrix 
or covalently bound to the polymer backbone. Polysaccharides, for instance, contain 
hydroxyl groups that allow direct reaction with drugs containing carboxylic acid function, 
producing ester linkages. Drugs lacking a carboxylic acid group require activation before 
the reaction takes place (Mehvar, 2000, Shrivastava, et al., 2009). Physical drug 
entrapment is by far the more often used loading method for drug delivery applications. 
The best incorporation strategy for an efficient entrapment must be selected according to 
the physicochemical characteristics of the pair drug-carrier. Several methods have been 
used for drug loading, such as dialysis, nanoprecipitation, solvent 
displacement/evaporation, desolvation or direct dissolution. The encapsulation efficiency 
is different for each specific nanosystem; for example, the anti-cancer taxol is 
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encapsulated with 100% and 20% efficiency on poly(lactide-co-glycolide) (Mu, et al., 
2003) and poly(ε-caprolactone) (Kim, et al., 2001) nanodevices, respectively.  
The incorporation of biomolecules without compromising its bioactivity constitutes a 
fundamental goal. Physical drug loading can be performed by incorporating the drug 
while producing the nanoparticles, or by incubating a concentrated drug solution with the 
already formed nano-carrier. Drug loading and entrapment efficiency depend on the 
solubility in the polymeric matrix, which is in turn related to the polymer composition, 
molecular weight, drug-polymer interactions, and the presence of functional groups (i.e., 
ester or carboxyl) (Govender, et al., 2000, Govender, et al., 1999, Panyam, et al., 2004).  
1.2.2 Targeting 
Drug delivery mediated by nanoparticles can be either an active or passive process. 
Passive delivery refers to the transport through leaky capillary fenestrations, into e.g., 
tumor interstitium and cells, by passive diffusion (Zambaux, et al., 1999). Selective 
accumulation of nanoparticles and drug then occurs by EPR effect. Active targeting 
involves the use of peripherally conjugated targeting moieties, for enhanced delivery to a 
specific site, based on molecular recognition. One such approach is to surface-coat 
nanoparticles with an antibody, which can interact with its specific antigenic target cell 
site. According to some authors, antibody targeting does not increase tumor localization, 
instead increasing internalization (Hatakeyama, et al., 2007, Kirpotin, et al., 2006). The 
targeting moieties may help cellular uptake. Thus, long circulation times will allow for 
effective transport of the nanoparticles to the tumor site through the EPR effect, the 
targeting molecule then enabling endocytosis of the nanoparticles (Figure 1.2). The 
internalization of the nanoparticle is important for effective delivery of bioactive agents, 
especially in gene delivery, gene silencing, and other biotherapeutics. Sophisticated 
strategies to control the intracellular trafficking of nanoparticles are being developed 
(Tarragó-Trani, et al., 2007, Watson, et al., 2005). Such advanced drug carriers can be 
intelligently designed based on the inherent properties of the target site such as pH, 
presence of enzymes or specific tissue markers. After internalization by endocytosis, 
nanoparticles end up in endosomes and then lysosomes, where the pH values of about 
5.5 (endosomes) and 4–5 (lysosomes) are found (Shen, et al., 2009). Thus, pH sensitive 
constructs may be used as a smart trigger system for drug release. 
For optimal therapeutic effect, the drug concentration must be maintained at an 
effective dose at the target site for the appropriate time-frame, with minimal dose 
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accumulation at off-target sites. For these purposes, careful design of multifunctional drug 
carriers with nano-dimensions has become a popular research subject.  
Antibody fragments containing only the variable region of the antibody – that governs 
the recognition specificity - are now more commonly used for active targeting of 
therapeutics, avoiding the presence of the constant Fc effector region. This region may 
trigger the complement activation or undesirable interaction with other cells, potentially 
leading to premature phagocytosis of the drug delivery system (Chapman, 2002). In 
addition, the smaller size of antibody fragments may be an important factor in the 
development of an actively targeting nanoparticle. Antibodies, or antibody fragments, are 
conjugated either directly to the nanoparticle surface or through linker molecules such as 
PEG. The conjugation reaction is commonly carried out using carbodiimide-mediated 
chemistry, which creates stable amide bonds between carboxylic acid groups in the 
nano-carrier and primary amine groups, including lysines and the N-terminus amine, in 
the antibody or antibody fragment (Chapman, 2002).  
Bloodstream
Vascular endothelial cell
Tumor tissue
Nanoparticles with targeting moietiesNanoparticles without targeting moieties
Healthy tissue
 
Figure 1.2. Targeting strategies for cancer therapy. Passive targeting can be achieved by EPR, 
an effect involving leaky vascular structures. Active targeting mediated by targeting ligands 
specifically localizes drug carriers at desired cells or tissues. The decoration of the 
nanoparticles with ligands improves its internalization by endocytosis. 
Cell-specific ligands have been popularly employed to confer tissue- or cell-specificity 
to drug delivery systems. Specific interaction between a targeting ligand and its cellular 
receptor generally enhances the cellular uptake of nano-carriers by a mechanism called 
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receptor-mediated endocytosis. Therefore, increasing the specific cellular uptake 
significantly improve the therapeutic efficacy achieved with a much lower dose 
(Schiffelers, et al., 2004). A variety of targeting ligands have been used in drug delivery 
systems, including galactose and lactose to target hepatocytes, mannose for dendritic 
cells, RGD peptide to target integrins on cell surfaces and lactoferrin for bronchial 
epithelial cells. 
Different targets may be addressed for cancer therapy purposes. Targeting 
angiogenesis has become a major area of focus. The growth of solid tumors is dependent 
upon the ability to generate an adequate blood supply. Anti-angiogenesis approaches are 
effective in limiting tumor growth, the transformed endothelial cells of the neovasculature 
becoming a preferential target. Main angiogenic targets are the vascular endothelial 
growth factor receptors, αvβ3 integrins, matrix metalloproteinase receptors, and vascular 
cell adhesion molecule-1. Cell proliferation markers are another important target for 
cancer therapeutics, as many of them are highly overexpressed by certain tumor cells. 
Actively targeting nanoparticles to cell proliferation receptors may be achieved using 
monoclonal antibodies. The selection of monoclonal antibodies for cancer targeting is 
based on four basic criteria: (1) the antigen of interest is overexpressed by tumor cells, 
(2) the antigen participates as a principle component in the progression of the disease, 
(3) the antigen, present on the tumor cell surface must be stable, and (4) the antigen is 
expressed by a large percentage of tumor cells and a large variety of tumors. The most 
established cell proliferation targets used by actively targeting nanoparticles include 
human endothelial, transferrin and folate receptors. Targeting highly expressed antigens 
is a promising area that can ensure the elimination of malignant tumors and metastatic 
cells that have not become large enough to induce angiogenesis.  
1.2.3 Drug release 
The nanoparticles made of biodegradable materials allow sustained drug release over 
periods of days or even weeks. Biodegradation should not only modulate the release of 
drugs for a desired period of time, but also enable the removal of the empty device. Drug 
release is affected by the particle size. Smaller particles have a larger surface-to-volume 
ratio, therefore most of the drug is at or near the particle surface, leading to faster drug 
release. In contrast, larger particles allow more drug encapsulation in the inner cores, 
providing a slower release. Thus, control of particle size provides a means of tuning the 
drug release rates. The release mechanism can be modulated also by the molecular 
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weight and the copolymer composition used. It has been shown that the higher the 
polymer molecular weight, the slower the in vitro release of drugs (Mittal, et al., 2007, 
Zambaux, et al., 1999). The release mechanism is a complex function of three main 
processes, i.e., drug diffusion, matrix swelling, and chemical reactivity of the drug/matrix. 
Recent studies focuses on biopolymers responsive to physiological changes such as pH, 
temperature and external stimuli such as light, that can trigger a control release of the 
therapeutic agent.   
 
 
1.3 Applications 
1.3.1 Small molecular weight drug delivery 
The sustained delivery of small drugs from polymer formulations has broad application 
in the treatment of several diseases – namely and noteworthy, the case of cancer. 
Biomaterial-mediated delivery schemes offer a unique method to deliver this kind of 
drugs. This section summarizes the polymer-based delivery systems for small drugs 
described in the literature, namely studies in vivo or using cell lines (Table 1.1).  
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Table 1.1. Nano-carriers for small molecular weight drug delivery 
Polymer Therapeutic 
agent Ligand Cell line Drug binding Stimuli References 
azo-dextran aspirin -- COS-1 simple mixing and irradiation with UV light UV–vis light 
(Patnaik, et al., 
2007) 
carboxymethyl 
chitosan-linoleic acid 
adryamycin (anti-
cancer) -- HeLa direct dissolution -- (Tan, et al., 2009) 
pullulan acetate adriamycin  (anti-
cancer) 
vitamin H 
(biotin) HepG2 dialysis method -- (Na, et al., 2003a) 
pullulan 
acetate/sulfonamide 
adriamycin (anti-
cancer) -- MCF-7 dialysis method pH (Na, et al., 2003b) 
poly[(maleilated 
dextran)-graft-(N-
isopropylacrylamide)] 
camptothecin 
(anti-cancer) -- L929 dialysis method pH, temperature (Li, et al., 2009a) 
poly(N-
isopropylacrylamide)/
chitosan 
camptothecin 
(anti-cancer) -- SW480 direct dissolution pH (Li Fan, 2008) 
poly[2-(N,N-
diethylamino)ethyl 
methacrylate]-block-
PEG 
cisplatin      (anti-
cancer) -- 
SKOV-3 
In vivo 
solvent displacement 
method pH (Xu, et al., 2006) 
poly (lactide-co-
glycolide)-PEG 
curcumin     (anti-
cancer) -- 
KBM-5, Jurkat, 
DU145, MDA-MB-
231, HCT116,SEG-1 
In vivo 
nanoprecipitation -- (Anand, et al., 2010) 
polylactide-co-
glycolide–PEG–folate 
docetaxel     (anti-
cancer) folate SKOV3 
emulsification/solvent 
diffusion method -- 
(Esmaeili, et al., 
2008) 
poly(D,L-lactic-co-
glycolic acid)-block-
PEG 
docetaxel    (anti-
cancer) 
PSMA 
aptamer LNCaP nanoprecipitation -- 
(Farokhzad, et al., 
2006) 
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Table 1.1- cont. 
Polymer Therapeutic
agent Ligand Cell line Drug binding Stimuli References 
glycol chitosan-5β-
cholanic acid 
docetaxel    
(anti-cancer) -- 
A549 
In vivo 
dialysis method -- (Hwang, et al., 2008) 
poly(l-histidine)-b-PEG-
folate  (75 wt.%) and 
poly(L-lactide)-b-PEG-
folate (25 wt.%) 
doxorubicin 
(anti-cancer) folate MCF-7 
. 
dialysis method 
pH (Lee, et al., 2005) 
chitosan-poly(acrylic 
acid) 
doxorubicin 
(anti-cancer) -- 
HepG2 
In vivo 
direct dissolution -- (Hu, et al., 2007) 
poly(ε-caprolactone)-
PEG-poly(ε-
caprolactone) 
honokiol  
(anti-inflammation) -- 
A549 direct dissolution -- (Wei, et al., 2009) 
ethylcellulose 
methylcellulose 
nimesulide 
(nonsteroid anti-
inflammation) 
-- 
fresh human 
blood desolvation method -- 
(Ravikumara, et al., 
2009) 
poly(ethylene oxide)-
modified poly(ε-
caprolactone) 
tamoxifen -- 
MDA-MB-231 
In vivo 
solvent displacement -- (Shenoy, et al., 2005) 
PEG-polycyanoacrylate paclitaxel    (anti-cancer) transferrin In vivo solvent evaporation -- (Xu, et al., 2005) 
poly (lactide-co-glycolide 
fumarate)/poly(lactide-co-
ethylene oxide fumarate) 
poly (lactide-fumarate)/ 
poly(lactide-co-ethylene 
oxide fumarate) 
paclitaxel    
(anti-cancer) -- 
HCT116 
In vivo 
dialysis method -- (He, et al., 2008) 
PEG750-block-poly(ε-
caprolactone-co-
trimethylenecarbonate) 
paclitaxel    
(anti-cancer) -- 
HeLa 
In vivo 
solvent evaporation -- (Danhier, et al., 2009b) 
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Table 1.1- cont. 
Polymer Therapeutic
agent Ligand Cell line Drug binding Stimuli References 
poly (lactide-co-glycolide)/ 
poly(ε-caprolactone)-PEG 
paclitaxel     
(anti-cancer) -- HeLa 
simple emulsion or 
nanoprecipitation method -- 
(Danhier, et al., 
2009a) 
linoleic acid/poly(β-malic 
acid) Chitosan 
paclitaxel     
(anti-cancer) -- In vivo 
sonication and dialysis 
method -- (Zhao, et al., 2009) 
poly(β-amino ester)-graft-
PEG 
paclitaxel, 
camptothecin    
(anti-cancer) 
-- 
SKOV-3 solvent displacement or dialysis method pH (Shen, et al., 2009) 
glycol chitosan-5β-
cholanic acid 
protophorphyrin 
IX (photosensitizer, 
photodynamic 
therapy) 
-- 
SCC7 
In vivo 
Ex vivo 
dialysis method -- (Lee, et al., 2009) 
poly(β-benzyl-l-
aspartate)-block-
poly(vinylpyrrolidone) 
prednisone 
(anti-inflammation) -- SW-1990 dialysis method pH 
(Wang, et al., 
2009a) 
poly (10-undecenoic acid-
b-N-isopropylacrylamide) 
prednisone 
(anti-inflammation) -- ECV304 dialysis method pH, temperature (Wei, et al., 2006) 
cellulose-g- poly(l-lactide) prednisone (anti-inflammation) -- 3T3 dialysis method -- (Dong, et al., 2008) 
galactosylated 
polycaprolactone-g-
dextran 
prednisone 
(anti-inflammation) galactose 
HepG2, 3T3 
In vivo 
dialysis method -- (Wu, et al., 2009) 
poly(ethylene oxide)-
modified poly(ε-
caprolactone) 
saquinavir  (HIV-
protease inhibitor) -- THP-1 solvent displacement -- (Shah, et al., 2006) 
water soluble chitosan thymol (anti-
microbial) -- 
Staphylococcus 
aureus 
Bacillus subtilis 
Escherichia coli 
sonication method -- (Hu, et al., 2009) 
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Several polymers have been exploited for the formulation of nanoparticulate carrier 
systems. PLA, PGA and PLGA have been extensively employed because of their 
biocompatibility, biodegradability and versatile degradation kinetics. For instance, 
haloperidol-loaded PLGA/PLA particles were produced by sonication or homogenization. 
The three most relevant properties regarding the release behavior were identified: 
polymer hydrophobicity, surface coating and particle size. The hydrophobicity of the 
polymer contributes to a reduction of the initial burst, extending the period of release. For 
example, the percentage of drug released after 1 and 35 days is respectively 46 and 70% 
for 220 nm PLA particles, as compared to 70 and 90% for PLGA particles with the same 
size. Coating the particle surface with chitosan considerably reduces the initial burst. For 
example, the initial burst registered at 1 day, using 220 nm PLGA particles, is reduced 
from 70 to 36% by surface coating with chitosan. Increasing the size of the particles also 
reduces both the initial burst and the rate of release. For example, increasing the size 
from 220 to 450 nm reduces the initial burst from 48 to 28%, a steady release of drug 
being observed over a 10 day time period in the later case, as compared to four days for 
the smaller particles (Budhian, et al., 2008).  
PEG has been extensively used to modulate the biodegradation, release profile, 
bloodstream clearance and biodistribution. For instance, nanoparticles engineered by 
blending PLA/PLGA homopolymers and PEG have been used to encapsulate 
betamethasone disodium 21-phosphate (BP). The drug release profile and the vascular 
circulation time-frame could be controlled by varying the composition/molecular weight of 
the polymer. The rate of in vitro BP release correlated inversely with the nanoparticles 
size and increased using PLGA instead of PLA homopolymers. Furthermore, higher PEG 
content reduces the uptake of nanoparticles by dendritic cells and accordingly improves 
the blood circulation time. Analysis of the BP organ biodistribution revealed a lower liver 
concentration when using blended nanoparticles instead of PLA nanoparticles (Ishihara, 
et al., 2009). The in vitro degradation of the PLGA–mPEG nanoparticles increases with 
the proportion of mPEG in the copolymer chains. As expected, the hydrophilicity of 
PLGA–PEG copolymers, as evaluated by water uptake or contact angle measurements, 
was found to increase with an increase in PEG content. The higher degradation rate of 
the nanoparticles with high mPEG content may be attributed to the improved 
hydrophilicity, which apparently overrides the decreased content of cleavable ester bonds 
(Avgoustakis, et al., 2002). 
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1.3.2 Protein, peptide and oligosaccharide delivery  
The oral route is the most convenient and comfortable mean for drug administration. 
However, the poor bioavailability, mainly due to the low mucosal permeability and lack of 
stability in the gastrointestinal (GI) environment, resulting in compound degradation prior 
to absorption, hinders a generalized use for proteins and peptides administration. One 
possible way to improve the GI uptake of proteins and peptides is the encapsulation in 
micro/nanoparticles that, while protecting from degradation in the GI tract, facilitate the 
transportation into the systemic circulation. Polymeric nanoparticles meet these attributes 
(Des Rieux, et al., 2006, Shu, et al., 2010).  
The rather large number of therapeutic proteins currently reaching the market or under 
clinical evaluation draws the urgent need for new delivery systems, using different routes 
of administration, which allow for improved stability – a main concern regarding 
therapeutic proteins – as well as controlled and targeted release. Cytokines emerge as a 
powerful tool for immunotherapy and vaccination purposes. Simultaneously, growth 
factors offer new opportunities for wound and tissue regeneration. Currently, the more 
effective approach to guarantee appropriate stability is protein pegylation. Other tools 
with more versatile properties are required. Colloidal polymeric carriers have arisen as a 
promising alternative for improving the transport of macromolecules: 
- proteins such as insulin (Damge, et al., 2007, Lin, et al., 2007b, Mi, et al., 
2008, Qian, et al., 2006, Sonaje, et al., 2009);  
- cytokines (Hasegawa, et al., 2009, Shimizu, et al., 2008) and growth factors 
(Bessa, et al., 2009);  
- peptides, e.g. RGD (Park, et al., 2004), cyclosporin A (Campos, et al., 2001, 
El-Shabouri, 2002), elcatonin (Prego, et al., 2006, Yamamoto, et al., 2005),  
vasoactive intestinal peptide (Gao, et al., 2007), anti-cancer glycoprotein lectin 
A-chain (Lee, et al., 2008) and a caspase inhibitor peptide (Aktas, et al., 2005)  
- oligossacharides, such as heparin (Bae, et al., 2009, Chen, et al., 2009, 
Oyarzun-Ampuero, et al., 2009).  
These recent reports on the development of new protein delivery systems are 
discussed below. 
The cationic nature of chitosan makes it an interesting polymer for the association with 
and delivery of labile negatively charged macromolecules. Several studies addressed the 
nasal delivery of insulin with chitosan nanoparticles (Wang, et al., 2009b, Zhang, et al., 
2008). The potential of protonated chitosan has been enforced by the recognition of its 
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ability to trigger the opening of tight junctions, thereby facilitating the transport of 
macromolecules through the epithelium. Indeed, it has been demonstrated that 
nanoparticles can enhance the oral bioavailability of encapsulated therapeutic proteins. 
For this purpose, a nanoparticulate system composed of trimethyl chitosan (TMC) and 
cysteine (Cys), attempting to combine the mucoadhesion and permeation enhancing 
effects, was tested. When reaching the small intestine, the positively charged 
nanoparticles - which interact electrostatically with the mucous layer - induce transient 
loosening of the tight junctions. The free thiol groups on TMC-Cys allow the formation of 
disulfide bonds with the cysteine-rich mucin. Therefore, a closer and prolonged action on 
the tight junctions favors both the paracellular transport of the insulin and nanoparticle 
internalization by enterocytes. Oral administration of insulin-loaded TMC-Cys 
nanoparticles led to notable hypoglycemic effects, which lasted until eight hours post-
administration, with a maximum blood glucose depression of 35% (Yin, et al., 2009).   
In cytokine immunotherapy, a suitable delivery system that ensures slow-release of 
cytokines is required, the short in vivo half-life of these molecules ruins its therapeutic 
eﬃcacy, while causing severe systemic toxic effects. Recombinant murine IL-12 (rmIL-
12) was successfully incorporated into cholesterol-bearing pullulan (CHP). The 
subcutaneous injection of the CHP/rmIL-12 complex led to a prolonged elevation of IL-12 
concentration in the serum. Repetitive administrations of the complex induced drastic 
growth retardation of reestablished subcutaneous fibrosarcoma, without causing toxicity 
(Shimizu, et al., 2008).  
Bone morphogenetic proteins (BMPs) are cytokines with a strong ability to promote 
new bone formation. Elastin-like nanoparticles, created by thermoresponsive self-
assembly, were developed for the combined release of bone morphogenetic protein-2 
(BMP-2) and bone morphogenetic protein-14 (BMP-14). These BMPs could be 
encapsulated efficiently into the elastin-like particles and delivered in a sustained way for 
14 days. The activity of the growth factors was retained and increased bioactivity on 
C2C12 cells was observed following the combined release of BMP-2 and BMP-14 
(Bessa, et al., 2009).  
The development of peptides and proteins acting on the central nervous system is 
drastically hindered by the blood-brain barrier (BBB). The surface engineering of 
nanoparticles with lectins opened a novel pathway for the delivery of drug-loaded 
biodegradable nanoparticles into the brain, following intranasal administration. The 
neuroprotective Vasoactive Intestinal Peptide (VIP) was efficiently incorporated into PEG-
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PLA nanoparticles surface-modified with wheat germ agglutinin. This formulation allows a 
more effective delivery, as compared with the intranasal application of the soluble 
peptide. This is partially attributed to the higher affinity of the wheat germ agglutinin-
conjugated nanoparticles to the olfactory mucosa, rather than to the respiratory one (Gao, 
et al., 2007). The peptide Z-DEVD-FMK, a caspase inhibitor, reduces vulnerability of the 
neuronal cells. The clinical application is hindered by its inability to cross the BBB and 
diffuse into the brain tissue. Thus, chitosan-PEG nanospheres bearing the OX26 
monoclonal antibody (affinity for the transferrin receptor) have been designed, which 
trigger the receptor-mediated transport across the BBB. An important amount of 
nanoparticles were located in the brain, outside of the intravascular compartment. Hence, 
OX26 functionalized chitosan-PEG nanoparticles are promising carriers for the transport 
of the anti-caspase peptide into the brain (Aktas, et al., 2005).  
The peptide Arg–Gly–Asp (RGD) draws much attention for tumor therapy applications, 
because it specifically binds αvβ3 integrins, expressed by angiogenic endothelial cells. 
Attempting to overcome the short half-lives of several systemic anti-angiogenic peptides, 
a carrier for the RGD peptide was produced, using self-assembled nanoparticles of 
hydrophobically modified glycol chitosan (HGC). A high RGD loading efficiency was 
achieved (over 85%), and the system showed prolonged and sustained release for about 
1 week. The RGD loaded-HGC nanoparticles displayed anti-angiogenic activity, markedly 
suppressing bFGF (inducer of angiogenesis) as well as preventing microvessel formation. 
Due to the sustained RGD peptide delivery, RGD-HGC nanoparticles significantly 
decreased tumor growth and microvessel density, improving the effect obtained injecting 
the free RGD peptide, either intravenously or intratumorally (Kim, et al., 2008a).  
Limitations in the management of extraocular diseases include the inability to provide 
long-term extraocular drug delivery without compromising intraocular structures. Since 
the cornea has negative charge, mucoadhesive polymers can interact with the 
extraocular structures, increasing the concentration and residence time of 
immunosuppressive peptide cyclosporin A (CyA). The hydrophobic peptide, CyA, was 
associated to chitosan nanoparticles. In vivo experiments showed that, following topical 
instillation of CyA-loaded chitosan nanoparticles to rabbits, it was possible to achieve 
therapeutic concentrations in external ocular tissues (i.e., cornea and conjunctiva) during 
at least 48 hours, while maintaining negligible or undetectable CyA levels in inner ocular 
structures (i.e., iris/ciliary body and aqueous humor), blood and plasma (Campos and Sa, 
2001).  
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Pulmonary drug delivery for both local and systemic action has many advantages over 
other delivery routes. The lungs offer a large surface area, a rather thin absorption 
barrier, low enzymatic metabolic activity and slow mucociliary clearance. Therefore, 
PLGA nanospheres, surface-modified with chitosan, were developed and used for 
pulmonary delivery of elcatonin, a calcitocin derivative (formulated for the management of 
several bone-related diseases). The coated nanospheres were eliminated from the lungs 
at slower rate. Loaded elcatonin reduced blood calcium levels to 80%, exhibiting a 
prolonged pharmacological action, for over 24 hours. The results showed that the 
nanospheres adhered to the bronchial mucus and lung tissue, allowing the sustained 
drug release at the adherence site. Additionally, flexible chitosan molecules on surface of 
the nanospheres enhanced the drug absorption, maybe by opening the intercellular tight 
junctions (Yamamoto, et al., 2005). 
The macromolecular drug heparin, a sulfated natural glycosaminoglycan, is vulgarly 
used as an injectable anticoagulant (Chen, et al., 2009). Recently, heparin has been 
loaded into nanoparticles of chitosan and hyaluronic acid, developed for anti-asthmatic 
therapy applications. The nanosystems were stable in phosphate buffered saline pH 7.4 
for at least 24 hours, and released 10.8% of unfractionated heparin within 12 hours of 
incubation. Fluorescent heparin-loaded nanoparticles were effectively internalized by rat 
mast cells. Ex vivo experiments, conducted to evaluate the capacity of heparin to prevent 
histamine release in rat mast cells, indicated that the free or encapsulated drug exhibited 
the same dose–response behavior (Oyarzun-Ampuero, et al., 2009). Intracellular delivery 
of heparin by chitosan-g-PEG/heparin polyelectrolyte complexes has also been used to 
trigger caspase activation and consequently promote apoptotic death of cancer cells 
(Bae, et al., 2009).  
1.3.3 Vaccine delivery 
The recent developments in nanotechnology increased considerably the interest in 
nano-particulate systems as a platform for the delivery of antigens. The key challenges 
are the induction of a potent and broad (both humoral and cellular) antigen-specific 
immune response, capable of protecting from infection (sterilizing vaccination) and/or 
disease (therapeutic vaccination) and finally, to develop effective immunity after a single 
injection of the vaccine. Particulate delivery systems mimic pathogens that are commonly 
recognized, phagocytosed, and processed by professional antigen-presenting cells 
(APCs). APCs, such as dendritic cells and macrophages, represent the sentinels of the 
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immune system and orchestrate antigen-specific T cell-mediated immune responses. 
Activated APCs migrate to regional lymph nodes where they present the antigen to T 
cells, thereby triggering cellular and humoral immunity. Most organisms are detected and 
destroyed within hours by defense mechanisms, which are not antigen-specific and do 
not require any prolonged period of induction. These are the mechanisms of innate 
immunity. Only when the infectious agent is capable of breaking this early line of defense, 
an adaptive immune response will develop. This includes generation of antigen-specific 
effector cells that specifically target the pathogen, secretion of antibodies (B cells), direct 
cytotoxic activity (T cells), or secretion of immunological mediators and effector molecules 
such as cytokines and chemokines. Although most of these effector cells will die within 
10–14 days after infection, some cells will survive, as highly reactive plasma cells (B 
cells) or memory cells (B and T cells), and prevent subsequent infection by the same 
microorganism. Along with long-lasting antibodies against a specific pathogen, the 
induction of memory cells is the final goal of preventive vaccination.  
Immunity against an infectious agent by vaccination can be achieved in various ways, 
normally including several components. Firstly, the antigen itself can be a synthetically 
produced peptide representing an epitope of a pathogen protein. It can also be the full-
length protein carrying several epitopes that are recognizable by B and T cells. Such full-
length proteins can be secreted from the pathogen or produced synthetically or 
recombinantly. Vaccine development has also focused on experimental vaccines where 
the gene encoding a particular protein is fused into a DNA or RNA plasmid. Secondly, the 
formulation or delivery system varies considerably from one vaccine to another. DNA and 
some protein vaccines can be administered in solution without adjuvant enhancement of 
the immune response. Today, still many of the most potent vaccines are given as a live 
attenuated or killed form of the particulate microorganism. A unique property, especially 
of live vaccines, is that they often induce strong T cell responses. This property is very 
much missed by protein or peptide vaccines administered with those adjuvants in general 
use today, e.g., aluminum salts. Thus, there is an urgent need for the development of 
potent and safe antigen-delivery systems. The development of nano-particulate vaccines 
is also motivated by safety concerns, e.g., to avoid the risk of infection induced by live 
attenuated vaccines and to suppress the excessive inflammation that is frequently 
caused by the use of Freund’s adjuvant or aluminum salts adjuvant. 
Cancer vaccines are a promising approach for anti-cancer therapy, as fewer side 
effects are induced than with other therapies and, more importantly, there is an 
opportunity for developing long-term immunity (Rosenberg, 2001). In contrast to general 
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medicines, which are directly targeted to specific molecules, cancer vaccines initiate a 
cascade of antigen specific immune responses against antigen-expressing tumor cells. 
Activating the immune system to trigger a specific response sufficient for the eradication 
of tumor cells, however, is a major challenge in the development of cancer 
immunotherapy.  
A possible key for the successful development of new generation of vaccines may lie 
in the use of targeted delivery systems (Table 1.2). Nanoparticulate systems are 
particularly well suited for the delivery of antigens specifically to DCs, inducing the 
subsequent activation of T cell immunity, given its ability to permeate the lymphatic 
draining system and reach DCs in the lymph nodes. However, antigen delivery to - and 
activation of - DCs is a complex problem, involving antigen transport to DC-rich areas, 
DC binding and eventually antigen uptake, and antigen processing and presentation. 
Before an antigen can be processed and presented by DCs, the biomaterial vehicle itself 
must be internalized by DCs. Immature DCs internalize exogenous solutes, particles, and 
necrotic or apoptotic cells through macropinocytosis, receptor-mediated endocytosis and 
phagocytosis (Sallusto, et al., 1995). Several studies confirmed that DCs can internalize 
polymeric nanoparticles (Elamanchili, et al., 2004), the internalization mechanism being 
partially controlled by altering the properties of the biomaterial vehicle, namely the size 
(Reddy, et al., 2006). Macropinocytosis is used to internalize extracellular fluid and 
smaller solutes such as macromolecules (Sallusto, et al., 1995) and particularly small 
nanoparticles (< 50 nm), whereas phagocytosis occurs when larger nanoparticles (> 500 
nm) are taken up (Lutsiak, et al., 2002, Thiele, et al., 2003). DCs also use surface 
receptors to endocytose ligands with a terminal sugar such as mannose (Avrameas, et 
al., 1996). Thus, both the physicochemical and biochemical character of biomaterial 
vehicles can be adjusted to tailor DC uptake. 
Following internalization, the biomaterial vehicle must then release the antigen 
intracellularly, in a manner that will enable processing by MHC class I, class II, or both 
(cross-presentation) pathways. The delivery of exogenous antigen inducing cellular 
immunity through the MHC class I pathway can be a challenging problem, as internalized 
particles are initially within endosomes but are trafficked  rapidly to lysosomes, where 
they are degraded enzymatically, preventing the antigen from being processed and 
presented. To avoid lysosomal trafficking, smart polymers have been designed. These 
polymers are broken down inside the endosomes, due to the presence of acid-
degradable acetal bonds, triggering the disruption of the endosomes in a pH-dependent 
fashion. The process occurs as follows: at pH 7.4 the polymers are PEGylated 
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(“masked”); however, after endocytosis the acid labile linker is hydrolyzed and the 
polymer backbone becomes de-PEGylated (“umasked”) and membrane-disruptive, 
causing endosomal disruption. The PEGs may be conjugated to the backbone via both 
acid-degradable linkages and disulfide bonds. These polymers release oligonucleotides 
and peptides into the cytoplasm as the endosome is acidified, avoiding the lysosomal 
fusion; releasing antigen into the cytoplasmic compartment enables processing by MHC 
class I instead of the MHC class II pathway (Murthy, et al., 2003). This strategy 
exemplifies how smart biomaterials may be engineered as to overcome biological barriers 
and control the intracellular biodistribution.  
Targeting lymph-node DCs, rather than peripheral ones, in the skin for example, offers 
many theoretical advantages (Randolph, et al., 2005). The avoidance of premature 
antigen presentation, because DCs in lymph nodes are already at the site of antigen 
presentation, is one potential benefit. For successfully targeting lymph-node-resident 
DCs, it is crucial to engineer biomaterial vehicles that can be readily taken up into 
lymphatic vessels after subcutaneous or intradermal injection, being then retained in 
draining lymph nodes. It has been well-established that particle size is among the most 
crucial factors for lymphatic uptake from the interstitial space (Swartz, 2001).  
As the mucosal route of administration (e.g., intranasal, oral) is considered a simple, 
safe, efficacious, non-invasive and less expensive method to deliver antigens, novel 
strategies for the achievement of safe and effective immunization strategies are under 
investigation regarding the routes of vaccination. Mucosal immunization is an attractive 
alternative to parenteral vaccination; using the appropriate delivery system it is possible 
to stimulate both mucosal and systemic immune responses (Sayin, et al., 2008). Mucosal 
vaccination offers also several benefits over parenteral route, including ease of 
administration, reduced side effects, possibility of self-administration and, especially in 
developing countries, reduced risk of the unwanted spread of infectious agents via 
contaminated syringes. 
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Table 1.2. Polymeric nanoparticles for vaccine delivery 
Polymer Antigen Remarks Route References 
poly-l-lysine coated 
polystyrene particles sOVA-C1 plasmid Particles of different sizes may target different APCs. intradermal 
(Minigo, et al., 
2007)  
poly-(ε-caprolactone) 
-poly(lactide-co-
glycolide) 
diphtheria toxoid 
Correlations between polymer characteristic (e.g., hydrophobicity) and 
route of administration, indicate that such characteristics can have 
interesting implications in immune responses. 
intranasal 
intramuscular 
(Singh, et al., 
2006)  
methoxyPEG–
poly(lactide-co-
glycolide) 
recombinant 
hepatitis B surface 
antigen (HBsAg) 
Delivery of HBsAg encapsulated within a nanoparticle is a superior way for 
generating faster immune responses, as compared to the non-
encapsulated counterpart. 
intraperitoneal  (Bharali, et al., 2008)  
poly lactic acid-PEG HBsAg 
Different compositions of PLA and PEG polymers were synthesized to 
stabilize the antigen. A comparison of their efficacy in the generation of 
effective immune responses is shown. 
nasal (Jain, et al., 2009)  
poly(γ-glutamic 
acid)-graft-L-
phenylalanine 
japanese 
encephalitis (JE) 
vaccine 
A single dose of JE vaccine with nanoparticles enhanced the neutralizing 
antibody titer.  intraperitoneal  
(Okamoto, et 
al., 2008)  
poly(γ-glutamic 
acid)-graft-l-
phenylalanine 
influenza 
hemagglutinin (HÁ) 
vaccine 
Subcutaneous immunization with a mixture of HA vaccine and 
nanoparticles induced higher mononuclear cell proliferation and production 
of IFN-γ, IL-4, and IL-6 upon HA restimulation. 
subcutaneous (Okamoto, et 
al., 2007)  
poly (d,l-lactide-co-
glycolide)–
polyethyleneimine 
DNA encoding 
Mycobacterium 
tuberculosis latency 
antigen Rv1733c 
The polyplexes were able to mature human dendritic cells and stimulated 
the secretion of cytokines, comparable to levels observed after 
lipopolysaccharide stimulation. 
intramuscular 
endotracheal 
(Bivas-Benita, 
et al., 2009)  
hydrophobically 
modified poly(γ-
glutamic acid) 
gp120 (human 
immunodeficiency virus 
-1) 
The protein-encapsulated nanoparticles induced cytotoxic T lymphocyte. 
Efficient uptake by immature DCs and induction of DCs maturation was 
observed. 
intranasal (Akagia, et al., 2007)  
chitosan 
DNA vaccine 
encoding mite dust 
allergen Der p 2 
Chitosan-DNA nanoparticles can generate a higher level expression of 
gene in vivo, therefore can preferentially activate specific Th1 immune 
responses thus preventing subsequent sensitization of Th2 cell-regulated 
specific IgE responses. 
oral (Li, et al., 2009b)  
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Table 1.2- cont. 
Polymer Antigen Remarks Route References 
chitosan 
plasmid DNA 
encoding surface protein 
of Hepatitis B virus 
(pRc/CMV-HBs(S)) 
Administration of nanoparticles resulted in serum anti-HBsAg titre and 
induced sIgA titre in mucosal secretions. Chitosan nanoparticles were able 
to induce humoral mucosal and cellular immune responses.  
nasal  (Khatri, et al., 2008)  
chitosan 
DNA plasmids 
expressing different M. 
tuberculosis epitopes 
Chitosan nanoparticles protect DNA from degradation by nucleases, induce 
dendritic cells maturation and increased IFN-γ secretion from T cells.   pulmonary 
(Bivas-Benita, et 
al., 2004)  
chitosan 
pcDNA3-VP1, 
encoding VP1, major 
structural 
protein of 
coxsackievirus (CVB3) 
Nasal administrated chitosan–DNA produced higher levels of serum IgG 
and mucosal secretory IgA. Strong cytotoxic T lymphocyte activities helped 
to effectively eliminate CVB3 viruses. 
intranasal (Xu, et al., 2004)  
low molecular 
weight chitosan 
(LMWC) 
plasmid DNA 
encoding human 
cholesteryl ester transfer 
protein C-terminal 
fragment  
LMWC had lower binding affinity to DNA, but mediated higher transfection 
efficiency. Polyplexes could elicit significant systemic immune responses, 
modulate the plasma lipoprotein profile and attenuate the progression of 
atherosclerosis. 
intranasal (Yang, et al., 2009)  
mono-N-
carboxymethyl 
chitosan  
N-trimethyl 
chitosan  
tetanus toxoid Surface charge and particle size exert an important influence in the production of an enhanced immune response.  intranasal 
(Sayin, et al., 
2008)  
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1.3.4 Gene delivery 
Nucleic acid-based biopharmaceuticals, such as pDNA, oligonucleotides (ODNs) and 
short interfering RNA (siRNA), are potential pioneering materials to cope with various 
incurable diseases. Cationic polymers condense DNA into nanosized polymer/DNA 
complexes (polyplexes), by a self-assembling process, consisting on the electrostatic 
interaction of the positively charged polymer with the negatively charged DNA. 
Polyplexes may interact with the negatively-charged cellular membrane, being 
internalized via endocytosis. In the intracellular environment, the polyplexes are normally 
located in endosomes that become acidified and finally fuse with lysosomes. In this case, 
DNA is prone to degradation by lysosomal enzymes. In order to transfer their DNA cargo 
successfully to the nucleus, polyplexes must escape from the endosome. After 
endosomal escape, polyplexes are located in the cytoplasm, ready to unpack DNA and 
deliver it to a suitable site near the nucleus or in the nucleus. Finally, after the DNA 
translocation into the nucleus, gene expression must occur. The low efficiency of 
polymer-mediated gene delivery may be due to the lack of mechanisms to overcome the 
physiological barriers. Cationic polymers need to have multiple functions to overcome 
these barriers, such as good DNA binding ability to condense DNA into polyplexes, high 
buffer capacity to induce endosomal escape and efficient intracellular vector unpacking to 
release DNA (Middaugh, et al., 2003). Therefore, understanding of the correlations 
between polymeric functionalities and gene delivery properties is important for the 
rational design of efficient cationic polymeric vectors.  
RNA may be advantageously used instead of DNA for gene delivery purposes. First, 
the delivery target is the cytosol, not the nucleus. Cytosol delivery is by far easier and 
more efficient than nucleus delivery. Quite recently, siRNA has emerged as a more 
powerful therapeutic genetic agent (Kim, et al., 2006). High sequence specificity and 
relatively small dose requirement of siRNA make it even more attractive. The most 
challenging hurdles are serum instability during circulation in the bloodstream (Chapman, 
2002), poor cellular uptake, and limitation in targeted delivery to specific tissues or cells. 
To address such problems, natural or synthetic polymeric delivery systems have been 
used. The natural polymers investigated for gene therapy include chitosan, collagen, 
gelatin and their modified derivatives (Dang, et al., 2006) (Table 1.3). Among the 
synthetic polymers, poly(l-lysine) or polyethylenimine and their analogs have been widely 
used (Park, et al., 2006) (Table 1.4).  
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Table 1.3.Natural-based polymers for gene delivery 
Polymer Therapeutic agent Target Remarks References 
chitosan 
sense or antisense 
oligodeoxynucleotides 
(ODNs) against malarial 
topoisomerase II gene 
-- 
Antisense-nanoparticles demonstrate a significant higher inhibition of human 
malaria parasite, as comparison with sense-nanoparticles and free ODNs. More 
easily dissociated complexes mediate a faster onset of action. 
(Foger, et al., 
2006)  
folate-N-trimethyl 
chitosan 
pDNA folate Folate conjugation increased intracellular uptake, transfection efficiency and induce endosomal escape. 
(Zheng, et al., 
2009)  
folic acid-chitosan pDNA (pVR1412) folate Nanoparticle with positive zeta potentials interact with the cell membrane allowing their endocytosis. 
(Mansouri, et 
al., 2006)  
Galactosylated 6-
amino-6-
deoxychitosan 
pDNA (pCMV-Luc) galactose 
The increase of transfection eﬃciency of Gal-6ACT was therefore likely due to 
improvements in intracellular traﬃcking and not due to the increase of cellular 
uptake., 
(Satoh, et al., 
2007)  
chitosan/hyaluroni
c acid 
pDNA(pEGFP-C1, 
pβ-gal) hyaluronan 
Polyplexes were able to provide high transfection without affecting cell viability, 
entering the corneal epithelial cells by CD44 receptor–mediated endocytic 
uptake.  
(Fuente, et al., 
2008)  
mannosylated 
chitosan pDNA (pGL3-Luc) mannose 
Cellular uptake mediated by mannose recognition. Reduced toxicity and high 
transfection efficiency. 
(Hashimoto, et 
al., 2006)  
chitosan –IL-1Ra 
folate- IL-1Ra- 
Chitosan 
IL-1Ra plasmid DNA folate 
Folate-chitosan-DNA nanoparticles containing the IL-1 Ra gene prevent bone 
damage and inflammation in rat adjuvant-induced arthritis model that 
overexpress folate receptors. 
(Fernandes, et 
al., 2008)  
PEG-Chitosan 
pDNA (pRE-
luciferase; pREP4;pCMV-
luciferase) 
transferrin 
KNOB 
protein 
The transfection efficiency was much impressive with KNOB (130-fold 
improvement), in HeLa cells. Chitosan exhibited limited buffering capacity. The 
clearance of the PEGylated nanoparticles was slightly slower than that of the 
unmodified nanoparticles. 
(Mao, et al., 
2001)  
chitosan plasmid pGL3-Luc -- Polyplexes are endocytosed and possibly released from endosomes due to 
swelling of both lysosomes and polyplexes, causing the endosome rupture. 
(Ishii, et al., 
2001)  
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Table 1.3- cont. 
Polymer Therapeutic 
agent Target Remarks References 
chitosan 
pDNA (pAAV-
tetO-CMV-mEpo and  
pCMVβ) 
-- Oral gene therapy was efficient in delivering genes to enterocytes. (Chen, et al., 2004)  
thiolated Chitosan 
pDNA (pEGFP-
N2) -- 
Improved gene delivery in vitro as well as in vivo. The extended pDNA release and 
subsequent gene expression were achieved by oxidation of introduced thiol groups to 
crosslink the thiolated chitosan.  
(Lee, et al., 
2007)  
quaternized 
(trimethylated) 
chitosan oligomer 
pDNA (pEGFcp1-
GFP) -- 
Transfection efficiency decreases increasing the degree of quaternization. The 
polymer effectively transfers the GFP gene into cells both in vitro and in vivo. 
(Zheng, et al., 
2007)  
6-N,N,N-
trimethyltriazole 
chitosan 
pDNA (EGFP-N1) -- 
The presence of the trimethyltriazole group led to significantly increased cellular 
uptake, which resulted in higher transfection efficiency in HEK 293 and MDA-MB-468 
cells. 
(Gao, et al., 
2009)  
methoxy PEG–
PEI–chitosan  pDNA (pVRfat-1) -- 
The mPEG increased the slow-releasing ability and water solubility, while PEI 
improved the transfection efficiency.  
(Xu, et al., 
2009b)  
chitosan/ poly(γ-
glutamic acid) (γ-
PGA) 
pDNAs (pEGFP-
N2, pGL4.13 and 
pEGFP-N2) 
-- 
The incorporation of γ-PGA in the chitosan nanoparticles facilitates the dissociation of 
chitosan and DNA, increasing transfection efficiency. Trypsin-cleavable proteins in 
cellular membrane affect internalization of polyplexes. 
(Peng, et al., 
2009)  
methylated 
collagen pDNA (pRELuc) -- 
Methylated collagen improved DNA binding ability and the stability of the complexes 
at physiological conditions, as compared with unmodified native collagen.  
(Wang, et al., 
2004)  
cationized gelatin 
plasmid DNA of 
transforming growth 
factor-βR (TGF-βR) 
siRNA expression 
vector 
-- 
The injection of polyplexes significantly decreased the level of TGF-βR and α-smooth 
muscle actin over-expression, the collagen content of mice kidney, and the fibrotic 
area of renal cortex, in contrast to free plasmid DNA injection. 
(Kushibiki, et 
al., 2005)  
PEG–modified 
thiolated gelatin pDNA (EGFP-N1) -- 
Nanoparticles released encapsulated plasmid DNA in response to varying 
concentrations of glutathione. 
(Kommareddy, 
et al., 2007)  
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Table 1.3- cont. 
Polymer Therapeutic agent Target Remarks References 
chitosan 
sense or antisense 
oligodeoxynucleotides 
(ODNs) against 
malarial topoisomerase 
II gene 
-- 
Antisense-nanoparticles demonstrate a significant higher inhibition of 
human malaria parasite, as comparison with sense-nanoparticles and free 
ODNs. More easily dissociated complexes mediate a faster onset of action. 
(Foger, et al., 
2006)  
folate-N-trimethyl 
chitosan 
pDNA folate Folate conjugation increased intracellular uptake, transfection efficiency 
and induce endosomal escape. 
(Zheng, et al., 
2009)  
folic acid-chitosan pDNA (pVR1412) folate Nanoparticle with positive zeta potentials interact with the cell membrane 
allowing their endocytosis. 
(Mansouri, et al., 
2006)  
Galactosylated 6-
amino-6-
deoxychitosan 
pDNA (pCMV-Luc) galactose 
The increase of transfection eﬃciency of Gal-6ACT was therefore likely 
due to improvements in intracellular traﬃcking and not due to the increase 
of cellular uptake., 
(Satoh, et al., 
2007)  
chitosan/hyaluroni
c acid 
pDNA(pEGFP-C1, 
pβ-gal) hyaluronan 
Polyplexes were able to provide high transfection without affecting cell 
viability, entering the corneal epithelial cells by CD44 receptor–mediated 
endocytic uptake.  
(Fuente, et al., 
2008)  
mannosylated 
chitosan pDNA (pGL3-Luc) mannose 
Cellular uptake mediated by mannose recognition. Reduced toxicity and 
high transfection efficiency. 
(Hashimoto, et al., 
2006)  
chitosan –IL-1Ra 
folate- IL-1Ra- 
Chitosan 
IL-1Ra plasmid 
DNA folate 
Folate-chitosan-DNA nanoparticles containing the IL-1 Ra gene prevent 
bone damage and inflammation in rat adjuvant-induced arthritis model that 
overexpress folate receptors. 
(Fernandes, et al., 
2008)  
PEG-Chitosan 
pDNA (pRE-
luciferase; 
pREP4;pCMV-
luciferase) 
transferrin 
KNOB protein 
The transfection efficiency was much impressive with KNOB (130-fold 
improvement), in HeLa cells. Chitosan exhibited limited buffering capacity. 
The clearance of the PEGylated nanoparticles was slightly slower than that 
of the unmodified nanoparticles. 
(Mao, et al., 2001)  
chitosan plasmid pGL3-Luc -- Polyplexes are endocytosed and possibly released from endosomes due to 
swelling of both lysosomes and polyplexes, causing the endosome rupture. (Ishii, et al., 2001)  
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Table 1.4. Polyethylenimine (PEI) and poly(l-lysine) (PLL)-based polymers for gene delivery 
Polymer Therapeutic 
agent Target Remarks References 
PEG-PEI 
(NanoGelTM) 
antisense 
oligonucleotide (ODN) 
targeting the mdr1 gene 
transferrin 
insulin 
Transport efficacy across the blood-brain barrier is increased by 
modification with transferrin or insulin. Improvement of ODN 
accumulation in the brain (15 fold). 
(Vinogradov, et 
al., 2004) 
lactoferrin-PEI pDNA lactoferrin 
Selectivity for bronchial epithelial cells. Lower cellular toxicity of 
polyplexes and higher transfection efficiency (5-fold higher), as 
compared with PEI/pDNA complexes. 
(Elfinger, et al., 
2007)  
RGD-PEG-PEI siRNA inhibiting VEGF receptor-2 RGD 
Selective tumor uptake, siRNA sequence-specific inhibition of protein 
expression within the tumor and inhibition of both tumor angiogenesis 
and growth rate. 
(Schiffelers, et al., 
2004)  
PEI-g-PEG-RGD pDNA (pCMV-sFlt-1) RGD 
Efficient inhibition on proliferation of endothelial cells that expressed 
sFlt-1 predominantly bound to exogenous VEGF and blocked the 
binding of VEGF to the full-length Flt-1 receptor. 
(Kim, et al., 
2005a)  
siRNA-PEG-
LHRH/PEI 
siRNA (VEGF-
vascular endothelial 
growth factor) 
luteinizing 
hormone- releasing 
hormone (LHRH) 
Enhancement of cellular uptake, as compared to those without LHRH, 
resulting in increased VEGF gene silencing efficiency via receptor-
mediated endocytosis. 
(Kim, et al., 
2008b)  
EGF-PEG-PEI pDNA (pCMVLuc) epidermal growth factor (EGF) peptides 
EGF-containing polyplexes were 10- to 100-fold more efficient than 
polyplexes without EGF. 
(Blessing, et al., 
2001)  
PEI pDNA Peptide (NL4-10K) 
Polyplexes displayed no toxicity in neuronal cells. Enhancement of 
gene expression (up to 1000-fold) and transfection efficiency (59-fold 
higher), in dorsal root ganglia, compared to nontargeting polyplexes. 
(Zenga, et al., 
2007)  
PEI-g-Clenbuterol pDNA (pCMVLuc) β2-adrenoceptor (clenbuterol) 
Specific cellular uptake into alveolar (transfection efficiency 14-fold 
higher than for unmodified PEI) but not bronchial epithelial cells. 
(Elfinger, et al., 
2009)  
folate–PEG–PEI pDNA (pCMV-Luc or pcDNA/rev-caspase-3) folate 
Higher transfection efficiency than other commercially available 
transfection agents. 
(Chul Cho, et al., 
2005)  
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Table 1.4- cont. 
Polymer Therapeutic 
agent Target Remarks References 
PEI-PEG-Fab’ pDNA (pCMVLuc) 
anti- glutamic 
acid decarboxylase 
(GAD) 
Selectivity toward the islet cells. High transfection efficiency in GAD-
expressing mouse insulinoma cells. 
(Jeong, et al., 
2005)  
HerPEI 
pDNA(pcDNA3-
CMV-Luc) anti-HER2 
The HerPEI polyplexes showed significantly greater transfection activity 
(up to 20-folds) than nonderivatized PEI-based polyplexes in the HER2 
overexpressing breast cancer cells. 
(Chiu, et al., 2004)  
mannose-PEI pDNA mannose 
Dendritic cells transfected with polyplexes containing adenovirus 
particles are effective in activating T cells of T cell receptor transgenic 
mice in an antigen-specific fashion. 
(Cotten, 1999)  
methoxypolyethylen
eglycol-PEI-
cholesterol 
pDNA (pmIL-12) -- Inhibition of tumor growth enhanced when combined with specific 
chemotherapeutic agents. 
(Fewell, et al., 
2005)  
dextran-PEI pDNA -- 
Stability of the complex in the presence of BSA. The transfection 
efficiency depended on the molecular weight of dextran and the grafting 
degree. 
(Tseng, et al., 
2003)  
acid-labile PEI pDNA (pCMV-Luc) -- 
The acid-labile PEI was much less toxic and showed comparable 
transfection efficiency to that of PEI25K. Polyplexes may be rapidly 
degraded in acidic endosome. 
(Kim, et al., 2005b)  
disulfide-crosslinked 
low molecular 
weight linear PEI- 
sodium hyaluronate 
pDNA (pBR322, 
pEGFP-C1) -- 
Polyplexes achieved significantly higher transfection efficiency than other 
polymer systems, especially in the presence of serum. (Xu, et al., 2009a)  
galactosylated PLL pDNA (pCAT) galactose 
Hepatoma cell line revealed high gene expression. After intravenous 
injection, polyplexes were rapidly eliminated from the circulation and 
preferentially taken up by the liver’s parenchymal cells. 
(Hashida, et al., 
1998)  
Lactosylated PEG-
siRNA/PLL RNAi lactose 
pH-responsive and targetable polyplexes exhibited significant gene 
silencing human hepatoma cells. (Oishi, et al., 2005)  
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Table 1.4- cont. 
Polymer Therapeutic 
agent Target Remarks References 
AWBP-PEG-PLL pDNA (pMNK) Artery wall binding peptide (AWBP) 
High transfection efficiency in bovine aorta endothelial cells and smooth 
muscle cells. (Nah, et al., 2002)  
Antibody-PLL pDNA(pSV-b-galactosidase) Anti JL1 
Polyplexes internalization into Molt 4 cells and human leukemia T cells.  
Higher in vitro transfection efficiency than polyplexes without targeting 
ligand. 
(Suh, et al., 2001)  
RGD-PEG-block-
PLL 
pDNA RGD 
Synergistic effect of cyclic RGD peptide and disulfide cross-links toexert 
the smooth release of pDNA in the intracellular environment via 
reductive cleavage. Enhanced transfection efficiency against HeLa cells, 
due to a change in their intracellular trafficking route. 
(Oba, et al., 2008)  
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Other synthetic alternative nano-carriers have been synthesized, engineered with 
linkages envisaging physiological degradation (Table 1.5). Specific targeting moieties 
may be conjugated to confer tissue specificity. Chitosan has emerged as an alternative 
non viral gene delivery system. The transfection efficiency of chitosan/DNA complexes is 
dependent on several factors: chitosan degree of acetylation and molecular weight 
(Huang, et al., 2005, Sato, et al., 2001, Wang, et al., 2007b), amine/phosphate ratio of 
chitosan/DNA complexes (Kim, et al., 2004, Weecharangsan, et al., 2008), serum 
concentration, pH (Sato, et al., 2001) and cell type (Bhattarai, et al., 2008, Corsi, et al., 
2003). Chitosan derivatives (glycol, o-carboxymethyl, trimethylated, thiolated and 6-
N,N,N-trimethyltriazole chitosan) including hydrophobic modifications (deoxycholic acid, 
5β-cholanic acid, N-acylated chitosan) have been used to overcome the limited chitosan 
solubility and improve transfection efficiency. Concerning biodegradation, chitosan is 
degraded into oligomers by lysozyme, and then further degraded by N-acetyl-
glucosaminidase, in animal cells. Both of these enzymes are present in the 
endosomal/lysosomal vesicles, thus the degradation and release of pDNA will start 
immediately after endocytosis of the chitosan polyplexes. Additionally, lysozyme is 
present at inflammation sites, which allow specific release. The chitosan cytotoxicity is 
lower than that of polyethylenimine, supporting the suggestion that chitosan may be a 
nontoxic alternative to polyethylenimine (Koping-Hoggard, et al., 2001). 
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Table 1.5. Other synthetic polymers for gene delivery 
Polymer Therapeutic agent Remarks References 
poly(imidazole/ 2-
dimethylaminoethylamino)
phosphazene 
pDNA Imidazole effect on cytotoxicity and transfection efficiency. Evaluation of half-lives under neutral and acidic conditions. (Yang, et al., 2008)  
poly[α-(4-aminobutyl)-L-
glycolic acid] (PAGA) 
pDNA( pCAGGS-Il10, 
pCAGGS-Il4) 
Combined administration of mouse Il4 and Il10 plasmids prevents the 
development of autoimmune diabetes in nonobese diabetic mice. (Ko, et al., 2001)  
poly(4-hydroxy-L-proline 
ester) pDNA(CMV-βGal) 
The minimum viability of cells incubated with poly(4-hydroxy-L-proline ester) 
was 85%, which is excellent when compared to the cases of polylysine 
(20%) and polyethylenimine (2%). 
(Putnam, et al., 
1999)  
poly(amido amine)s 
containing multiple 
disulfide linkages 
pDNA Buffer capacity of poly(amido amine)s in the pH range 7.4-5.1. High transfection efficiency and gene expression, in the presence of serum. (Lin, et al., 2007a)  
cationic amphoteric 
polyamidoamine pDNA (pEGFP) 
Evaluation of toxicity and hemolytic activity in the pH range 4.0-7.4. 
Circulation time and organ accumulation assessment. Study of complex 
stability and transfection efficiency 
(Ferruti, et al., 
2007)  
three blocks of amino 
acids Ac-(AF)6-H5-K15-
NH2 (FA32) 
doxorubicin, pCMV-
luciferase, pCMV-p53 
Co-delivery of drug and gene using nanoparticles was demonstrated via 
confocal imaging, luciferase expression in the presence of doxorubicin, and 
synergy in cytotoxic effect towards HepG2 cells. 
(Wiradharma, et al., 
2009)  
N,N-
diethylethylenediamine-
polyurethane 
pDNA (pCMV-βgal) Cytotoxicity was substantially lower and transfection efficiency comparable to the well-known gene carrier poly(2-dimethylaminoethyl methacrylate (Yang, et al., 2004)  
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Polyethylenimine (PEI), often considered the gold standard of gene transfection, is one 
of the most prominent examples of cationic polymers capable of gene transfection. The 
transfection efficiency of PEI has been related to the buffering effect exerted by the 
amines, with different pKa values, over a wide range of pH. This buffering ability gives 
PEI an opportunity to escape the endosome (proton sponge effect) (Boussif, et al., 1995). 
PEI, as poly-L-lysine (PLL), often show a relatively high cytotoxicity and, depending on 
the ionic strength, a tendency to aggregate and precipitate (Pasumarthy, et al., 2001). 
The conjugation with PEG prevents the inter-particular aggregation of the complexes, 
increasing their stability (Choi, et al., 1998, Petersen, et al., 2002). 
The non-degradability of non-viral carriers may represent a major limitation, since it 
implies they are not removed by physiological clearance systems and, therefore, can 
possibly accumulate within cells or tissues, eliciting further cytotoxicity. The backbone 
linkages of most polymeric gene carriers consist of a –C–C– bond or amide bond, which 
are not degraded in physiological solutions. Additionally, the biodegradation of the 
polymer may provide an extra tool to release the plasmid DNA into the cytosol. In an 
effort to develop alternative non-toxic and effective nano-carriers modified polymers, with 
functional groups labile under physiological conditions (ester, phosphorus or disulfide 
bonds), were produced. The use of the disulfide bond as bioreducible linker has received 
much attention in recent years (Lin, et al., 2006, Oupicky, et al., 2002). The disulfide bond 
can be cleaved intracellularly by reducing enzymes such as glutathione reductase and 
sulfhydryl components like glutathione. Since the concentration of these reducing species 
is much higher in the cytoplasm than in plasma (intracellular versus extracellular 
glutathione concentration 0.5–10 mM versus 2–20 µM) (Lin, et al., 2008), the disulfide 
bond is relatively stable in the extracellular environment, but rapidly degradable inside the 
cells, due to the higher amounts of thiols. To achieve high efficiency of polymer-mediated 
gene delivery, endosomal escape is required. This mechanism can be improved with the 
addition of chloroquine or membrane-active peptide (Wolfert, et al., 1998). An alternative 
method to promote endosomal lysis consists in engineering the carrier cationic polymers 
with histidine or imidazole groups. The transfection enhanced activity is assigned to the 
imidazole heterocycle, which displays a pKa around 6, thus possessing a buffering 
capacity at the endolysosomal pH (Yang, et al., 2008). 
Anti-angiogenic therapy has become an important route for cancer treatment. Among 
factors that regulate angiogenesis, the vascular endothelial growth factor (VEGF) 
appears to be the most critical regulator of tumor-induced angiogenesis, which is 
essential for the survival of rapidly proliferating cancer cells and sustained growth of 
General Introduction | Chapter 1 
Gonçalves, C. | 2010 35 
tumor. For this purpose, a PEG-conjugated VEGF-siRNA was complexed with 
polyethylenimine. Intravenous as well as intratumoral administration of these polyplexes 
significantly inhibited VEGF expression at the tumor tissue, suppressing tumor growth in 
an animal tumor model, without showing any detectable inflammatory responses in mice 
(Kim, et al., 2008c).  
Multidrug resistance remains a major barrier to the success of anticancer 
chemotherapy (Teicher, 2009). Overexpression of drug efflux transporters, such as P-
glycoprotein, enables cancer cells to develop resistance to multiple anticancer drugs. A 
novel approach to overcome drug resistance consist in using the siRNA-mediated 
silencing the expression of the efflux transporter. Because P-glycoprotein plays an 
important role in the physiological regulation of endogenous and xenobiotic compounds, it 
is important to deliver the P-glycoprotein targeted siRNA (associated with anticancer 
drugs) specifically to tumor cells. Recent studies have shown that nanoparticles 
formulated with poly(D,L-lactide-co-glycolide) and polyethyleneimine result in sustained 
siRNA delivery and efficient gene silencing Nanoparticles were surface functionalized 
with biotin for active tumor targeting. In vivo studies, in a mouse model of drug-resistant 
tumor, demonstrated significantly greater tumor growth inhibition following treatment with 
biotin-functionalized nanoparticles encapsulating both paclitaxel and P-glycoprotein 
targeted siRNA. Remarkably, this effect was obtained using a paclitaxel dose ineffective 
in the absence of gene silencing (Patil, et al., 2010). Recently, dual nanogels, for co-
delivery of drug and gene, were synthesized and evaluated as carriers (Wang, et al., 
2007a, Wiradharma, et al., 2009). Inhibition of ret/PTC1 oncogene, in the papillary thyroid 
carcinoma, has been achieved after administration of siRNA using chitosan-coated 
biodegradable poly(isobutylcyanoacrylate) nanoparticles. The nanoparticles protect the 
ret/PTC1 siRNA from in vivo degradation, leading to significant tumor growth inhibition 
after intratumoral administration, correlated to reduced ret/ PTC1 levels(Martimprey, et 
al., 2008). 
A novel approach for the control of inflammation in rheumatoid arthritis was reported. 
The strategy consisted in using chitosan/siRNA nanoparticle to silence the TNF-α 
expression in peritoneal macrophages. The nanoparticles, containing an unmodifed anti-
TNF-α DsiRNA, mediated TNF-α knockdown (~66%) in primary peritoneal macrophages, 
in vitro. Histological analysis of joints revealed minimal cartilage destruction and 
inflammatory cell infiltration in anti-TNF-α-treated mice. Therefore, nanoparticle-mediated 
TNF-α knockdown in peritoneal macrophages may be a method to reduce local and 
systemic inflammation, and a novel strategy for arthritis treatment(Howard, et al., 2009). 
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Other approach hypothesized that IL-1Ra (Interleukin-1 receptor antagonist) gene 
delivery can defend against inflammatory bone turnover, in rheumatoid arthritis patients.  
As compared to naked DNA and chitosan–DNA, folate–chitosan–DNA nanoparticles were 
less cytotoxic and enhanced IL-1Ra protein synthesis in vitro, offering a better protection 
against inflammation and abnormal bone metabolism in vivo (Fernandes, et al., 2008). 
Prevention of Respiratory Syncytial Virus (RSV) bronchiolitis, potentially reducing the 
later development of asthma associated with severe respiratory infections, was also 
evaluated using gene therapy. Plasmids expressing a short interfering RNA against the 
RSV-NS1gene (siNS1), were complexed with chitosan. Treatment of rats with siNS1, 
prior to RSV exposure, was effective in reducing virus titers in the lung, preventing the 
inflammation and airway hyperresponsiveness associated with the infection and asthma 
development (Kong, et al., 2007). Similary, topical delivery of 5% imiquimod cream mixed 
with siRNA for natriuretic peptide receptor A (siNPRA) nanoparticles protected against 
asthma. In a mouse asthma model, the treatment with a imiquimod cream - containing 
siNPRA chitosan nanoparticles - significantly reduced the airway hyperresponsiveness, 
eosinophilia, lung histopathology and pro-inflammatory cytokines IL-4 and IL-5 in lung 
homogenates. By combining the treatment of imiquimod and siNPRA nanoparticles, a 
better protection against airway inflammation was achieved (Wang, et al., 2008). 
The feasibility of applying nanotechnology against Plasmodium falciparum, malarial 
parasites, was also investigated using antisense ODNs against malarial topoisomerase II 
gene, incorporated in chitosan nanoparticles. The in vivo use of nanoparticles against 
malaria is possible only if they are harmless to red blood cells. The erythrocyte 
membrane contains anionic glycoproteins, which can interact with protonated amino 
groups of chitosan. This process induces a curvature of the cell membrane, leading to 
rupture and hemoglobin release. In the presence of plasma, however, the membrane 
damage is reduced, an effect that might be explained by adsorption of negatively charged 
plasma proteins on the surface of charged particles; the plasma shielding effect suggests 
that chitosan nanoparticles indeed do not harm erythrocytes in vivo. Nanoparticles with 
negative surface charge exhibited a significantly stronger inhibitory effect (∼87% 
inhibition) on the parasite growth in comparison to the positive ones (∼74% inhibition) or 
free ODNs (∼68% inhibition). This was the first study demonstrating the susceptibility of 
human malaria parasite to antisense nanoparticles (Foger, et al., 2006). 
In conclusion, nanoparticulate systems are new tools that promise a revolution in the 
field of drug delivery. Nanodevices are suited to achieve the ideal of a controlled and 
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targeted release of bioactive molecules. Among the available nanosystems, self-
assembled polymeric nanogels are particularly attractive, since they are easy to produce, 
affordable, and may effectively incorporate a variety of drugs, including 
biopharmaceuticals. Furthermore, they may be decorated with different kinds of 
molecules, improving the stability and target ability. 
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2. Self –assembled nanoparticles of dextrin 
substituted with hexadecanethiol 
 
Adapted from Biomacromolecules (2007) 8, 392-398 
he amphiphilic molecule dextrin-VA-SC16 (dexC16) was synthesized and 
studied in this work. DexC16 has a hydrophilic dextrin backbone with grafted 
acrylate groups (VA), substituted with hydrophobic 1-hexadecanethiol (C16). A versatile 
synthetic method was developed allowing control of the dextrin degree of substitution with 
the hydrophobic chains (DSC16, number of alkyl chains per 100 dextrin glucopyranoside 
residues). Materials with different DSC16 were prepared and characterized using 1H NMR. 
DexC16 self assembles in water through association of the hydrophobic alkyl chains, 
originating nanoparticles. The nanoparticles properties were studied by dynamic light 
scattering (DLS), fluorescence spectroscopy, and atomic force microscopy (AFM). 
 
T 
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2.1 Introduction 
Amphiphilic molecules, such as surfactants or lipids, spontaneously self-assemble in 
water, forming self-aggregates, such as micelles, bilayer membranes, tubes and vesicles. 
Amphiphilicity of biopolymers is one of the most important factors for their self-
organization in water. Among the different types of amphiphilic polymers, water-soluble 
polymers with hydrophobic molecules grafted on side chains have received special 
attention. By self-assembling, the hydrophobic segments are segregated from the 
aqueous exterior to form an inner core surrounded by hydrophilic chains. Polymeric 
micelles or nanoparticles with a hydrophobic core and hydrophilic shell are thus prepared. 
This kind of structure is suitable for trapping hydrophobic substances, such as fluorescent 
probes (Akiyoshi, et al., 1993), proteins (Akiyoshi, et al., 1998), and hydrophobic 
pharmaceuticals (Liu, et al., 2005). The size, density and colloidal stability of 
nanoparticles can be controlled by changing the degree of substitution of hydrophobes 
and its hydrophobicity (Akiyoshi, et al., 1996). The association mechanism is mainly 
governed by the alkyl side chain concentration and length and is little influenced by the 
molecular weight of the polymer backbone (Petit-Agnely, et al., 2000). However, with low 
molecular weight polymers, the hydrophobic aggregates are not connected via the 
polymer backbone (Petit-Agnely, et al., 1999). The study of nanogels (hydrogel 
nanoparticles) has intensified during the past decade due to enormous potential 
applications in the development and implementation of new environmentally responsive 
materials, biomimetics, biosensors, artificial muscles and drug delivery systems (Lee, et 
al., 2004). Solid nanoparticles made from biodegradable polymers have been widely 
investigated for long-term delivery of drugs (Hans, et al., 2005). They can potentially 
provide benefits such as increased therapeutic effect, prolonged bioactivity, controlled 
release rate, and finally decreased administration frequency, thereby increasing patient 
compliance. 
Nanostructures spontaneously form when the concentration of the polymer is higher 
than its critical micelle concentration (CMC). Self-assembly in water of a hydrophobically 
modified dextrin (dexC16) was investigated in this work. The structural change upon 
dilution of the dexC16 self-aggregates in water was investigated by fluorescence in the 
presence of pyrene as the fluorescent probe. Pyrene shows interesting photophysical 
properties due to the long lifetime of its monomers. Pyrene is one of the few condensed 
aromatic hydrocarbons which show significant fine structure (vibronic bands) in its 
monomer fluorescence spectra in solution. The vibrational fine structure intensities 
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undergo significant perturbations on going from nonpolar solvents to polar solvents with 
high permanent dipoles. The five predominant peaks of pyrene are numbered I-V, and 
peak III shows maximum variations in intensity relative to peak I. The I3/I1 ratio will be 
used for determination of the CMC (Nizri, et al., 2005). The CMC value depends mostly 
on the chemical structure of the amphiphilic polymer and the number of hydrophobic 
chains grafted on the polymer backbone. Other relevant properties of the nanoparticles, 
such as the size, stability, and shape, were also evaluated in this work. 
 
 
2.2 Experimental section 
2.2.1 Materials 
Dextrin-VA was synthesized by transesterification of dextrin with vinyl acrylate (VA) as 
described by Ferreira et al. (Ferreira, et al., 2002) for the transesterification of dextran 
with VA, with few modifications. The transesterification of dextran requires an enzyme 
(Proleather), but using dextrin as substrate the enzyme does not catalyse the 
transesterification. In this work, dextrin-VA with 20 acrylate groups per 100 dextrin 
glucopyranoside residues was used. Dimethyl sulfoxide (DMSO), triethylamine (TEA), 
and deuterium oxide (D2O) were from Aldrich. Regenerated cellulose tubular membranes, 
with 3500 MWCO, were obtained from Membrane Filtration Products. 
Pyrene (Py) was from Aldrich and was used after appropriate recrystallization. Distilled 
water was used for the preparation of aqueous solutions. 
2.2.2 Synthesis of dexC16 
Dextrin-VA and 1-hexadecanethiol were dissolved in dimethyl sulfoxide (equivalent VA 
= 0.0413 M). Different molar percentages of 1-hexadecanethiol (10%, 20%, 40%, 60%, 
and 100% relative to VA) were added to the reaction mixture in order to obtain different 
degrees of substitution (DS). Triethylamine (1 mol equiv to VA) was added to the reaction 
mixture. The medium was stirred for 24 h, at 50 ºC. The mixture was dialysed for 48 h 
against water with frequent water change. After freezing, the mixture was lyophilized and 
stored.  
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2.2.3 Sample preparation 
Lyophilized dexC16 was dissolved in water under stirring at 50 ºC and then further 
sonicated for 20 min until a clear solution was obtained. The degree of solubility of dexC16 
depends on the degree of substitution. Increasing the degree of substitution reduces the 
solubility. In the range of DSC16 used, to prepare a 1.0 g/dL solution, 3 h of stirring is the 
maximum time required to dissolve dexC16. 
2.2.4 Dynamic light scattering  
The size distribution was determined with a Malvern Zetasizer, MODEL NANO ZS 
(Malvern Instruments Limited, U.K.). A dispersion of nanoparticles in ultrapure water (1 
mL) was analysed at 25 ºC in a polystyrene cell using a Helium-Neon laser - wavelength 
of 633 nm and a detector angle of 173º. The dispersion was filtered through a 0.45 µm 
pore. 
2.2.5 1H NMR 
Lyophilized dexC16 was dispersed in deuterium oxide (1.0 g/dL). Solutions were 
transferred to 5 mm NMR tubes. 1D 1H NMR measurements were performed with a 
Varian Unity Plus 300 spectrometer operating at 299.94 MHz. 1D 1H NMR spectra were 
measured at 298 K with 80 scans, a spectral width of 4800 Hz, a relaxation delay of 1 s 
between scans, and an acquisition time of 3.75 s. 
2.2.6 Fluorescence spectroscopy 
Fluorescence measurements were performed on a Varian Cary Eclipse fluorescence 
spectrofluorometer using a quartz cell. The pyrene spectra were obtained using an 
excitation wavelength of 337 nm and recording the emission over the range 350-500 nm 
at a scan rate of 120 nm/min. The slit width was set at 20 nm for the excitation and 2.5 
nm for the emission. The fluorescence intensity, for each vibronic peak, was measured at 
the maximum of each peak. 
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2.2.7 Atomic force microscopy  
Tapping-mode imaging was carried out on a Nanoscope IIIa Multimode (Digital 
Instruments, Veeco) scanning probe microscope. A silicon tip doped with phosphorus, 
with a radius curvature of less than 10 nm (RTESP, VEECO), was used. This tip has a 
typical resonance frequency of 288-328 kHz and a typical force constant of 20-80 N/m. A 
scan rate of 1.4-1.8 Hz was sufficient to maintain a good signal-to-noise ratio. A drop of 
aqueous solution (0.01 g/dL) of dexC16 was placed on new-cleaved HOPG surface, 
thoroughly rinsed with water, and dried under a N2 flux.  
 
 
2.3 Results and discussion 
2.3.1 Synthesis of the dextrin-VA-SC16 
The reaction between the thiol moiety and the acrylate group of dextrin-VA is a 
Michael addition with thiol acting as a nucleophile (Scheme 2.1).  
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Scheme 2.1. Synthesis of DexC16. 
 
 
1H NMR was used to analyse the structure of the reaction product. The signals 
between 5.8 and 3.0 ppm in the 1H NMR spectrum of dextrin-VA are assigned to protons 
from the dextrin scaffold. The protons from the acrylate group, attached to the dextrin 
backbone are observed between 6.6 and 6.0 ppm (Ferreira, et al., 2002), as shown in 
Figure 2.1. The presence of two different positional isomers in dextrin-VA was revealed 
by the 1H-1H COSY and 1H-13C HMQC spectra. The two positional isomers are located at 
positions 2 and 3 in the glucopyranosyl residues (data not shown) in the main dextrin 
backbone. For the sake of simplicity, only the 2-O-acryloyl regioisomer is represented in 
Scheme 2.1.  
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Figure 2.1 1H NMR spectra of dextrin-VA (DSVA 20%) in D2O at 25 ºC. 
 
 
The reaction between the grafted acrylate and the thiol hexadecanethiol follows a 
mechanism of Michael addition. The intensity of the signals from protons of the 
unsaturated carbons of the acrylate groups decreases as the reaction progresses, and 
the signals should eventually disappear completely when all acrylate groups are grafted 
with thiol moieties. Simultaneously, a new signal assigned to the methylene protons 
should appear. Preliminary experiments were carried out without a base catalyst. 
Although it was possible to identify the signals corresponding to the grafted alkyl moiety, 
between 2.0 and 0.6 ppm, the acrylate protons are still detected. Using TEA as a catalyst, 
the signals from thiol moieties have higher intensity and the acrylate signals completely 
disappear, confirming the success of the synthesis (Figure 2.2). Therefore, a base 
catalyst must be used for a high reaction yield to be obtained. 
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Figure 2.2. 1H NMR spectra in D2O of dextrin-VA reacted with hexadecanethiol (a) without or (b) 
with TEA. 
In order to ascertain whether the thiol is covalently bound, dexC16 was washed several 
times with n-hexane. As no differences were detected in the 1H NMR analysis, it may be 
concluded that the alkyl chain is covalently bound to acrylate. 
DLS was also used to check the possibility of self-polymerization of acrylic groups at 
50 ºC. The size distribution of dextrin-VA in DMSO was evaluated before and after stirring 
at 50 ºC for 24 h. No differences were observed; therefore, the polymerization does not 
take place during the synthesis reaction. 
(a) 
(b) 
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2.3.2 Degree of substituion 
The synthesis of dexC16 with different degrees of substitution was accomplished by 
varying the molar ratio hexadecanethiol/VA in the reaction mixture. The 1H NMR 
spectrum of dexC16, in deuterated water, was used to determine the degree of 
substitution obtained (DSC16, amount of alkyl chains per 100 dextrin glucopyranoside 
residues). DSC16 was calculated as a peak area ratio in the NMR spectra, according to 
Equation 2.1: 
(Equation 2.1)   
 
where x is the average integral corresponding to the protons from alkyl moieties (2.0 - 
0.6 ppm) and y is the integral of all dextrin protons (3.0 - 5.8 ppm). Table 2.1 presents the 
DS values obtained for dexC16 and the respective efficiency. The data presented in Table 
2.1 correspond to the equilibrium position as it was verified by performing the assay with 
longer reaction times. 
 
Table 2.1. Dextrin degree of substitution obtained using different hexadecanethiol/VA molar 
ratio 
Theoretical DS a (%) Obtained DS b (%) Efficiency c (%) 
10 2 20 
20 4 20 
40 14 35 
60 23 38 
100 59 59 
a Calculated as the molar ratio of hexadecanethiol to acrylate groups (×100) in the reaction mixture. b 
Determined by 1H NMR. The value shown is the calculated using equation 2.1, and multiplied by 5 to obtain 
the DS relatively to acrylate groups. c Calculated as the ratio of the obtained to the theoretical DS (×100). 
 
These results demonstrate that the synthesis method is versatile, allowing production, 
in a simple two-step procedure, of materials with controlled amounts of grafted 
hydrophobes. Thus, fine tuning the properties of the materials is possible. Furthermore, 
different hydrophobic chemicals may be grafted (for instance thiocholesterol). 
100
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2.3.3 Formation of nanoparticles 
The dissolution of dexC16 in water is expected to give rise to micelle formation, owing 
to the amphiphilic nature of the molecule. The nanoparticles formation was accessed 
using both 1H NMR and AFM.  
Due to the limited mobility of the alkyl hydrophobic chains inside the nanoparticles, the 
shape and width of the 1H NMR  signals assigned to the alkyl chain protons (2.0 - 0.6 
ppm) are dependent on the solvent (D2O/DMSOd) used to record the 1H NMR spectra. 
The 1H NMR signals assigned to the methyl (0.8 ppm) and methylene (1.1 ppm) groups 
are sharp in DMSO (Figure 2.3a), which is a good solvent for dexC16. Progressive 
broadening at the base is noticeable as the percentage of water in D2O/DMSO mixtures 
increases (Figure 2.3b). In pure D2O extensive broadening is noticeable (Figure 2.3c). 
The shape of the 1H NMR alkyl chain signals in deuterated water is characteristic of a 
superposition of peaks representing a collection of chemically identical species yet 
possessing various degrees of mobility (Hrkach, et al., 1997). This result suggests that 
alkyl chains have different environments when dispersed in water. Some chains might be 
involved in hydrophobic microdomains (low mobility) with others remaining exposed to 
the hydrophilic solvent (high mobility). In DMSO, all hydrophobic chains are exposed to 
the solvent, having the same mobility. 
Figure 2.3. 1H NMR spectra of dexC16 (1.0 g/dL) in (a) DMSO-d6, (b) 10% D2O in DMSO-d6 and (c) 
D2O. 
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In addition, self-assembled particles were observed using AFM. The AFM images 
(Figure 2.4) reveal spherical nanoparticles. The AFM results indicate that, for dexC16 with 
DSC16 7.0%, the mean diameter of nanoparticles is roughly 20 nm. In general, the 
nanoparticles appear to have a narrow size distribution. 
 
Figure 2.4. Tapping mode AFM image of dexC16 (DSC16 7.0%) nanoparticles adsorbed on HOPG 
(or graphite) from aqueous solution (0.01 g/dL). 
2.3.4 Nanoparticles stability 
To evaluate the stability of nanoparticles, the size was determined by DLS at 25 ºC up 
to 56 days (Figure 2.5). 
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Figure 2.5. Colloidal stability of nanoparticles in water. The dexC16 (DSC16 7.0%) solution (0.1 
g/dL) was stored at 25ºC up to 56 days. The error bar is for standard deviation (n=5). 
Nanoparticles conserved their size during this study, indicating the high colloidal 
stability of nanoparticles in the aqueous medium. 
2.3.5 Size and size distribution  
The dynamic light scattering (DLS) studies were done using a Nano-ZS (Malvern) 
instrument. Solutions with different concentrations of dexC16 (DSC16 7.0%) were prepared 
by dilution of a 0.1 g/dL solution and analysed by DLS. The results are presented in 
Figure 2.6. DLS provides valuable information on the homogeneity of the dispersion. A 
single sharp peak in the DLS profile implies the existence of a single population of 
particles. The polydispersity index (PdI) is also helpful in the characterization of the size 
distribution. PdI-values close to 1 are indicative of heterogeneity.  
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Figure 2.6. Size distribution of dexC16 (DSC16 7.0%) aqueous dispersion (a) 0.01 and (b) 0.1 g/dL. 
 
Figure 2.6 shows that the dilution of the sample has an effect on the particle size in the 
concentration range used. The hydrodynamic diameter of the predominant population of 
nanoparticles increases slightly with decreasing concentration. The DLS results are in 
good agreement with AFM results presented above. The small nanoparticles with a 
diameter of around 10-15 nm are the predominant population.  
2.3.6 Critical micelle concentration  
Pyrene may be used as a fluorescent probe to detect aggregate formation (Nichifor, et 
al., 2004). The fluorescent properties of pyrene change when it is transferred from an 
aqueous environment to the hydrophobic microenvironment of the nanoparticles. Figure 
2.7 presents the fluorescence spectra of pyrene in water (1×10-6 M) and in the presence 
of dexC16. The CMC was determined from the change in the ratio of intensities of the third 
and first peak (I3/I1) in the emission spectra. 
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Figure 2.7. Emission spectra of (a) an aqueous solution of pyrene (1×10-6 M) and (b) an aqueous 
solution of pyrene (1×10-6 M) with dissolved dexC16 (DSC16 7.0%) at a polymer concentration of 
0.02 g/dL, λex = 337 nm. 
The pyrene concentration is in all experiments very low (1×10-6 M) to prevent excimer 
formation (detectable at ≈ 470 nm). The I3/I1 values, corresponding to samples with 
different polymer concentrations, were calculated and plotted in Figure 2.8. 
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Figure 2.8. Fluorescence intensity ratio I3/I1 as a function of the dexC16 (DSC16 7.0%) 
concentration. 
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At low polymer concentrations, I3/I1 is almost constant and equal to 0.62, i.e., pyrene 
experiences an aqueous environment. For higher polymer concentrations I3/I1 starts to 
increase, showing that pyrene senses a less polar environment due to its solubilization in 
the hydrophobic domains that are formed by self-assembly (for polymer concentration > 
0.0008 g/dL), where it senses a less polar environment. The curve is sigmoidal, as 
observed for other amphiphilic polymers. The ratio I3/I1 eventually reaches a constant 
value as there are enough nanoparticles to solubilise all pyrene molecules. The variation 
in pyrene fluorescence is due to the partition between water and the hydrophobic 
microdomains, until equilibrium (or probe saturation) occurs.  
The CMC determination from fluorescence data can be based on different 
assumptions, due to the relatively large concentration range over which the fluorophore 
response stretches. Different researchers have proposed the CMC as either the onset, 
the offset, or the midpoint of the increased fluorophore response ratio as a function of the 
polymer concentration (Nichifor, et al., 2004). In this study, the polymer concentration 
corresponding to the onset of the variation was considered the CMC as it indicates the 
onset of the association event (Figure 2.8). This event can be an incipient association of 
side-chain hydrophobes (at least the very first association of two hydrophobes). The 
results on Figure 2.8 demonstrate that a phase transition occurs when the polymer 
concentration increases (CMC of about 0.0008 g/dL) owing to a structural reorganization 
of the dissolved molecules that leads to formation of hydrophobic domains. Dissolution of 
pyrene in these domains results in higher fluorescence intensity and I3/I1 values. 
The variation in the particle sizes, as a function of the concentration, can also be 
studied by DLS. Figure 2.9 shows the particle size and the respective percent volume for 
dexC16 (DSC16 7.0%) at polymer concentrations ranging between 0.0001 g/dL and 0.1 
g/dL. 
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Figure 2.9. Size     and the respective percent volume () obtained in consecutive analysis for 
dexC16 (DSC16 7.0%) at (a) 0.0001 g/dL, (b) 0.001 g/dL, (c) 0.01 g/dL and (d) 0.1 g/dL. While in 
experiments a, c and d a consistent measure of the particles size was possible, for the 
concentration used in experiment b, close to CMC, the size detected varies from one 
measurement to another, suggesting that the material is unstable and particles with different 
size are present in the mixture. 
The particle size detected depends on the sample concentration, a dramatic reduction 
in size being detected as the concentration reaches CMC (as roughly estimated by DLS, 
and showing good agreement with the fluorescence experiments). The particles have a 
hydrodynamic diameter inferior to 20 nm for the higher concentrations (Figure 2.9c and d) 
and a hydrodynamic diameter of about 120 nm for the lower concentrations (Figure 2.9a). 
A transition is noticeable at about 0.001 g/dL (Figure 2.9b). Thus, it appears that the 
polymer is not very soluble, and probably aggregates are being detected in the DLS 
measurements for the low polymer concentration. In fact, dextrin – obtained from starch - 
is not very soluble, giving rise to colloidal dispersions in water. As the concentration 
increases, the hydrophobic domains give rise to formation of nanoparticles with a 
hydrophobic core (as shown in the fluorescence experiments). Apparently, nanoparticles 
(◊)      
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formation gives rise to a more compact structure induced by the hydrophobic force. The 
beginning of the association event seems to occur close to 0.001 g/dL, corresponding to 
the CMC, in good agreement with the fluorescence results.  
 
 
2.4 Conclusions 
In the present study we report the synthesis of a hydrophobized dextrin polymer, 
dexC16. The synthesis method is versatile as it allows controlling the degree of 
substitution with hexadecanethiol and therefore fine-tuning the properties of the materials. 
DexC16 self-aggregates in water, originating colloidally stable (over 2 months) 
nanoparticles with a narrow size distribution. A diameter of about 20 nm was determined 
by DLS and AFM. The CMC value, around 0.001g/dL, was determined using pyrene as a 
fluorescent probe and confirmed by DLS. The value determined is lower than that 
reported for the most common low molecular weight surfactants. The low CMC may be 
due to the low solubility of dextrin. Reaction of dextrin-VA with other (thiol) nucleophiles 
might open access to a variety of amphiphilic materials with tailored properties. 
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3. Characterization of the self-assembly 
process of hydrophobically modified 
dextrin 
 
Adapted from European Polymer Journal (2008) 44, 3529-3534 
ydrophobized dextrin, randomly substituted by long alkyl chain, forms stable 
hydrogel nanoparticles by self-assembling in water. Hydrophobic chains, 
distributed along the polymer backbone, promote the formation of hydrophobic 
microdomains within the nanoparticles. The influence of degree of substitution with 
hydrophobic chains (DSC16) on nanoparticles size, colloidal stability, density, aggregation 
number and nanoparticle weight was studied. Size distribution was also evaluated at 
different pH, urea concentration and ionic strength conditions. As shown by dynamic light 
scattering and transmission electron microscopy, the particles are spherical having a 
diameter of about 20 nm. The more substituted polymer forms more densely packed 
hydrophobic microdomains, such that the colloidal stability (in water and PBS buffer) of 
nanoparticles is increased. The knowledge of the aggregate building process and the 
characteristics of the nanoparticles are crucial for the design of drug delivery systems. 
 
H 
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3.1 Introduction 
Self-assembled hydrogel nanoparticles have potential biomedical and pharmaceutical 
application due to their biomimetic properties, i.e., their resemblance to biological 
macromolecules. Amphiphilicity is one of the important factors for the molecular self-
organization in water.  Various amphiphilic polymers, such as block copolymers (Chen, et 
al., 2006 a, b, Gaucher, et al., 2005, Letchford, et al., 2007, Liang, et al., 2006) and 
hydrophobized polymers (Na, et al., 2000, Roux, et al., 2007), have been synthesized 
and studied. Water-soluble polymers hydrophobically modified with hydrophobes grafted 
to the side chains have special interest. The hydrophobic chains lead to a self-assembly 
of the polymer, in water, promoting the formation of microdomains within the hydrogel 
nanoparticles. The microdomains solubilise therapeutic agents, namely hydrophobic 
drugs. Therefore, they can be used as drug delivery systems. 
The attention of the researchers has mainly focused on the preparation of drug-loaded 
polymeric nanoparticles by varying the polymer/drug ratio, and analysing the drug loading 
content, entrapment efficiency and drug release profiles. Less attention has been paid to 
the aggregate building process and to the characterisation of the aggregates. Such 
assemblies of amphiphilic macromolecules are of interest both for understanding of 
supramolecular assembly in nature and for designing new materials in biotechnology and 
medicine. The size, density and stability of the hydrogel nanoparticles may be controlled 
by changing the hydrophobic group, and also the degree of substitution (Akiyoshi, et al., 
1996, Nichifor, et al., 2004). Akiyoshi and others developed a variety of nanogels made of 
hydrophobized polysaccharides such as pullulan, mannan and dextran (Akiyama, et al., 
2007, Akiyoshi, et al., 1993, Kim, et al., 2000). 
In this work, dextrin derivatives were used for the preparation of self-assembled 
hydrogel nanoparticles, a new system reported in a previous work (Gonçalves, et al., 
2007). The hydrophobized polysaccharide form relatively monodisperse and colloidally 
stable nanoparticles (≈20 nm), in water, upon self-aggregation. The nanoparticles 
characteristics depend on the polymer concentration, degree of substitution with 
hydrophobic chains (C16), ionic strength and additives. One of the most fundamental and 
important structural parameters of micellar aggregates is the aggregation number, the 
average number of hydrophobic molecules in a micelle unit (Turro, et al., 1978, 
Vorobyova, et al., 2001). The aim of the present work is to study the aggregate building 
process and the characteristics of the nanoparticles formed. This fundamental information 
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enables us to design a useful nanosized delivery system suitable for carrier of 
hydrophobic drugs.  
 
 
3.2 Experimental section 
3.2.1 Materials 
Dextrin-VA-SC16 (dexC16) was synthesized as described previously (Gonçalves, et al., 
2007). In this work, dextrin-VA with 20 acrylate groups per 100 dextrin glucopyranoside 
residues (DSVA 20%) was used. 
Pyrene (Py) and cetylpyridinium bromide (CPB) were obtained from Aldrich. Pyrene 
was used after recrystallization. Ultra-pure water (Milli Q) was used for the preparation of 
aqueous solutions. 
3.2.2 Preparation of self-assembled nanoparticles 
Lyophilized dexC16 was dissolved in ultra-pure water under stirring, at 50 ºC, and then 
further sonicated for 20 min until a clear solution was obtained. The solution of self-
assembled nanoparticles was then filtrated through a 0.20 µm filter and stored at room 
temperature. 
3.2.3 Size distribution and zeta potential 
The size distribution, zeta potential and nanoparticle weight were determined with a 
Malvern Zetasizer, NANO ZS (Malvern Instruments Limited, U.K.), using a He-Ne laser 
(wavelength of 633 nm) and a detector angle of 173º. Size distribution and zeta potential 
were determined by dynamic light scattering (DLS). 
For size distribution measurements, a dispersion of nanoparticles in ultra-pure water or 
PBS buffer (1 mL) was analysed at 25 ºC in a polystyrene cell. The concentration of 
nanoparticles was adjusted by dilution with ultra-pure water of concentrated nanoparticle 
dispersion. 
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The DLS cumulants analysis provides the characterization of a sample through the 
mean value (z-avg) for the size, and a width parameter known as the polydispersity, or 
polydispersity index (PdI). The z-avg diameter is the mean hydrodynamic diameter, 
determined from the intensity of scattered light. The fundamental size distribution 
generated by DLS is an intensity distribution; this can be converted, using Mie theory, to 
a volume distribution. This volume distribution can also be further converted to a number 
distribution. In the present work, we will consider the z-avg as the best approach to the 
actual nanoparticles size. 
For zeta potential measurements, the aqueous solutions of nanoparticles at different 
pH values were obtained by dissolving dexC16 with DSC16 6.1% (0.1 g/dL) in phosphate-
citrate buffer (pH 2.2-8.0). Each sample was analysed in a folded capillary cell. The zeta 
potential values were calculated using the Smoluchowski equation. Repeated 
measurements were performed (3 times) and the values reported are average values.  
3.2.4 Static light scattering 
Nanoparticle weight was determined by static light scattering (SLS). The intensity of 
scattered light produced by macromolecules is proportional to the product of the weight-
average nanoparticle weight and the concentration of the macromolecule. For molecules 
that show no angular dependence in the light scattering (when molecules are not large 
enough to accommodate multiple photon scattering), the relationship between the 
intensity of scattered light and the molecular weight is given by the Rayleigh equation. In 
the present study the nanoparticle weight will be evaluated using the follow equation 
(Equation 3.1): 






+= CA
NPR
KC
w
22
1
θ
  
(Equation 3.1) 
NPw is the weight-average nanoparticle weight, A2 is the second virial coefficient and C 
is the sample concentration, K is an optical constant as defined below (Equation 3.2): 
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  (Equation 3.2) 
NA, Avogadro`s constant; λ0, laser wavelength; n0, solvent refractive index; dn/dc, 
differencial refractive index increment. 
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Rθ is the Rayleigh ratio – the ratio of scattered light to incident light of the sample. The 
standard approach for weight measurements is to first measure the scattering intensity of 
the analyte used relative to that of a well described “standard” pure liquid with a known 
Rayleigh ratio. Toluene was used as standard. The refractive index increment (dn/dc) 
used in SLS measurements was measured in a differencial refractometer. For the present 
polymer dn/dc of 0.140 mL/g was obtained. In the plot of KC/Rθ versus C (known as 
Debye plot) the intercept is equivalent to 1/NPw and the slope allows the calculation of the 
second virial coefficient A2. The second virial coefficient is a property describing the 
interaction strength between the nanoparticles and the solvent. For samples where A2 >0, 
the nanoparticles are stable in solution. When A2 = 0, the nanoparticle-solvent interaction 
is equivalent to the nanoparticle-nanoparticle interaction and the solvent is described as a 
theta solvent. When A2<0, the nanoparticles are unstable, and aggregate. 
A glass cell was used for nanoparticle weight measurements. All dispersions were 
filtered using disposable 0.20 µm filters. This filtration has a significant effect on the size 
distribution, reducing the polydispersity index. A larger PdI being observed when a 0.45 
µm filter was used. 
3.2.5 Transmission electron microscopy 
For visualization by transmission electron miscroscopy (50 kV; Zeiss EM 902C), 
nanoparticles were adsorbed to glow-discharged carbon-coated collodion film on 400-
mesh copper grids. Grids were washed with deionized water and stained with 0.75% 
uranyl acetate. 
3.2.6 Fluorescence spectroscopy 
Fluorescence measurements were performed on a VARIAN Cary Eclipse fluorescence 
spectrofluorometer using a quartz cell. Experiments were performed with Py as a 
fluorescent probe (1×10-6 M) and CPB as a quencher (0.01-0.1 mM). A stock solution of 
CPB (1 mM in methanol) was prepared, and aliquots of this solution were added to empty 
flasks in the amount required for the final CPB concentration. Methanol was evaporated 
and then a polymer solution with a 0.3 g/dL concentration, prepared in 1×10-6 M Py, was 
added to each flask. The mixtures were left to equilibrate under mild shaking for 24h. The 
pyrene spectra were obtained using an excitation wavelength of 337 nm, and recording 
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the emission over the range 350-500 nm, at a scan rate of 20 nm/min. The slit width was 
set at 20 nm for the excitation and 2.5 nm for the emission.  
 
 
3.3 Results and discussion 
3.3.1 Size of the dexC16 self-aggregates  
Several samples of dexC16 were prepared, as reported previously, with DSC16 (C16 
groups per 100 dextrin glucopyranoside residues) of 3.4, 4.8, 6.0, 8.8 and 10.0%. The 
size and size distribution of the self-assembled hydrogel nanoparticles in aqueous 
medium were measured by DLS. Figure 3.1 shows the particle size of the samples at 
different polymer concentrations. The concentration range is above critical micelle 
concentration (≈ 0.0008 g/dL) and below the solubility limit (≈ 1.0 g/dL) (Gonçalves, et al., 
2007). 
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Figure 3.1. Mean hydrodynamic diameter (z-avg) analysis of self-assembled hydrogel 
nanoparticles with DSC16 4.8, 6.0, 8.8 and 10.0%. 
The mean hydrodynamic diameter obtained, for samples with DSC16 4.8, 6.0, 8.8 and 
10.0%, was 20.0 ± 1.2, 19.6 ± 1.1, 22.7 ± 1.1 and 22.6 ± 0.7 nm, respectively (± 
confidence interval at 95%), with corresponding average polydispersity index of 0.390, 
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0.354, 0,559 and 0.306. These results indicate that the particle size of the self-assembled 
hydrogel nanoparticles is only slightly influenced by the DSC16 or polymer concentration. 
As can be seen in Figure 3.2, the size distribution of hydrophobized polysaccharide in 
water, upon self-aggregation, is relatively monodisperse. The intensity distribution is 
rather influenced by the presence of larger particles, while the volume distribution 
provides a better approach to characterize the more representative population. 
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Figure 3.2. Size distribution in (a) intensity (%) and (b) volume (%), of aqueous dispersion 0.02 
g/dL of dexC16 with DSC16 8.8%. 
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In addition, the self-assembled nanoparticles were observed using transmission 
electron microscopy (TEM). Figure 3.3 reveals spherical nanoparticles with a 
predominant population with diameters of about 20 nm for dexC16 with DSC16 8.8%. The 
TEM results are in good agreement with DLS results presented above.  
 
Figure 3.3. Transmission electron microscopy of negatively stained nanoparticles with DSC16 
8.8%. 
3.3.2 Aggregation number 
Fluorescence quenching is a common method for the measurement of the aggregation 
number. The method is based on the quenching of a probe´s emission using a specific 
quencher (Q). Both probe and quencher should have a high affinity for the nanoparticles. 
Considering a well-defined but unknown microdomains concentration [MD] and a 
concentration of quencher [Q], selected such that it resides exclusively in the 
nanoparticles, then Q will be distributed among the available nanoparticles. If a 
fluorescent molecule P, which is also entirely associated with nanoparticles, is now added 
to the system, P will partition between nanoparticles containing Q and the “empty” 
nanoparticles. A Poisson distribution of the P and Q among the nanoparticles may be 
assumed. If P is fluorescent only when it occupies an empty nanoparticle, then the 
measured ratio of fluorescence intensities (I/I0), obtained in the presence (I) or absence 
(I0) of Q, is related by the Equation 3.3: 
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(Equation 3.3) 
In this work, CPB was used as the pyrene quencher. We used a low concentration of 
CPB (0.01-0.1 mM) to minimize a possible aggregation of this pyridinium surfactant 
(critical micelle concentration of CPB is about 0.6 mM). For the quenching experiments, 
the polymer concentration used was in the range where saturation with pyrene takes 
place, that is, where a constant value for the ratio I3/I1 is reached (Gonçalves, et al., 
2007).  
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Figure 3.4. Variation of ln(I0/I) as a function of CPB concentration, for different degree of 
substitution of the polymer. 
The plots of ln(I0/I) versus [Q] give straight lines (Figure 3.4) allowing the calculation of 
[MD] and then Nagg, according to Equation 3.4: 
][MD
cN Hagg =   (Equation 3.4) 
where cH is the hydrophobic groups concentration, in mM. 
The fluorescence quenching study reveals that the hydrophobic microdomains (MD) 
have a number of alkyl chains that increases with DSC16, from 4 to 18, in the range of the 
DSC16 values analysed (Figure 3.5). 
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Figure 3.5. Aggregation number (Nagg) of the microdomains as a function of the degree of 
substitution, for a polymer concentration of 0.3 g/dL. 
The more substituted polymer forms more densely packed hydrophobic microdomains, 
due to an increase in the number of alkyl chains. However, the nanoparticle diameter is 
not significantly influenced. The higher Nagg of the more substituted material (higher 
DSC16) probably corresponds to nanoparticles with improved stability, due to the 
increased hydrophobic interaction on the microdomains. The stability of nanoparticles 
obtained with DSC16 4.8 and 8.7% was evaluated up to 7 days. Aqueous dispersions (0.1 
g/dL) were stored in the DLS polystyrene cell, at room temperature. The size distribution 
was constant, for DSC16 8.7%, with low polydispersity index (< 0.5), up to 7 days. In the 
case of DSC16 4.8% some aggregates are detected in the first day of the assay (≈ 500 
nm), but the main peak was conserved. The stability was also evaluated for DSC16 8.7% 
in PBS (0.1 g/dL). The sample was highly stable, since no aggregates were detected and 
the low polydispersity index was also conserved. Indeed, as expected, the more 
substituted dexC16 forms more compact hydrophobic microdomains, such that the 
colloidal stability of nanoparticles is increased. 
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3.3.3 Weight of the dexC16 self-aggregates  
The nanoparticle weight (NPw) and the second virial coefficient (A2) of the dexC16 self-
aggregates were studied, for different degrees of substitution, using the Debye plot. The 
second virial coefficient (A2) of the nanoparticles is positive, revealing stability in aqueous 
medium. The value obtained, divided by the molecular weight (Mw) of a single polymer 
chain, provide the number of polymer (dexC16) molecules within a nanoparticle. Thus, 
using the aggregation number determined by quenching experiments, a comprehensive 
characterization of nanoparticle is possible, namely the estimation of the number of 
polymer molecules (molecules/NP) and hydrophobic moieties per nanoparticle (C16/NP), 
number of hydrophobic molecules within one hydrophobic microdomain (Nagg) and 
number of hydrophobic microdomains (MD/NP). The results are presented in Table 3.1. 
As shown, dexC16 used for the nanoparticle weight determination has not the same DSC16 
as one used for Nagg determination (see Figure 3.5). Therefore, the values of Nagg used 
for nanoparticle characterization (Table 3.1) were obtained using the trend line shown in 
Figure 3.5. 
 
Table 3.1. Nanoparticles characterization with different DSC16. 
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3.4 0.4 2231 336 4.75e-4 151 60 5 12 13 
4.8 0.6 2278 346 4.95e-4 152 91 6 15 10 
6.0 0.8 2318 411 3.82e-4 177 142 7 20 9 
8.8 1.1 2412 418 4.93e-4 173 190 11 17 10 
10.0 1.3 2452 530 2.53e-4 216 281 13 22 10 
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The nanoparticle weight determination (by SLS) allows an estimation of the number of 
polymer molecules, per nanoparticle, in the range 151-216 (Table 3.1), depending on the 
degree of substitution. 
The Nagg value has been calculated under the assumption that all hydrophobes are 
involved in hydrophobic microdomains. This assumption might be true for polymers with 
higher degrees of substitution (Nichifor, et al., 2004), where the density of the side alkyl 
chains is high enough. Therefore, Nagg corresponds to the maximum number of 
hydrophobes that can exist within microdomain. 
From the experimental hydrodynamic radius (RH) and NPw values, one can calculate 
the average polymer density (φH) within a nanoparticle, as defined by Equation 3.5, where 
NA is Avogadro´s number.  
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The average polymer density, for samples with DSC16 4.8, 6.0, 8.8 and 10.0%, was 
0.14, 0.17, 0.11 and 0.15 g/mL, respectively. These results indicate that the nanoparticles 
have about 85-90 wt% of water; they may be considered hydrogel-like structures. 
3.3.4 Influence of pH, urea and ionic strength   
The magnitude of the zeta potential gives an indication of the stability of the colloidal 
system. If particles in a suspension have a large zeta potential value, negative or positive, 
then they will repeal each other and the particles do not aggregate. However, if the 
particles have a low zeta potential value (close to zero), then there is no electrostatic 
force to prevent the particles to aggregate. The most important factor that affects zeta 
potential is pH. The variation of hydrodynamic diameter and zeta-potential of 
nanoparticles with the pH was studied. 
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Figure 3.6. Particle size and zeta potential of nanoparticles with DSC16 6.1% (0.1 g/dL) as a 
function of pH solution. 
Figure 3.6 shows that the nanoparticles size is not sensitive to the pH medium. In the 
pH range studied, the zeta potential is almost constant and close to zero. Indeed, the 
polymer is made of glucose, and the hydroxyl glucose residues have a high pKa (12.35), 
and thus the material is expected to be poorly ionized in the analysed pH range. Although 
the low zeta potential, the nanoparticles are stable. The stability can be attributed to the 
solvation forces. Typically, solvation forces are ignored in colloidal analysis, because they 
are difficult to access and quantify. It has been noted that solvation forces can be 
comparable to, or greater than, van der Waals forces (Fichthorn, et al., 2006).  
In order to further understand the nature of the associations exhibited by dexC16 in 
aqueous medium, the effects of urea and salt (NaCl) on nanoparticle size was studied.  
Urea can produce twofold effects: firstly, urea may break intra-molecular hydrogen 
bond, an effect that may lead to the uncoiling of dextrin molecules, which would assume 
a more extended conformation. Secondly, urea can severely disturb the hydrophobic 
interactions. It was found that particle size slightly increases with the urea concentration. 
Using DSC16 8.8% (0.1 g/dL), the nanoparticles size increase from 25.8 to 31.3 nm, 
corresponding to an urea concentration up to 7 M. Thus, urea seems to perturb the 
hydrophobic interactions inducing the nanoparticles to “swell”, although it is noticeable 
that the size increase is not dramatic. Indeed, the driving force for hydrophobic 
association in aqueous systems is partially attributed to the need for the hydrophobic 
moieties to minimize the surface area of contact with water, and consequently minimize 
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the amount of water that must be “structured” in order to solubilise them. The addition of 
urea to aqueous solutions disrupts the structuring ability of water, thereby weakening the 
hydrophobic interactions in the solution (Philippova, et al., 2001). Therefore, urea may 
hinder the formation of hydrophobic domains, although it does not prevent the formation 
of nanoparticles.  
The effect of NaCl concentration on the hydrodynamic diameter of nanoparticles 
obtained with DSC16 9.0% (0.1 g/dL) was also studied. An increase of the average particle 
size, in the same range as observed with urea, may be observed. Nanoparticles size 
increase from 23.7 to 35.5 nm, corresponding to NaCl concentration in the range 0-0.6 M. 
Since nanoparticles bears a rather low charge, considering the zeta potential, the size 
increase is not likely to arise from the double layer compression and subsequent 
aggregation. 
The interaction forces between colloidal nanoparticles determine the dispersion and 
stability of their suspensions. Electrostatic, van der Waals, depletion, and solvation forces 
exist between solid particles suspended in a liquid. However, for nanoparticles, the 
absolute and relative magnitudes of these forces are not well-known. It is difficult to 
measure forces acting upon nanoparticles, experimentally. 
The general conclusion that may be drawn from these results is that the nanoparticles 
have a slightly higher size when prepared in buffer (irrespective of the pH), in the 
presence of a salt or urea (irrespective of the concentration). The rather high stability of 
these nanoparticles must be remarked. 
 
 
3.4 Conclusions 
In the present study we evaluated the influence of the degree of substitution on the 
self-assembly process of a hydrophobized dextrin polymer, dexC16. The size of self-
assembled hydrogel nanoparticles was evaluated as a function of DSC16. The 
nanoparticles size is only slightly influenced by DSC16 or polymer concentration. The 
fluorescence quenching study reveals that the more substituted polymer forms more 
densely packed hydrophobic microdomains, such that colloidal stability (in water and 
PBS) of nanoparticles is increased. The nanoparticles are stable in the presence of urea 
and at different pH and ionic strength. Small size, low density and high stability of the 
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nanoparticles obtained can promote a stable entrapment of bioactive and hydrophobic 
molecules, and allow them to circulate in the blood long enough to reach the desired 
therapeutic effects. 
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4. Dextrin nanoparticles: Studies on the 
interaction with murine macrophages and 
blood clearance 
 
Adapted from Colloids and Surfaces B: Biointerfaces (2010) 75, 483-489 
he uptake of nanoparticles by cells of the mononuclear phagocytic system 
limits its use as colloidal drug carriers, reducing the blood circulation time 
and the ability to reach biological targets. In this work, the interaction between dextrin 
nanoparticles - recently developed in our laboratory - and murine bone marrow-derived 
macrophages was evaluated. Cytotoxicity and nitric oxide production were studied, using 
the MTT assay and the Griess method, respectively. Fluorescein-labelled nanoparticles 
were used to assess the phagocytic uptake and blood clearance after intravenous 
injection. The phagocytic uptake was analysed in vitro by confocal laser scanning 
microscopy and fluorescence activated cell sorting. The results show that the 
nanoparticles are not cytotoxic and do not stimulate the production of nitric oxide by 
macrophages, in the range of concentrations studied. Nanoparticles are phagocytosed by 
macrophages and are detected inside the cells, concentrated in cellular organelles. The 
blood clearance study showed that the blood removal of the nanoparticles occurs with a 
more pronounced rate in the first 3 h after intravenous administration, with about 30% of 
the material remaining in systemic circulation at this stage. Given the fairly high blood 
circulation time and biocompatibility, the dextrin nanoparticles are promising carriers for 
biomedical applications. Both applications targeting phagocytic, antigen-presenting cells 
(for vaccination purposes) and different tissues (as drug carriers) may be envisaged, by 
modulation of the surface properties. 
 
T 
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4.1 Introduction 
Many colloidal carriers, such as liposomes, nanocapsules and nanoparticles, have 
been developed as intravenous drug delivery systems. These systems may improve the 
absorption of poorly water-soluble pharmaceuticals, protect sensitive molecules against 
in vivo degradation, modify the distribution of drugs in the body and increase the patient`s 
compliance, by avoiding repeated injections. The rapid removal of intravenously 
administered colloidal drug carrier systems by the mononuclear phagocytic system (MPS) 
is an obstacle to the efficient targeting of solid tumours and inflammatory tissues 
(Mosqueira, et al., 2001, Oyewumi, et al., 2004). When nanoparticles enter the blood-
stream, they instantly encounter a complex environment of plasma proteins and 
phagocytic cells. Opsonization promotes recognition and uptake by cells of the MPS, 
especially macrophages in the liver (the Kupffer cells), but also spleen and bone marrow 
macrophages (Stolnik, et al., 1995). Recent research has focused on the modification of 
nanoparticles surface to avoid opsonization. In this context, poly(ethylene glycol) (PEG) 
was found to decrease the interactions of the particles with blood proteins, avoiding 
recognition by the MPS and thus increasing the circulation time in the blood (Zahr, et al., 
2006). As one of the most promising alternatives to PEG, polysaccharides have been 
widely investigated. The advantage of polysaccharide coating is the steric protection of 
nanoparticles against non-specific interactions with proteins, ensuring particle stability in 
blood circulation. Additionally, as polysaccharides offer reactive groups for modification, 
active targeting may be obtained by grafting ligands onto the nanoparticles surface 
(Lemarchand, et al., 2004, Lemarchand, et al., 2005, Lemarchand, et al., 2006, Ma, et al., 
2008).  
Knowledge on the interaction between macrophages and drug carriers is essential in 
the design of more effective therapeutic strategies using nanobiotechnological devices. 
Macrophages may be the therapeutic target, for the treatment of macrophage-associated 
pathologies or vaccination purposes, given their activity as antigen-presenting cells 
(Schroer, et al., 1980, Underhill, et al., 1999). Otherwise, when other targets are 
envisaged, phagocytic activity should ideally be avoided, providing the drug carrier time 
enough to reach the target. Macrophages are phagocytic cells that produce antimicrobial 
molecules, in the phagosome, and secrete a variety of substances, whose actions range 
from induction of cell growth to cell death, in addition to their role in antigen-presentation 
to T cells. These substances produced by macrophages, such as nitric oxide and 
cytokines, are involved in host defence against pathogenic micro-organisms, parasites or 
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tumour cells. The phagocytic process starts when macrophages recognize foreign 
particles or pathogens, becoming thereafter activated, a process that leads to the 
secretion of a number of chemical mediators of inflammation. These molecules are very 
aggressive, not only against foreign molecules or particles, but also to the host tissues. 
Among them, nitric oxide (NO) is a key marker of activation of inflammation (Fiorito, et al., 
2006).  
After administration of colloidal carriers, the in vivo distribution largely depends on their 
particle size (Sonavane, et al., 2008) and surface properties (Esmaeili, et al., 2008). As 
referred above, in many instances it is desirable to increase the blood circulation time of 
the drug carriers. Elimination of the nanoparticles from systemic circulation can occur by 
different mechanisms: uptake by phagocytic cells, extravasation through endothelium and 
renal excretion. Nanoparticle uptake by the phagocytic cells may occur both in the 
bloodstream by monocytes and in tissues by resident phagocytes (e.g., Kupffer cells in 
the liver, dendritic cells in the lymph nodes, spleen macrophages). Nanoparticles can 
escape the circulation through the gaps, also called fenestrations, of the endothelial 
barrier. Fenestrations and the vasculature can undergo modifications under various 
pathological conditions. For instance, tumor growth induces the development of 
neovasculature characterized by discontinuous endothelium, with large fenestrations. 
Depending on the reports, the “ideal” size requirements for nanoparticles developed for 
cancer treatment vary from 70 to 200 nm. Larger particles can be rapidly taken up by the 
mononuclear phagocytic system cells (Gaumet, et al., 2008). Small particles (<5.5 nm) 
are described to be rapidly and efficiently excreted in the urine (Choi, et al., 2007).  
In previous work, nanoparticles obtained by self-assembling of hydrophobized dextrin 
were developed and characterized in our laboratory. The nanoparticles obtained have 
high colloidal stability and spherical shape (Gonçalves, et al., 2007). Size distribution 
obtained by dynamic light scattering showed two distinct populations, with 25 and 150 
nm, the smaller being the predominant one (Gonçalves, et al., 2008). In the present work, 
the ability of these nanoparticles to interact with bone marrow-derived macrophages 
(BMDMs) was analysed. The use of nanoparticles labelled with a fluorochromic probe 
allowed the detection of internalization by BMDM and the evaluation of the blood 
clearance profile. These are the major goals of this work: to ascertain whether the dextrin 
nanoparticles are effectively internalized by phagocytic cells (relevant for vaccination 
purposes) and estimate the blood circulation time (crucial for the development of drug 
delivery applications). 
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4.2 Experimental section 
4.2.1 Materials 
Dextrin-VA-SC16 (VA: vinyl acrylate, SC16: alkyl chain) was synthesized as 
comprehensively described previously (Gonçalves, et al., 2007). In this work, a sample of 
dextrin-VA-SC16 (dexC16) with 13 acrylate groups (DSVA 13%) and 6 alkyl chains (DSC16 
6%) per 100 dextrin glucopyranoside residues was used. Dimethyl-sulfoxide was 
purchased from Fluka. The chemicals 4',6-diamidino-2-phenylindole (DAPI), 
lipopolysaccharide (LPS), saponine and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich. SAMSA (5-((2-
(and-3)-S-(acetylmercapto) succinoyl) amino) fluorescein was obtained from Invitrogen. 
IFN-γ was obtained from R&D systems. Sephadex G25 PD10 columns were obtained 
from Amersham Biosciences.  
4.2.2 Animals 
Eight-week-old female BALB/c mice, an inbred strain with high genetic homogeneity 
between individuals, obtained from Harlan Interfauna Ibérica (Barcelon, Spain), were 
housed under specific-pathogen-free conditions with food and water ad libitum. The 
experiments involving mice were conducted under the guidelines and approval of the 
Research Ethics Committee of the Life and Health Sciences Research Institute (Braga, 
Portugal) and of the governmental agency Direcção Geral de Veterinária (Lisbon, 
Portugal). 
4.2.3 Culture of murine BMDM 
Macrophages were obtained from the bone marrow, as previously described (Pedrosa, 
et al.,1994, Torrado, et al.,2007). This method allows the differentiation of a homogenous 
primary culture of macrophages that retains the morphological, physiological and surface 
marker characteristics of these phagocytes (Tushinski, et al.,1982, Warren, et al.,1985, 
Zhang, et al.,2008). Briefly, mice were sacrificed using CO2, and the femurs were 
removed under aseptic conditions. Bones were flushed with 5 mL cold Hanks` balanced 
salt solution (HBSS; Gibco, Paisley, United Kingdom). The resulting cell suspension was 
centrifuged at 500 ×  g and resuspended in Dulbecco`s modified Eagle`s medium 
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(DMEM; Gibco), supplemented with 10 mM HEPES (Sigma, St. Louis, MO), 1 mM 
sodium pyruvate (Gibco), 10 mM glutamine (Gibco), 10% heat-inactivated fetal bovine 
serum (Sigma), and 10% L929 cell conditioned medium (complete DMEM [cDMEM]). To 
remove fibroblasts or differentiated macrophages, cells were cultured for a period of 4 h 
on cell culture dishes (Nunc, Naperville, IL) with cDMEM. Nonadherent cells were 
collected with warm HBSS, centrifuged at 500 ×  g, distributed in 24-well plates at a 
density of 5 510×  cells /well, and incubated at 37 ºC in a 5% CO2 atmosphere. On day 4 
after seeding, 0.1 mL of L929 cell conditioned medium was added, and medium was 
renewed on the seventh day. After 10 days in culture, cells were completely differentiated 
into macrophages. 
4.2.4 Preparation of self-assembled nanoparticles 
Lyophilized dexC16 was dissolved in culture medium under stirring and further 
sonicated for 20 min. A stock solution (3 mg/mL) of nanoparticles was prepared. The 
nanoparticle concentration was adjusted by dilution of concentrated nanoparticle 
dispersion, with culture medium, in the wells. All solutions were sterilized by filtration 
through a 0.22 µm membrane. The nanoparticles formation was confirmed by dynamic 
light scattering and visualized in atomic force microscopy. 
The size distribution was determined with a Malvern Zetasizer, MODEL NANO ZS 
(Malvern Instruments Limited, U.K.). A dispersion of nanoparticles was analysed at 25 ºC 
in a polystyrene cell, using a Helium-Neon laser - wavelength of 633 nm and a detector 
angle of 173º.  
Tapping mode imaging was carried out on a Nanoscope IIIa Multimode (Digital 
Instruments, Veeco) scanning probe microscope. A silicon tip doped with phosphorus, 
with a radius curvature of less than 10 nm (RTESP, VEECO), was used. This tip has a 
typical resonance frequency of 288-328 kHz and a typical force constant of 20-80 N/m. A 
scan rate of 1.4-1.8 Hz was sufficient to maintain a good signal-to-noise ratio. A drop of 
nanoparticles dispersion was placed on new-cleaved HOPG surface, thoroughly rinsed 
with water and dried under a N2 flux.  
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4.2.5 Cytotoxicity test 
The cytotoxicity of the dextrin nanoparticles was evaluated, in vitro, using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The tetrazolium salt 
is widely used to quantify cytotoxicity, by colorimetry. The tetrazolium salts are 
metabolically reduced to highly coloured end products, formazans (Mosmann,1983). The 
colourless MTT is cleaved to formazan by the succinate-tetrazolium reductase system 
which belongs to the mitochondrial respiratory chain and is active only in viable cells.  
Nanoparticles, at different concentrations, were incubated with cells, for 24 or 48 h. 
Then, MTT was added to the culture medium to a final concentration of 0.5 mg/mL. After 
3 h of incubation, the insoluble formazan crystals were solubilized with DMSO, and the 
absorption was measured at 570 and 690 nm in an automated ELISA plate reader. For 
each sample, the background optical density (690 nm) was subtracted; the test was 
performed in triplicate. 
4.2.6 Nitric oxide quantification 
The nitric oxide production was evaluated by quantifying the nitrite accumulation in cell 
culture supernatants using the Griess method (Green, et al.,1982). Despite this method 
quantifies only nitrites, not nitrates, for the sake of the comparison carried out in this work 
it is sufficient. As a positive control, BMDM culture was challenged with 
lipopolysaccharide (LPS) and gamma interferon (IFN-γ). LPS is an endotoxin of the 
bacterial cell wall, well known to stimulate the release of different markers of inflammation 
by macrophage cells. It is used to stimulate macrophages in order to obtain a background 
of activation/inflammation, as it is usually done in studies concerning the inflammatory 
potential of different biochemical agents. IFN-γ is a cytokine produced by T-lymphocytes 
and NK cells which activates the antimicrobial mechanism of macrophages. 
BMDM cells (5 510×  cells /well) were incubated, at 37 ºC in a 5% CO2 atmosphere, for 
24 or 48 h, in the presence of different concentrations of nanoparticles (1.0, 0.5 and 0.1 
mg/mL). Assays were carried out either with and without LPS (100 ng/mL) and IFN-γ (1 
ng/mL). The final volume used was 1 mL per well. Then, 100 µL of Griess reagent was 
added to 100 µL of sample culture medium, and the absorbance was measured at 550 
nm. Nitrite concentrations in the medium were finally determined by using standard 
solutions of sodium nitrite (0-100 µM).  
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4.2.7 Uptake of nanoparticles by the BMDM 
4.2.7.1 Preparation of fluorescein-labelled nanoparticles 
Fluorescein is a fluorescent probe quite commonly used in biological studies, owing to 
its biocompatibility. In order to label the nanoparticles with fluorescein, the following 
solutions were prepared: (1) Nanoparticle solution – 10 mg of dexC16 were dissolved in 
1.3 mL of sodium phosphate buffer 0.1 M pH 7 and stirred for 30 min; (2) fluorescein 
solution - 5 mg of SAMSA fluorescein were dissolved in 0.5 mL of NaOH 0.1 M and 
stirred for 15 min. Afterwards, 7 µL of HCl 6 M and 0.1 mL of NaPO4 buffer 0.5 M pH7 
were added and stirred for 10 min. Finally, these two solutions were mixed up and stirred 
for 30 min. Unbound fluorescein was separated using a Sephadex G25 PD10 column 
equilibrated with PBS. Nanoparticles labelled with fluorescein were eluted with PBS and 
sterilized by filtration through a 0.22 µm membrane before use. Fluorescein labelling did 
not affect the properties of the nanoparticles, as estimated by dynamic light scattering. 
4.2.7.2 Fluorescence studies 
The assessment of phagocytosis, after incubating the fluorescent-labelled 
nanoparticles with murine macrophages, was attempted by spectrofluorimetry. In this 
study, Fluorescein-containing nanoparticles (1.0, 0.5 or 0.1 mg/mL) were added to BMDM 
cultures, which were pre-stimulated with LPS (100 ng/mL) and IFN-γ (1 ng/mL) on a 96-
well plate. As a control, 0.5 mg/mL nanoparticles were incubated with cells without LPS 
and IFN-γ. Following incubation periods of 3 or 6 h, the culture medium was collected and 
cell monolayers were rinsed four times with PBS to remove the non-phagocytosed 
nanoparticles. Then, 200 µL culture medium and 2 µL saponine (10%) were added and 
the cell lysates collected 10 min after incubation. Fluorescence intensity was measured in 
both the cell lysate and the collected culture medium, using a spectrofluorimeter. 
4.2.7.3 Confocal observation of the macrophages 
In order to evaluate the phagocytic activity, macrophages (5 510×  cells/well) were 
seeded on coverslips and stimulated with LPS (100 ng/mL) and IFN-γ (1 ng/mL). Then, 
the cell culture was incubated with or without fluorescein-containing nanoparticles (1.0 or 
0.1 mg/mL) for 6 h. The cover glasses were washed twice with PBS and cells were fixed 
Dextrin nanoparticles: Studies on the interaction with murine macrophages and blood clearance | Chapter 4 
Gonçalves, C. | 2010 99 
with methanol absolute (-20ºC) for 10 min. Following PBS washing (twice), cells were 
labelled with DAPI (staining nucleous-blue) for 15 min. Vectashield was used as an anti-
fading. Cover glasses were analysed using a laser scanning confocal microscope LEICA 
SP AOBS SE (Leica Microsystems, Germany), equipped with HC PL APO Lbl. Blue 63x / 
140 Oil objective.   
4.2.7.4 FACS analysis 
Cells (5x105 cells/mL) were seeded in 96-well plates and incubated at 37 ºC and 5% 
CO2. After removal of the growth medium, the cells were pre-stimulated with LPS (100 
ng/mL) and IFN-γ (1 ng/mL) and treated with fluorescein-linked nanoparticles (1.0, 0.5 or 
0.1 mg/mL), for 3 or 6 h. As a control, 0.5 mg/mL nanoparticles were incubated with cells 
not pre-stimulated with LPS and IFN-γ. After incubation, cells were washed four times 
with PBS and collected with 100 µL of cooled EDTA. Then cells were transferred to 
fluorescence activated cell sorting (FACS) tubes with 1 mL PBS and centrifuged at 500 ×
 
g for 10 min. After removal of the supernatant, cells were resuspended in 500 µL of FACS 
buffer (EDTA with 1% BSA).  
Flow cytometric analysis was performed using a FACS Coulter Epics XL (Applied 
Cytometry Systems, United Kingdom). The cells were excited with a 488 nm laser and 
green fluorescence collected using a 530 ± 30 nm band pass filter. Data were analysed 
using EXPO32 software (Applied Cytometry Systems, United Kingdom), which statistical 
functions were used to quantify the proportion of cells with green fluorescence, 
corresponding to the percentage of macrophages with phagocytosed nanoparticles.  
4.2.8 Blood clearance  
On the day of experiments, mice were grouped (N = 3) according to pre-defined 
periods of time (0, 3, 5, 10 and 24 h). A solution of fluorescein-containing nanoparticles 
(100 µL, 0.3 mg/mL) was injected in the tail vein. The injections were well tolerated and 
no adverse effects were recorded during the observation period. After pre-defined periods 
following nanoparticles administration, blood was collected through tail cut. Blood was 
centrifuged (14,000 rpm, 40 min, 4 ºC) and the fluorescence of supernatant was 
analysed. The samples corresponding to the beginning of the experiment (0 h) were 
collected immediately after injection. Fluorescence measurements were performed on a 
VARIAN Cary Eclipse fluorescence spectrofluorometer using a quartz cell. The 
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fluorescein spectra were obtained using an excitation wavelength of 485 nm, and 
recording the emission over the range 500-590 nm, at a scan rate of 125 nm min-1. The 
slit width was set at 5 nm for the excitation and 10 nm for the emission.  
 
4.3 Results and discussion 
Self-assembled nanoparticles were observed using dynamic light scattering (DLS) and 
atomic force microscopy after filtration through a 0.22 µm membrane. The AFM image 
(Figure 4.1a) shows that nanoparticles have spherical shape. The fundamental size 
distribution generated by DLS is an intensity distribution - quite sensitive to the presence 
of larger particles - which can be converted, using Mie theory, to a volume distribution. 
This volume distribution can also be further converted to a number distribution. The DLS 
analysis reveal two populations in the intensity distribution (Figure 4.1b), with roughly 20 
and 100 nm. The conversion to number distribution (Figure 4.1c) highlights only the 
smaller population of nanoparticles, the predominant one. The nanoparticles size was not 
affected by the fluorescein labelling (data not shown).  
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Figure 4.1. AFM image (a) and size distribution by intensity (b) and by number (c) of 
nanoparticles dispersion (1.0 mg/mL). 
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It should be remarked that the material used on the development of the nanoparticles, 
dextrin, is a very promising biomaterial, available in medical grade and accepted by FDA 
(Hreczuk-Hirst, et al., 2001, Treetharnmathurot, et al., 2009). However, in spite of its 
biocompatibility and availability on large amounts, it is under exploited in the biomedical 
field.  
4.3.1 BMDM cultures: cytotoxicity and nitric oxide production  
The nanoparticles toxicity was studied using BMDM cultures and the MTT assay. 
Figure 4.2a shows the results. The presence of nanoparticles, in the range of 
concentrations studied, does not affect cell viability as measured by the MTT assay. Cells 
treated with nanoparticles showed a optical density similar to the control (untreated cells). 
Furthermore, the cells exhibit normal morphology. Similar experiments performed with 
fibroblast cultures produced similar results (data not shown). It must be remarked that the 
concentration of nanoparticles used in these assays exceeds the values likely to be 
reached in vivo, therefore it may be concluded that the dextrin nanoparticles are not 
cytotoxic.  
The nanoparticles effect on the nitric oxide production by cultured macrophages was 
analysed (Figure 4.2b). Cells were incubated for 48 h with nanoparticles alone and the 
production of nitric oxide was not detected in the conditions of the assay. Moreover, as 
expected, the addition of LPS and IFN-γ to the culture medium induced nitric oxide 
production. The effect of combining LPS and IFN-γ with different nanoparticles 
concentration was therefore studied. This analysis revealed that the release of nitric oxide 
was similar, irrespective of the presence of nanoparticles. The presence of the 
nanoparticles seems not to promote any inflammatory action or elicit a reactive response 
when in contact with macrophages. 
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Figure 4.2. BMDM viability (a) with different nanoparticles concentrations (1.0 or 0.1 mg/mL) and 
nitric oxide production (b) using 0.5 or 0.1 mg/mL nanoparticles, after 24 h () or 48 h () of 
incubation. For nitric oxide assay BMDM were stimulated with LPS (100 ng/mL) and IFN-γ (1 
ng/mL). For negative control cells were incubated only with nanoparticles. The error bar 
corresponds to the standard deviation. 
4.3.2 Uptake of nanoparticles 
Particle size is known to play a primary role in the interaction of nanoparticles with 
phagocytic cells. Larger particles are rapidly taken up by the mononuclear phagocytic 
system, and smaller ones have a minor chance of being sequestered by phagocytic cells. 
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Therefore, the size of the nanoparticles has a critical effect on their behavior in biological 
systems.  
In order to detect the internalization of the nanoparticles by the macrophages, 
fluorescence intensity was measured before (0 h) and after 3 or 6 h of contact of 
fluorescein-labelled nanoparticles with BMDM, both in cell lysates and in the culture 
medium. The results are shown in Figure 4.3.  
The fluorescence intensity was assessed in the macrophage culture medium, following 
incubation with the nanoparticles. No differences were seen throughout the periods of 
observation (Figure 4.3a), the majority of nanoparticles remaining outside the phagocytic 
cells. However, when lysates of BMDM cultivated in the presence of nanoparticles were 
analysed, an increased fluorescence intensity (Figure 4.3b) was detected at the higher 
concentrations tested. The variations in fluorescence intensity, although slight ones, 
suggest the occurrence of phagocytic processes. The hardly detectable variations in 
fluorescence intensity suggest that the nanoparticles concentration is far beyond the 
saturation of the cells. The cell activation does not affect the phagocytic activity of BMDM, 
since no significant difference was observed irrespective of the stimulation with LPS and 
IFN-γ (data not shown).  
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Figure 4.3. Fluorescence intensity of the fluorescein-labelled nanoparticles in the culture 
medium before (t = 0 h) and after (t = 3 h or 6 h) contact with cells (a) and for BMDM cell lysate 
(b) after incubation with 1.0, 0.5 or 0.1 mg/mL nanoparticles. Bars represent 0 h (), 3 h () or 6 
h (). The error bar corresponds to the standard deviation. 
Bocca, et al., using the same methodology, reported substantial differences in the 
internalization of stealth and non-stealth solid lipid nanoparticles (average diameter 100 
nm), the former undergoing the fastest uptake. The phagocytic uptake of stealth 
fluorescent nanoparticles was very low - as in this work, with the dextrin nanoparticles - 
corresponding to about 5% of the initial dose, after 90 min of incubation with murine 
macrophages (Bocca, et al., 1998). Fang, et al. reported the influence of nanoparticles 
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size on macrophage uptake. The study was performed using poly 
methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate (PEG-PHDCA) 
nanoparticles with different size (80, 170 and 240 nm). No significant uptake differences 
were observed in the first 0.5 h. However, after 2 h remarkable differences were 
observed and the uptake percentage was lower for nanoparticles with 80 nm (Fang, et 
al., 2006). Again, as in this work, only a minor fraction of the nanoparticles are taken up 
by the cells.  
Confocal microscopy was used to further examine the uptake of fluorescein-labelled 
nanoparticles by macrophages. In the control culture (Figure 4.4a) only nucleus stained 
with DAPI are visible. Cells incubated with nanoparticles show small green spots (Figure 
4.4b and c), in the cytoplasm, that can be attributed to the fluorescein in the internalised 
nanoparticles. Fluorescent material is concentrated in cellular organelles, irrespective of 
the concentration used. The cell membrane is not visible, suggesting that the 
nanoparticles are not adsorbed on the cell surface, as confirmed by the FACS analysis 
(see below). Apparently, as suggested by the fluorescence depletion studies, the 
nanoparticles concentration seems to largely exceed the uptake ability of macrophages. 
Ongoing work focuses on the analysis of the nanoparticles intracellular trafficking. 
(a) (b) (c)
 
Figure 4.4. Fluorescence images of BMDM obtained by confocal microscopy, without 
nanoparticles contact (a), and with 6 h of incubation with fluorescein-containing nanoparticles, 
0.1 mg/mL (b) or 1.0 mg/mL (c). 
The results obtained by FACS analysis confirm the confocal microscopy observations. 
The cell viability was confirmed with propidium iodide. The percentage of fluorescent 
macrophages after incubation with labelled nanoparticles was very high, as shown in 
Figure 4.5. Furthermore, an additional assay using a cell-impermeable dye (trypan blue, a 
fluorescein quencher), was performed. Since the fluorescence was not reduced in the 
presence of trypan blue (data not shown), it may be concluded that the nanoparticles are 
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indeed concentrated inside the macrophages, as shown by confocal microscopy, and not 
just adsorbed on the cell membrane.  
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Figure 4.5. Percentage of macrophage cells that incorporated fluorescein-labelled nanoparticles 
(1.0, 0.5 or 0.1 mg/mL), after 3 h () or 6 h (), measured by FACS analysis. 
As suggested by the confocal microscopy images, shown in Figure 4.4, the amount of 
nanoparticles internalised is similar for the different concentrations used, suggesting that 
a saturation of the uptake ability of the cells occur in the range of concentrations tested. 
The phagocytic activity of BMDM cells is not affected by activation with LPS and IFN-γ, 
since no significant difference was observed (data not shown). The effective 
internalization suggests that the nanoparticles may be used for vaccination purposes, 
carrying synthetic antigens to phagocytic cells. Considering this possibility, ongoing work 
aims at clarifying the kinetics of the phagocytosis, the concentration dependence effects, 
and the intracellular fate of the nanoparticles.  
4.3.3 Blood clearance  
Long systemic circulation time is a highly demanded feature for nanoparticles-based 
drug delivery systems, providing the carriers enough time to reach their targets and to 
release their content in a continuous and controlled-way.  
The fluorescein-labelled nanoparticles were used for blood clearance studies, after 
intravenous injection. The blood clearance profile for fluorescein-labelled nanoparticles is 
shown in Figure 4.6. The elimination of nanoparticles from systemic circulation is 
relatively fast in the first 3 h, then proceeding at lower rate. In the first period studied, 3 h, 
about 65% of the nanoparticles were removed from the bloodstream and in the next 2 h 
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another 15% fade away. At 24 h, only 5% of the injected dose is circulating in the 
bloodstream. The clearance rate of dextrin nanoparticles observed in the blood clearance 
profile may be related with the nanoparticles size distribution. The small nanoparticles 
should be small enough to cross the endothelial barrier or to be eliminated by renal 
clearance. Thus, the nanoparticles remaining longer periods may correspond to the 
population of larger nanoparticles. Further biodistribution studies by scintigraphy are 
being carried out in our laboratory, using nanoparticles labelled with radioactive 
samarium (complexed with quelating agent). Preliminary results show renal accumulation 
of the nanoparticles and consequent excretion in the urine, thus reinforcing the 
hypothesis of filtration of the smallest nanoparticles, at least in the kidney. Biodegradation 
by serum α–amylase is not likely to occur. Indeed, enzymatic hydrolysis of dexC16 by α–
amylase, in vitro, was not detected by dynamic light scattering or reducing sugar method 
(data not shown). We assume that the polymer modification with alkyl chains blocks the 
enzyme action: since the dextrin used has very low degree of polymerization – about 12 - 
every glucose residue is quite close to the alkylic graft, which is likely to avoid the 
amylase action. 
 
Figure 4.6. Blood clearance profile of fluorescein-labelled nanoparticles. Inset shows the 
percentage of the initial (0 h) fluorescence, remaining in the bloodstream at different time. The 
error bar corresponds to the standard deviation. 
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The blood clearance profile obtained is very similar to others reported for polymeric 
nanoparticles. Micelles prepared from conjugates of polyethylene glycol (PEG) and 
phosphatidylethanolamine (PE), with the size of 7-35 nm, have circulation half-lives from 
1.2 to 2.1 h depending on the molecular size of PEG block (Lukyanov, et al., 2002). A 
recent study evaluated the circulation kinetics and biodistribution of core-crosslinked 
(CCL) and non-crosslinked (NCL) micelles based on mPEG5000 and N-(2-
hydroxyethyl)methacrylamide-oligolactates (mPEG-b-p(HEMAm-Lacn)). CCL and NCL 
micelles have the same size (57 nm). The NCL micelles were rapidly eliminated from the 
circulation and only 6% of the injected dose was present after 4 h, probably due to 
interactions with plasma proteins which lead to recognition by macrophages. Contrary to 
NCL assemblies, CCL micelles displayed significantly prolonged circulation times, and 
50% of the injected dose was still present in the systemic circulation after 6 h. At 24 h 
post-injection, 5% of the injected dose was in the blood circulation and 10% and 1.7% 
were taken up by the liver and spleen, respectively. A relatively high accumulation in the 
abdominal skin was observed, attributed to extravasation into areas that experience 
pressure and/or micro-traumatised areas in the skin, which is allowed by long circulation 
time and small size (Rijcken, et al., 2007). 
 
 
4.4 Conclusions 
In vitro studies with BMDM revealed that nanoparticles are non-cytotoxic and do not 
elicit a reactive response when in contact with macrophages. Moreover, FACS analysis 
and confocal observation demonstrated that BMDM internalize the nanoparticles. A 
saturation of the cells uptake ability is observed in the range of concentrations tested. 
The in vivo study showed that, after intravenous injection, a relatively fast removal of the 
nanoparticles occurs in the first 3 h, then continuing slowly up to 24 h. The blood 
clearance profile reveal a moderately long circulation time, compatible with drug delivery 
or diagnostic applications. Dextrin nanoparticles may also be used to address phagocytic 
cells. Ongoing work aims at modifying nanoparticles surface with PEG, intracellular 
trafficking analysis and scintigraphy-based biodistribution studies.  
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5. Dextrin nanoparticles as a curcumin 
delivery system; studies on the stability 
of self-assembled nanoparticles  
 
 
 
 
 
 
 
 
 
urcumin is a natural polyphenol with anti-oxidative, anti-inflammatory and 
anti-cancer properties. Its therapeutic potential is substantially hindered by 
the rather low water solubility and bioavailability, hence the need for suitable carriers. In 
this study, we show that self-assembled nanoparticles – also called nanogels or 
macromolecular micelles – obtained from hydrophobically modified dextrin are effective 
curcumin nanocarriers. The stability and loading efficiency of curcumin in the dextrin 
nanoparticles depends on the polymer/curcumin ratio; higher stability is achieved in water 
than in PBS buffer, as analysed by dynamic light scattering. Fluorescence resonance 
energy transfer experiments were carried out to evaluate the spatial re-
distribution/assembly of aqueous dispersions of dexC16 nanoparticles. The in vitro release 
of curcumin and cytotoxicity on HeLa cell cultures were estimated using the MTS assay. 
 
C 
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5.1 Introduction  
Curcumin is a multi-functional and pharmacologically safe natural agent. Chemically it 
is a low-molecular-weight polyphenol derivative, extracted from rhizomes of Curcuma 
species. Used as a food additive for centuries, it has been recently demonstrated that 
curcumin is highly pleiotropic, interacting physically with diverse molecular targets, which 
includes transcription factors, growth factors and their receptors, cytokines, enzymes, and 
genes regulating cell proliferation and apoptosis (Goel, et al., 2008). Curcumin possess 
potent anti-inflammatory, anti-tumor and anti-oxidative (free radical scavenging activity) 
properties. Pre-clinical data shows that curcumin inhibits the formation of tumors in 
animal models of carcinogenesis, induce apoptosis in cancer cells of different tissues or 
organs, such as colon, breast, prostate and lung, acting on a variety of signal 
transduction pathways and molecular targets involved in the development of cancer 
(Lopez-Lazaro, 2008). The ability of curcumin to induce apoptosis in cancer cells, without 
cytotoxic effects on the healthy ones, is suggestive of a relevant anti-cancer potential. For 
instance, curcumin leads to apoptosis in scleroderma lung fibroblasts without affecting 
normal lung fibroblasts (Tourkina, et al., 2004). Preferential uptake of curcumin by tumor 
cells compared to normal cells was also demonstrated.  
Curcumin, being a lipophilic molecule, interacts with the cellular membrane and is 
subsequently internalized, probably by diffusion. The higher curcumin uptake by tumor 
cells, against normal ones, has been assigned to various hypothetic factors, including the 
different membrane structure, protein composition and larger size (Kunwar, et al., 2006). 
The anti-oxidant activity of curcumin has been identified as the key mechanism by which 
this dietary phytochemical prevents cancer in vivo. Curcumin also allows reduction of 
oxidative and inflammatory stress in Alzheimer patients (Lim, et al., 2001). Indeed, 
curcumin has also been shown to inhibit mediators of inflammation such as cyclo-
oxygenase-2 and lipooxygenase (two enzymes involved in inflammation) (Huang, et al., 
1991), inducible nitric oxide synthase (enzyme that catalyzes the production of nitric 
oxide) (Chan, et al., 1998), cytokines and NF B.  
Despite all these promising characteristics, a major problem with curcumin is the very 
low solubility in aqueous solutions, which limits bioavailability and clinical efficacy. 
Interest in the development of nanocarriers for curcumin therapy is emerging. Polymeric 
nanoparticles have gained attention due to several advantages, such as low toxicity, high 
stability and small size, which may allow passive targeting of solid tumor tissues by 
enhanced permeation and retention (EPR) effect. Being highly hydrophobic, curcumin is 
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insoluble in water but soluble in ethanol, dimethylsulfoxide and acetone. The 
encapsulation of a highly hydrophobic compound like curcumin in nanocarriers makes it 
readily soluble in aqueous systems, improving the ease of dosing and making 
intravenous administration possible. In a clinical study, after oral administration of 2 g kg-1 
of curcumin to rats, a maximum serum concentration of 1.35±0.23 µg mL-1 was observed 
at time 0.83 h, whereas in humans the same dose of curcumin resulted in extremely low 
(0.006±0.005 µg mL-1 at 1 h) serum levels (Shoba, et al., 1998). 
In a previous work, we described the production and characterization of new dextrin 
nanoparticles - also called nanogels or macromolecular micelles - obtained by self-
assembling of hydrophobically modified dextrin. The use of this material for curcumin 
solubilisation and delivery is now reported. Curcumin loading efficiency, stability and 
release profile were studied. The biocompatibility of nanoparticles and the bioactivity of 
the curcumin/nanoparticles formulation were evaluated using the (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS assay) using 
HeLa cell cultures.  
 
 
5.2 Experimental section 
5.2.1 Materials 
Dextrin-VA-SC16 (dexC16) was synthesized as comprehensively described previously 
(Gonçalves, et al., 2007). DexC16 is composed by a hydrophilic dextrin backbone with 
grafted acrylate groups (VA - vinyl acrylate), which are partially substituted with long alkyl 
chains (SC16). In this work, dexC16 with a degree of substitution of dextrin with acrylate 
groups and alkyl chains was respectively 13.0% (DSVA) and 6.0% (DSC16). Curcumin was 
purchased from Fluka and (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) (MTS) from Promega. SAMSA (5-((2-(and-3)-S-
(acetylmercapto) succinoyl) amino) fluorescein (SAMSA-F) and QSY-7 amine 
hydrochloride (QSY-7) were obtained from Invitrogen. Ethanol was purchased from 
AppliChem. 
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5.2.2 Preparation of polymeric nanoparticles  
Polymeric nanoparticles were obtained by dispersion of dexC16 in water, avoiding the 
use of any organic solvent. Lyophilized dexC16 was dispersed in water or phosphate-
buffered saline (PBS) solution under stirring at 50ºC, until a clear solution was obtained. 
The solution was then filtrated through a 0.22 µm syringe filter. The polymer 
concentration must be higher than 0.008 mg/mL, previously identified as the critical 
micelle concentration (CMC) (Gonçalves, et al., 2007) required for the amphiphilic 
polymer to self-assemble in water, originating nanostructures containing hydrophobic 
domains, allowing the solubilization of hydrophobic molecules.  
5.2.2.1 SAMSA-F labelled nanoparticles 
In order to label the nanoparticles with SAMSA fluorescein (SAMSA-F), the following 
solutions were prepared: (1) Nanoparticle solution – 10 mg of dexC16 were dissolved in 
1.3 mL of sodium phosphate buffer 0.1 M pH 7 and stirred for 30 min; (2) fluorescein 
solution - 5 mg of SAMSA-F were dissolved in 0.5 mL of NaOH 0.1 M and stirred for 15 
min. Afterwards, 7 µL of HCl 6 M and 0.1 mL of NaPO4 buffer 0.5 M pH 7 were added and 
stirred for 10 min. Finally, these two solutions were mixed up and stirred for 30 min. 
Unbound fluorescein was separated using gel filtration in a sephadex G25 PD10 column 
equilibrated with PBS. SAMSA-F-labelled nanoparticles were eluted with PBS, sterilized 
by filtration through a 0.22 µm membrane and stored at 4ºC. SAMSA-F labelling did not 
affect the nanoparticles size distribution, as estimated by dynamic light scattering. 
5.2.2.2 QSY-7 labelled nanoparticles 
In order to label the nanoparticles with QSY-7, the following solutions were prepared: 
(1) Nanoparticle solution – 5 mg of dexC16 were dissolved in 2 mL DMSO; (2) QSY-7 
solution - 5 mg of QSY-7 were dissolved in 1.0 mL of DMSO. Then, 246 µL of QSY-7 
solution and nanoparticle solution were mixed up and 1 µL of TEA was added; the 
mixture was stirred overnight at room temperature, and dialysed for 48 h against 
frequently changed water. To guarantee total removal of unbound QSY-7, the labelled 
nanogel was further purified by gel filtration in a sephadex G25 PD10 column equilibrated 
with PBS. Nanoparticles labelled with QSY-7 were eluted with PBS, sterilized by filtration 
through a 0.22 µm membrane and stored at 4ºC. QSY-7 labelling did not affect the 
nanoparticles size distribution, as estimated by dynamic light scattering. 
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5.2.3 Curcumin loading, efficiency and stability 
Curcumin has been loaded into the hydrophobic domains of nanoparticles. The 
physical entrapment of curcumin in the nanoparticles was performed following the 
nanoparticles formation, as described ahead. A stock solution of curcumin in ethanol with 
a concentration of 2.7 mM was prepared. The required volume of curcumin from this 
solution was added to the nanoparticles solution (final concentration of ethanol < 1%). 
The effect of polymer/curcumin ratio on the loading efficiency and stability of the 
formulation was studied. Different formulations were prepared by varying the curcumin 
(10, 30, 50 µM) and polymer (0.1, 0.25, 0.5, 1.0 or 2.0 mg/mL) concentrations. In order to 
evaluate the stability of the dispersion, the solutions were kept under stirring at 37ºC up to 
8 days. The resultant solution was centrifuged at 4000 rpm (Sigma 4K-15 refrigerated 
centrifuge) and 4ºC, for 10 min, to remove the insoluble curcumin. The clear yellowish 
supernatant was carefully collected and analyzed spectrophotometrically. The 
quantification was carried out using a calibration plot obtained with curcumin 
concentrations between 0.3 and 30 µM. The entrapment efficiency was calculated by the 
Equation 5.1: 
[ ]
[ ] added
edencapsulat
CM
CM
=(%)efficiencyEntrapment   (Equation 5.1) 
The size distribution of loaded and unloaded nanoparticles was determined by 
dynamic light scattering (DLS) using a Malvern Zetasizer, MODEL NANO ZS (Malvern 
Instruments Limited, U.K.). The nanoparticles dispersion was analysed at 25ºC in a 
polystyrene cell, using a He-Ne laser - wavelength of 633 nm and a detector angle of 
173º. The DLS analysis provides the characterization of a sample through the mean 
value (z-avg) for the diameter, and a width parameter known as the polydispersity index 
(PdI). 
5.2.4 Curcumin release  
In the present work, the release of curcumin from the nanoparticles was studied using 
sink conditions – sample in a dialysis membrane – and a closed system - sample in a 
flask. The curcumin loaded nanoparticles (30 µM of curcumin and 1.0 mg/mL of polymer 
in an aqueous solution) were maintained in a glass flask or transferred to a dialysis bag. 
The dialysis bag (molecular cut off of 10 kDa) was placed in 200 mL of distilled water or 
PBS, shaken under 500 rpm at 37ºC. At predefined timeframe (up to 24 h), a sample of 
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200 µL was withdrawn from each condition, centrifuged to guarantee removal of 
unentrapped curcumin and the supernatant was analyzed spectrophotometrically (Jasco 
V560). At the end of the assay, after 24 h, the size distribution of the nanoparticles was 
evaluated by DLS. 
5.2.5 Fluorescence measurements  
To understand the spatial re-distribution/assembly of distinct dispersions of dexC16 
nanoparticles, after mixing, fluorescence resonance energy transfer (FRET) was used. 
FRET is a distance-dependent interaction between the electronic excited states of two 
dye molecules in which excitation is transferred from a donor molecule to an acceptor 
one without emission of a photon. Thus, FRET is a technique suitable for investigating a 
variety of biological phenomena that produce changes in molecular proximity. In this 
work, the pair fluorescein/QSY-7 was used as donor/acceptor. Non-fluorescent 
acceptors, such as QSY dyes, have the particular advantage of eliminating the potential 
problem of background fluorescence resulting from direct (i.e., nonsensitized) acceptor 
excitation. In this study, FRET is detected by quenching of donor fluorescence.  
Nanoparticles with covalently attached SAMSA-F and those with the non-fluorescent 
acceptor QSY-7 were mixed; then, PBS solution was added for the system to reach the 
required final concentration of material. Steady-state as well as time resolved 
fluorescence studies were performed to evaluate the distribution/re-distribution of each 
population after mixing. Additional studies were performed with SAMSA-F labelled 
nanoparticles (0.115 mg/mL) diluted in distilled water or PBS, over time, using time 
resolved fluorescence to ascertain the occurrence of structural modifications.  
The steady-state fluorescence measurements were performed with a Spex Fluolog 3 
spectrofluorimeter at room temperature. All spectra were corrected for the instrumental 
response of the system. The excitation wavelength was set at 460 nm. The steady state 
quenching ratio was calculated using the emission spectra area of SAMSA-F labelled 
nanoparticles between 470 nm and 600 nm in the presence (I) and absence (Io) of QSY-7 
labelled nanoparticles. 
The fluorescence decay times were determined using the frequency-doubled output of 
a Ti:Sa laser at 399 nm for excitation and measuring the emission at 540 nm. The decay 
curves were gained by Time Correlated Single Photon Counting (TCSPC) using a Becker 
& Hickl SPC-150 computer board collecting the photon detection events from a 
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Hamamatsu MCP R3809U-51 photon counting unit. The time resolution was 20 ps. Data 
fitting was done with the Picoquant Fluolog software by deconvolution of the Instrument 
Response Function (IRF), allowing the recovery of the average life time in the presence 
(τ) and absence (τ0) of QSY-7 labelled nanoparticles. 
5.2.6 Cell culture and cytotoxicity assay 
The cytotoxicity of free or encapsulated curcumin was evaluated by MTS, a 
colorimetric assay that gives a measure of the mitochondrial metabolic activity. Human 
cervical cancer cells (HeLa) were counted and seeded at 4101× cells/well into 24-well cell 
culture plates, in cDMEM medium with 10% fetal bovine serum, and allowed to adhere for 
24 h at 37ºC and 5% CO2 atmosphere. Afterwards, the culture medium was decanted and 
replaced with fresh culture medium or with the test conditions. Nanoparticles (0.10 or 
0.25 mg/mL), free or encapsulated curcumin (30 µM) were tested. Then, plates were 
incubated for 24 or 48 h in triplicate, at 37ºC, 5% CO2. The viability of the cells after 
treatment was determined by the MTS assay, as described ahead. The culture medium 
of each well was decanted and replaced with 100 µL of fresh culture medium. Then, 20 
µL of “CellTiter 96® AQueous One Solution Reagent” was added into each well and the 
plates were incubated for 2 h at 37ºC, 5% CO2. The amount of soluble formazan 
produced by cellular reduction of the MTS was measured at 490 nm. The absorbance at 
490 nm is proportional to the cell number. 
 
5.3 Results and discussion 
5.3.1 Curcumin loading, efficiency and stability 
The possibility of enhancing curcumin's solubility using polymeric nanoparticles as 
nanocarrier was investigated in this work. Soluble curcumin obtained in a suitable solvent 
such as ethanol (Figure 5.1) exhibits intense absorption in the wavelength range from 
350 to 550 nm, with a maximum absorption at 428 nm. The addition of curcumin 
dissolved in ethanol to water (to a final concentration of ethanol < 1%), leads to curcumin 
precipitation. On the other hand, the addition of curcumin to aqueous solutions of 
nanoparticles results in a bright yellow solution (Figure 5.1a), suggesting the entrapment 
of curcumin, presumably into the hydrophobic domains within the nanoparticles. Indeed, 
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the UV-Vis spectra reveal an intense absorption at 428 nm, confirming the curcumin 
dissolution (Figure 5.1b).  
 
 
 
 
 
 
 
 
 
Figure 5.1. Supernatant of curcumin (a) dissolved in different solvents (from left: ethanol, 
aqueous solution of nanoparticles, PBS solution of nanoparticles, water and PBS solution) and 
(b) ultraviolet-visible absorbance spectra for each condition. 
The size of the self-assembled nanoparticles, with or without curcumin, was 
determined by dynamic light scattering. The mean diameters (z-avg) of unload or 
curcumin-loaded nanoparticles were found to be 61.1 nm (PdI 0.243) and 74.6 nm (PdI 
0.368) for water or 59.2 nm (PdI 0.209) and 90.9 nm (PdI 0.422) for PBS solution, 
respectively. The colloidal stability of nanoparticles (in water or PBS solution) has been 
previously assessed (Gonçalves, et al., 2008) using dexC16 with a higher degree of 
substitution (DSC16 8.7% vs 6.0% in this work), up to 7 days. High stability was observed 
in both water and PBS solution, since no aggregates were detected and a low 
polydispersity index was conserved. The more substituted polymer forms more densely 
packed hydrophobic domains, such that the colloidal stability of nanoparticles is 
increased. In this work, the stability of nanoparticles with DSC16 6.0%, without curcumin, 
in water or PBS solution, was evaluated (Table 5.1), up to 12 days.  
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Table 5.1. Evaluation of mean hydrodynamic diameter (z-avg) and polydispersity index (PdI), of 
dexC16 (DSC16 6.0%) dispersed in distilled water or PBS solution, up to 12 days.  
 
Water PBS solution 
time z-avg (nm) PdI z-avg (nm) PdI 
freshly  prepared 61.1 0.243 59.2 0.290 
3 days 62.3 0.304 72.2 0.312 
5 days 61.0 0.270 79.1 0.285 
12 days 58.7 0.244 100.0 0.247 
 
 
A general conclusion may be drawn from the results: the nanoparticles prepared in a 
saline solution (buffer) present an increased size along with the incubation period, 
apparently associated to a swelling process when compared to those dispersed in water. 
A successful nanodelivery system should have a high drug-loading capacity, thereby 
reducing the quantity of carrier for administration. Additionally, drug-loaded nanoparticles 
should be able to retain the drug for a prolonged time in circulation, for effective targeting 
of tissues. In this work, different formulations were prepared to evaluate the effect of 
polymer/curcumin ratio on the loading efficacy and stability, using both distilled water or 
PBS solution as the dispersion medium. Figure 5.2 shows the concentration of curcumin 
obtained using different proportions of nanoparticles and curcumin. 
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Figure 5.2. Curcumin loading into dextrin nanoparticles in (a) aqueous or (b) PBS solution of 
different formulations varying the curcumin (10, 30, 50 µM) and polymer (0.1, 0.25, 0.5, 1.0 or 2.0 
mg/mL) concentrations, () 3 h, () 24 h or () 8 days after incubation. 
The results of curcumin loading in aqueous solution (Figure 5.2a) show that for a 
constant polymer concentration, the higher curcumin loads results in lower stability over 
time. For instance, for the highest polymer concentration studied (2.0 mg/mL), 10 or 30 
(a) 
(b) 
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µM of curcumin remain stable until 8 days. The lower curcumin concentration tested (10 
µM) is stabilized by a polymer concentration of 0.25 mg/mL. Increasing the curcumin 
concentration to 30 µM, requires a polymer concentration of at least 1.0 mg/mL. Thus, as 
could be expected, there is an optimal proportion of curcumin/nanoparticle that allows a 
stable system to be obtained; high loadings results in unstable systems. Curcumin 
loading in PBS solution (Figure 5.2b) shows similar results in the first period of 
observation (3 h). However, a relevant difference is noticeable for longer incubation time 
frames: curcumin solutions are unstable for every formulations studied.  
To evaluate the spatial re-distribution/assembly of distinct dispersions of dexC16 
nanoparticles, after mixing, nanoparticles with covalently attached SAMSA-F and those 
with the non-fluorescent acceptor QSY-7 were mixed and fluorescence measurements 
were performed. Comparing the fluorescence intensity of SAMSA-F in the steady state, 
or the fluorescence decay time in the time resolved fluorescence, with or without acceptor 
dye, some differences are evident. Both steady state and time resolved fluorescence 
measurements show a quenching effect as can be concluded from I0/I> 1 and τ0/τ> 1 
(Table 5.2). But as these ratios are different, we conclude that part of the quenching 
effect results from a non-fluorescent ground-state complex formation between SAMSA-F 
and QSY-7 labelled dexC16 (Valeur, 2002). 
 
Table 5.2. SAMSA-F fluorescence quenching by QSY-7. 
[SAMSA-F NPs] = 0.115 mg/mL [SAMSA-F NPs] = 0.080 mg/mL 
[QSY-7 NPs] = 0.20 mg/mL  [QSY-7 NPs] = 0.14 mg/mL  
Io/I 1.26 Io/I 1.24 
τo/τ 1.18 τo/τ 1.20 
 
 
The formation of ground-state complexes between SAMSA-F and QSY-7 implies a 
dynamic behavior of the nanoparticles, through an exchange of dexC16 molecules among 
them. The quenching effects observed in the time resolved measurements (τ0/τ> 1) 
indicate that there is also energy transfer from SAMSA-F to QSY-7 for the population of 
labelled dexC16 not forming ground-state complexes (without influence on the 
fluorescence decay). The measurements were done few seconds after mixing and results 
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remained constant up to 30 min (data not shown) suggesting a rapid exchange of dexC16 
between nanoparticles, upon mixing. The dilution of nanoparticles dispersion 
(concentration always kept above the CMC) does not change the quenching efficiency 
(Table 5.2). As FRET is a distance-dependent phenomenon, the nanoparticles dilution 
would result in a decrease of quenching efficiency if the energy transfer occurs between 
different particles (inter-nanoparticle) due to an increase of the average nanoparticles 
distance. So we conclude that this energy transfer takes place within the individual 
nanoparticle (intra-nanoparticle). Although we have not performed similar studies in water 
it is expected that a similar exchange occurs.  
We then tried to see if SAMSA-F can report on the observed structural changes of 
nanoparticles with aging time, in line with the observed instability of curcumin in 
nanoparticles and with the observed growth of particle size. Figure 5.3 shows the 
SAMSA-F fluorescence decays for nanoparticles dispersed in distilled water or in PBS 
over time, up to 14 days. We can see that there is a systematic trend of faster decay of 
SAMSA-F with aging time in the case of nanoparticles in PBS but not in distilled water. 
This can be explained by assuming an alteration of the SAMSA-F environment with time 
from an initially more hydrophobic to a more hydrophilic pocket, as a nanoparticle 
enlargement would lead to a possibly increased exposure of SAMSA-F to water resulting 
in a decreased decay time. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. SAMSA fluorescence decays for nanoparticles dispersed in water or in PBS up to 14 
days. 
 
time (ns) 
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5.3.2 Curcumin release 
To ascertain the suitability of dextrin nanoparticles as delivery systems for hydrophobic 
drugs such as curcumin, the in vitro release was studied. In the literature, different 
methods are reported to evaluate the release profiles using nanoparticles. Open (Shaikh, 
et al., 2009) or closed systems (Das, et al., 2009) have been described. In the former 
case (open system or sink conditions), dialysis membranes are often used. For closed 
systems, loaded-nanoparticles are incubated, enclosed in a flask, under agitation. In the 
present work, the release study of curcumin from nanoparticles was carried out using 
both approaches. At pre-defined time intervals, the soluble drug was quantified 
spectrophotometrically, after centrifugation. This method is based on the fact that 
unentrapped curcumin precipitates after centrifugation, only the entrapped curcumin 
being quantified.  
The results obtained for closed systems show that curcumin remain stable within 
nanoparticles, up to 24 hours, confirming the high stability of the formulation in the 
conditions used. In our opinion, this method assesses curcumin stability instead of 
curcumin release. Using dialysis membrane method, a fast transfer of free curcumin 
across the dialysis bag provided evidence for the presence of sink condition under 
experimental conditions (inset Figure 5.4b). Using the sink method, a sustained release 
was observed for either release mediums. After 1 and 5 h of incubation, the fractions of 
curcumin released were respectively 51.7% and 26.1% using distilled water and 42.7% 
and 19.4% the PBS solution. The release profile without initial burst indicates the 
absence of curcumin adsorbed on the surface of nanoparticles (Mulik, et al., 2009). The 
nanoparticles size distribution was evaluated at the end of dialysis process. The z-avg 
value remained constant during the dialysis process against water (74.7 nm) and slightly 
increased when using PBS solution (103 nm). 
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Figure 5.4. In vitro curcumin release from dextrin nanoparticles (1.0 mg/mL) using (a) closed 
system or (b) dialysis membrane. For dialysis membrane method, distilled water () or PBS 
solution () were used as release medium; free curcumin in ethanol was tested (inset).  
It is well-known that drug release is affected by particle size. Smaller particles have a 
larger surface-to-volume ratio; therefore, most of the drug associated with small particles 
would be at or near the particle surface, leading to faster drug release. In contrast, larger 
particles have large cores, which allow more drug encapsulation per particle, providing a 
slower release. Thus, control of particle size provides a means of tuning the drug release 
(a) 
(b) 
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rates. In the current case, the fairly low size of the nanoparticles may explain the 
complete release of curcumin in a 24 h timeframe. 
5.3.3 Cytotoxicity assay 
An evaluation of the cytotoxicity of nanoparticles was carried out in a previous study, 
using murine bone marrow-derived macrophages: no significant toxicity was found for up 
to concentrations of 1.0 mg/mL (Gonçalves, et al., 2010). In this work, the cytotoxicity of 
the nanoparticles and its formulations with curcumin were evaluated with the HeLa cell 
line. Previous studies on cytotoxicity of HeLa cells showed that the IC50 of free curcumin 
and complexed curcumin was 14.85 and 12.69 µM, respectively; otherwise, complexed 
curcumin showed a cytotoxic effect that was comparable to that of free curcumin (Sahu, 
et al., 2008). 
 
Figure 5.5. Cell viability of HeLa cells after () 0h, () 24h or () 48h of incubation with different 
concentrations of nanoparticles, nanoparticles-loaded curcumin or free curcumin. Empty 
nanoparticles were used to test the cytotoxicity of the nanocarrier. 
In this study, as a positive control, HeLa cells were kept in the culture medium 
(DMEM) without any treatment. Nanoparticles concentration tested do not induce cell 
death up to 48 h, indeed the number of viable cells in contact with nanoparticles is similar 
to the control. The curcumin cytotoxicity (free or loaded on nanoparticles) was assessed. 
Nanoparticles (0.10 or 0.25 mg/mL) were loaded with curcumin (30 µM). When treated 
with curcumin, cells react to encapsulated curcumin (irrespective of the nanoparticles 
concentration) as effectively as free curcumin. The benefit of curcumin entrapment into 
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nanoparticles is to overcome the limited bioavailability after in vivo administration without 
any organic solvent use. 
 
5.4 Conclusions 
Dextrin nanoparticles served as an effective ‘‘nanocarrier’’ for the formulation of 
lipophilic curcumin by increasing its water solubility, improving its stability, and controlling 
its release profile. Incorporation of curcumin into nanoparticles did not compromise its 
cytotoxicity in HeLa cell line. Therefore, dextrin nanoparticles hold promise as delivery 
system for the development of an injectable formulation of curcumin for the treatment of 
human cancers. The small size of this system can be advantageous for passive targeting 
of tumor tissues by the EPR effect. 
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6. Studies on the biodistribution of dextrin 
nanoparticles 
 
 
 
 
 
he characterization of biodistribution is a central requirement in the 
development of biomedical applications based on the use of nanoparticles, 
in particular for controlled drug delivery. The blood circulation time, organ biodistribution 
and rate of excretion must be well characterized in the process of product development. 
In this work, the biodistribution of recently developed self-assembled dextrin 
nanoparticles is addressed. Functionalization of the dextrin nanoparticles with a DOTA-
monoamide-type metal chelator, via click chemistry, is described. The metal chelator-
functionalized nanoparticles were labelled with the γ-emitting 153Sm3+ radioisotope and the 
blood clearance rate and organ biodistribution of the nanoparticles were obtained. The 
effect of PEG surface coating on the blood clearance rate and organ biodistribution of the 
nanoparticles was also studied. 
 
 
T 
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6.1 Introduction 
 Nanomedicine has emerged in recent years as an exciting area for chemists, 
materials scientists, engineers and medical doctors, converging in the development of 
new tools for diagnostics and therapeutics (Fernandez-Montesinos, et al., 2009) (Leary, 
et al., 2006) (Farokhzad, et al., 2006). A rather large number of nanostructures have 
been developed over the past few decades. Well-defined polymeric nanostructures, on 
the same size-scale as proteins and cellular structures, are promising vehicles for 
diagnostics and drug-delivery (Weinstein, et al., 2010). The capability to carry and 
release a therapeutic payload in a controlled way, coupled to imaging ability opens the 
way to theragnostics (Shubayev, et al., 2009). A major limitation in the use of (polymeric) 
nanoparticles in vivo is their premature elimination from the circulatory system by the 
mononuclear phagocyte system (MPS), which prevents the nanoparticles from reaching 
their target (Owens, et al., 2006). The disposal of particles through the MPS begins with 
the adsorption of serum proteins (opsonins) onto the surface of the nanoparticles, 
followed by macrophage recognition, phagocytosis, and subsequent sequestration in the 
liver, spleen, and/or bone marrow. To address these limitations, several methods have 
been developed to mask or camouflage nanoparticles from the MPS. Among these, the 
preferred one is the grafting of poly(ethylene glycol) (PEG) onto the surface of 
nanoparticles (Peracchia, et al., 1999a). The purpose of the PEG chains is to block the 
adhesion of opsonins present in the blood serum, such that the particles remain invisible 
to phagocytic cells. Using transmission electron microscopy, it has been possible to 
visualise the protein rejecting capabilities of PEGylated surfaces (Peracchia, et al., 
1999b). PEG 5,000 has proved to be a threshold for maximum reduction of protein 
adsorption (Gref, et al., 2000) and lower uptake in the liver (Pressly, et al., 2007). 
In recent years, the Michael addition of thiols to acrylates, acrylamides and 
vinylsulfones has acquired the status of a click reaction: it can be performed selectively 
under mild (aqueous) conditions. The major disadvantage of this reaction in comparison 
to the dipolar addition of azides to terminal alkynes is the possibility of thiol oxidation to 
disulfide and its inherent lack of bio-orthogonality, deriving from many endogenous thiols 
(Hiemstra, et al., 2007, Van Dijk, et al., 2009). Recently, our research group has reported 
the preparation of the acrylate ester functionalized dextrin: dexVA. The Michael addition 
of hexadecanethiol to dexVA generates an amphiphilic material, dexC16, which self-
assembles in water into well defined nanoparticles, stable macromolecular micelles 
(nanogel) (Gonçalves, et al., 2007). Importantly, the dexC16 nanoparticles can be loaded 
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with a hydrophobic cargo, e.g., curcumin (anti-cancer drug), for drug delivery purposes 
(Bisht, et al., 2007, Shaikh, et al., 2009). 
To evaluate the potential of the dexC16 nanogel for drug delivery purposes, the 
nanogel was labelled, via Michael addition of a thiol-functionalized fluorescent probe to 
the acrylate groups, and its blood clearance was studied in BALB/c mice (Gonçalves, et 
al., 2010). Although the blood clearance of the nanogel could be readily followed by 
fluorescence measurements, its organ distribution profile could not be evaluated, possibly 
due to quenching effects of the fluorescent probe in the organ´s homogenates. It is widely 
accepted that the physical and chemical properties of the nanoparticles, including particle 
size, surface charge, and surface hydrophilicity, are important parameters determining 
their biological fate after intravenous administration (Li, et al., 2008). It is, therefore, 
crucial to devise a labelling methodology that conserves the native nanoparticle 
properties. To obtain the biodistribution profile of the nanoparticles in experimental 
animals, we envisaged labelling the nanogel with a radioactive label. With this goal, we 
have synthesized a new ω-thiol functionalized DOTA-monoamide type metal chelator 
(DOTA=1,4,7,10-tetraazacyclododecanetetraacetic acid) for covalent functionalization 
(via Michael addition) and labelling (complexation) of a suitable Ln3+ (e.g., 153Sm3+) 
radioisotope. DOTA-like chelators are well known to form lanthanide (III) chelates of high 
thermodynamic and kinetic stability, which is of crucial importance for in vivo applications 
(Port, et al., 2008). 
In the present study, the biodistribution and blood clearance of dextrin nanoparticles 
labelled with 153Sm3+-DOTA-type chelates has been studied in experimental animals after 
intravenous administration. The effect of surface decoration with PEG on the 
biodistribution was also evaluated.  
 
 
6.2 Experimental section 
6.2.1 Materials 
Dextrin-VA (dexVA) and dextrin-VA-SC16 (dexC16) were synthesized as 
comprehensively described before (Gonçalves, et al., 2007). DexVA is the dextrin 
backbone with grafted acrylate ester groups (VA - vinyl acrylate). DexC16 is composed by 
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the hydrophilic dextrin backbone with grafted VA groups, which are partially substituted 
with long alkyl hexadecanethioalkyl chains (SC16). In this work, dexC16 with 13 acrylate 
groups (DSVA 13%) and 6 hexadecanethioalkyl chains (DSC16 6%) per 100 dextrin 
glucopyranoside residues was used. 
O-[2-(3-Mercaptopropionylamino)ethyl]-O′-methylpolyethylene glycol 5,000 (PEG-SH), 
europium (III) chloride hexahydrate 99.99%, samarium (III) chloride hexahydrate 99% 
(SmCl3), dimethyl sulfoxide (DMSO), triethylamine (TEA) and deuterium oxide (D2O) were 
purchased from Aldrich. Regenerated cellulose tubular membranes, with 3500 MWCO, 
were obtained from Membrane Filtration Products. 
153SmCl3 was produced at the Instituto Tecnológico e Nuclear, Lisbon, Portugal with a 
specific radioactivity of > 5 GBq/mg. For this purpose, 153Sm2O3 was prepared from a 
98% 152Sm enriched Sm2O3 target, sealed into a quartz vial and welded into an aluminum 
can, by neutron irradiation using a thermal flux of 2.3X1013 n/cm2.s. After irradiation, the 
sample was opened, dissolved in 1 M HCl, and the final 153SmCl3 solution was brought to 
a stock concentration of 1.9 X10-3 M. 
6.2.2 Synthesis of ω-thiol functionalized metal chelator  
Synthesis of tris-tert-butyl 2,2',2''-(10-(2-((2-(4-mercaptobutanamido)ethyl)amino)-2-
oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (3) (Scheme 6.1): to a 
solution of compound 2 (430 mg, 0.70 mmol) in methanol (30 cm3) was added 
triethylamine (0.17 cm3, 1.2 mmol) and γ-butyrothiolactone (0.61 g, 6.0 mmol). The 
reaction mixture was stirred at 50 ºC under nitrogen atmosphere for 6 hours and left 
stirring at room temperature overnight. The reaction mixture was concentrated under 
reduced pressure and the residue was purified by a flash chromatography (100% CH2Cl2 
 CH2Cl2/EtOH (70:30)) to afford the title compound (3) as a colorless oil (0.162 g, 32%). 
1H NMR (300 MHz, D2O): δ = 1.46 (s, 27H, tert-Bu), 1.97 (m, 2H, C(O)CH2CH2CH2SH), 
2.49 (m, 2H, C(O)CH2CH2CH2SH), 2.57 (m, 2H, C(O)CH2CH2CH2SH), 2.20-3.80 (broad, 
overlapped signals with a integration corresponding to approximately 28 H, N(CH2)2N, 
NCH2C(O) and C(O)NHCH2CH2NHC(O)), 8.2 and 8.6 (broad signals,  
C(O)NHCH2CH2NHC(O)). 
Synthesis of 2,2',2''-(10-(2-((2-(4-mercaptobutanamido)ethyl)amino)-2-oxoethyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (4): compound (3) (162 mg, 226 
µmol) was dissolved in a mixture ethanol/aqueous HCl 6 M (1/1 v/v; 20 cm3) and left to 
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stirring overnight at room temperature. The solution was concentrated under reduced 
pressure and further dried under vacuum to afford the title compound (4), in the 
hydrochloride form, as a white vitreous solid (121 mg). 1H NMR (300 MHz, D2O): δ = 1.88 
(m, 2H, J = 7.5 Hz, C(O)CH2CH2CH2SH), 2.38 (t, 2H, J = 7.5 Hz,  C(O)CH2CH2CH2SH), 
2.54 (t, J = 6.9 Hz, 2H, C(O)CH2CH2CH2SH), 3.00-3.70 (broad, overlapped signals with a 
integration corresponding to approximately 28 H, N(CH2)2N, NCH2C(O) and 
C(O)NHCH2CH2NHC(O)). 13C NMR (75.4 MHz, D2O): 24.82 (C(O) CH2CH2CH2SH), 34.34 
(C(O) CH2CH2CH2SH), 37.12 (C(O) CH2CH2CH2SH), 38.61 (CH2), 38.83 (CH2), 39.88 
(CH2), 41.74 (CH2), 48.21 (CH2), 48.84 (CH2), 50.54 (CH2), 51.30 (CH2), 51.57 (CH2), 
53.49 (CH2), 55.71 (CH2), 55.83 (CH2), 56.50 (CH2), 170.66 (C(O)OH), 173.25 (C(O)OH), 
174.92 (C(O)NH), 176.42 (C(O)NH). MS (ESI-LR): m/z (%): 577.5 (18), 571.5 (66.5) 
[M+Na]+, 549.5 (100) [M+Na]+, 447.5 (5). 
 
 
 
Scheme 6.1.Synthesis of the ω-thiol functionalized metal chelator DOTA-butyroamide (4) and its 
Eu3+ complex (5): a) γ-butyrothiolactone/TEA/MeOH; b) HCl/EtOH; c) EuCl3.6H2O 
6.2.3 Preparation of DOTAdexC16 or DOTAdexC16PEG materials 
In the first step dexVA was reacted with the ω-thiol-functionalized metal chelator (4) to 
afford the metal chelator-grafted material. In the second step, hexadecanethiol was 
added to the former material to afford the DOTAdexC16 material (9). Finally, a thiol-
functionalized PEG molecule was added to produce the DOTAdexC16PEG material (11). 
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Scheme 6.2. Synthesis of the DOTAdexC16 and DOTAdexC16PEG and its Eu3+ complexes. 
DexVA is the dextrin backbone with grafted acrylate ester groups (Scheme 6.2). For 
the sake of simplicity, the grafted acrylate groups are represented at position 2 of the 
glucopyranoside ring (major regioisomer), although grafting in position 3 (minor 
regioisomer) can be detected by 1H NMR, as reported before (Carvalho, et al., 2007). 
DexC16 is composed by the hydrophilic dextrin backbone with grafted VA groups, which 
are partially substituted with hexadecanethiol chains (SR = hexadecanethiol). In this 
work, dexC16 (8) with 13 acrylate groups (DSVA 13%) and 6 hexadecanethiol chains 
(DSC16 6%) per 100 dextrin glucopyranoside residues was used. For the sake of clarity 
the unreacted VA ester groups are not shown on the materials (only substituted VA ester 
groups are represented). DexVA (50 mg, DSVA 13%, 38.45 µmol equivalent VA) was 
dissolved in DMSO (0.931 cm3). To this solution was added a solution of compound 4 (11 
mg, 19.23 µmol, 50% mol to VA groups) and triethylamine (16 µL, 0.115 mmol, 3 molar 
equivalents to VA groups). The medium was stirred for 24 h, at 50 ºC. In the second step 
the addition of hexadecanethiol (6) was performed as previously reported (Gonçalves, et 
al., 2007). Briefly, hexadecanethiol (7.95 mg, 30.76 µmol, 80 % relatively to VA groups) 
and triethylamine (11 µL, 38.45 µmol, 1 mol equivalent to VA groups) were added to the 
reaction mixture. The medium was stirred for 24 h, at 50 ºC. The mixture was dialysed for 
48 h against water, with frequent water changes. After freezedrying, material (9) was 
obtained as a white candyfloss-like material and stored at room temperature.  
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DOTAdexC16PEG (11) was obtained by dissolving DOTAdexC16 (9) (15 mg, 12.2 µmol 
equivalent VA), PEG-SH (7) (18 mg, 3.66 µmol, 30% mol to VA groups) and triethylamine 
(3.4 µL, 24.4 µmol, 2 mol equivalent to VA groups) in DMSO (0.295 cm3). The mixture 
was stirred for 24 h, at 50 ºC and then dialysed for 48 h against water, with frequent water 
changes. After freezedrying, the product was obtained as a white candyfloss-like material 
and stored at room temperature. 
6.2.4 Complexation of Eu3+ with ω-thiol functionalized chelator and 
DOTAdexC16 materials 
In order to ascertain the success of DOTA coupling to dexC16 and its chelating 
capacity, DOTAdexC16 (9) was complexed with Eu3+ as a model metal ion. The 
[Eu(DOTAdexC16)] (10) complex was prepared by mixing a solution of EuCl3.6H2O with a 
solution of DOTAdexC16 in D2O. A slight excess (5%) of Eu3+ was used in relation to the 
amount of metal chelator used in the synthesis of the DOTAdexC16 material. The reaction 
mixture was adjusted to pH 5.5 by adding aqueous NaOD (0.1 mM) and was allowed to 
react for 24 h at 50 ºC. The reaction mixture was adjusted to pH 7.0, filtered through a 0.2 
µm filter and characterized by 1H NMR, DLS and zeta potential measurements. 
The number of DOTA groups attached to the polymer backbone was estimated by 
back titration of excess (uncomplexed) Eu3+ metal with EDTA in the presence of the 
complexometric indicator, xylenol orange (Brunisholz, et al., 1959). The amount of 
chelator agent grafted to the dexC16 material was estimated 0.152 µmol of DOTA chelator 
units/mg DOTAdexC16 material. 
6.2.5 Preparation of [153Sm(DOTAdexC16)] and [153Sm(DOTAdexC16PEG)] 
chelates for biodistribution studies  
To a dispersion of DOTAdexC16 or DOTAdexC16PEG (5 mg) in sodium acetate buffer 
(400 µL, 0.4 M, pH 5) 153SmCl3  (1 mCi) was added. Each solution was stirred at 80 ºC for 
5 h. After that, cold SmCl3 was added to each solution in order to obtain an equimolar 
Sm3+:DOTA ratio. The final solution was heated at 80 ºC for 2 h and stayed overnight at 
room temperature. The radiolabelled nanoparticles were purified using a Sephadex G-25 
column eluted with 0.4 M acetate buffer. The nanoparticle dispersions were concentrated 
by centrifugal filtration (centricons, MWCO 10 kDa) to afford the pure radioligands. The 
complexation yield is ca 50 % in both cases.  
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6.2.6 Size distribution and zeta potential 
The size distribution and zeta potential of nanoparticles were determined with a 
Malvern Zetasizer, NANO ZS (Malvern Instruments Limited, UK), using a Helium-Neon 
laser (wavelength of 633 nm) and a detector angle of 173º. Nanoparticles dispersion (1 
mL) was analysed at 25 ºC and 1.0 mg/mL. The DLS analysis provides the 
characterization of a sample through the mean value (z-avg) for the size and a width 
parameter known as the polydispersity or polydispersity Index (PdI). The z-avg is the 
mean hydrodynamic diameter, determined from the intensity of scattered light, which can 
be converted to other distributions. In the present work, the z-avg is considered the best 
approach to the actual nanoparticles size. Nanoparticles dispersion was analysed in a 
polystyrene cell or in a folded capillary cell, for size distribution or zeta potential 
measurements, respectively. The zeta potential values were calculated using the 
Smoluchowski equation (Hunter, 1981). Repeated measurements were performed for 
each analysis (3 times) and the values reported are average values.  
6.2.7 1H NMR 
Nanoparticles were dispersed in deuterium oxide (10.0 mg/mL). Dispersions were 
transferred to 5 mm NMR tubes. 1D 1H NMR measurements were performed with a 
VARIAN UNITY Plus 300 spectrometer operating at 299.94 MHz. 1D 1H NMR spectra 
were measured at 298 K with 80 scans, a spectral width of 4800 Hz, a relaxation delay of 
1 s between scans and an acquisition time of 3.75 s. 
6.2.8 Blood clearance and biodistribution studies 
The biodistribution of dextrin nanoparticles labelled with 153Sm3+ was evaluated 
following intravenous administration in Wistar rats. Groups of four animals were 
anesthetized and injected in the femoral vein with ca 100 µl (20-100 µCi) of the 
nanoparticles mixture. After pre-defined periods of time, the rats were sacrificed and their 
tissues (liver, spleen, lungs, bone (femur of left hind leg), intestines (small and large), 
kidney, heart and brain were excised, weighed and tissue radioactivity measured in a γ 
well-counter. Blood samples were obtained at appropriate periods of time, weighted and 
radioactivity counted. The same procedure was used to evaluate the influence of the 
presence of PEG chains in the nanoparticles biodistribution: a group of four animals was 
injected in the femoral vein with the radiolabelled DOTAdexC16PEG and sacrificed 2 h 
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later for organs collection. The national regulations for the care and use of laboratory 
animals have been observed in this study. 
 
6.3 Results and discussion 
6.3.1 Synthesis of ω-thiol functionalized metal chelator  
We have previously described the synthesis of the bifunctional metal prochelator (2) 
bearing a functional amine group ready for conjugation to (bio)molecules (André, et al., 
2004). In this work, we have used γ-butyrothiolactone as a protected activated ω-thiol 
carboxylic acid equivalent (Scheme 6.1). This procedure allows performing the amide 
coupling without coupling reagents, avoiding potential purification problems related to the 
removal of the urea biproducts and auxiliary nucleophiles. Acidic deprotection of the ω-
thiol functionalized prochelator (3) afforded the chelator (4), in the hydrochloride form, in 
an aggregate 31% yield over two steps. DOTA-monoamide type metal chelators and its 
conjugates form Ln3+ complexes of high thermodynamic and kinetic stability, as required 
for in vivo studies, given the toxic effects of free (unchelated) Ln3+ ions.  
6.3.2 Preparation of DOTAdexC16 or DOTAdexC16PEG materials 
With the ω-thiol functionalized DOTA synthon (4) on hand, one can envisage two 
pathways for the synthesis of the DOTAdexC16 material: either, performing first the 
Michael addition of the ω-thiol functionalized metal chelator to the acrylate-functionalized 
dextrin (dexVA), followed by the Michael addition of hexadecanethiol, or by reversing the 
addition order. We have noted before, during the synthesis of the dexC16 material, that 
even using a large molar excess of hexadecanethiol in relation to the acrylate groups 
does not give a full acrylate addition. Some acrylate groups are much less reactive, 
reflecting possibly their grafting position on the glucopyranoside ring and/or some degree 
of steric hindrance. By grafting first the metal chelator to the acrylate-functionalized 
dextrin allows using a large excess of hexadecanethiol (cheap, commercially available 
reagent) in the second step in order to push the degree of substitution towards the 
optimal value. We have established previously that the dexC16 material with DSVA 13% 
and DSC16 6% is suitable for forming stable nanoparticles within a narrow size range. In 
the 1H NMR spectrum of the dexC16 material (Figure 6.1a) signals assigned to the 
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hexadecane moiety (δ = 0.75–1.75 ppm) are clearly visible. The 1H NMR spectrum of the 
DOTAdexC16 material (Figure 6.1c) displays a set of new broad low intensity signals 
assigned to the grafted DOTA-butyroamide chelator (e.g., δ =1.9, 2.4 and 2.7 ppm, 
assigned to the methylene groups of the terminal mercaptobutyl moiety) as can be 
inferred from the 1H NMR spectrum of the DOTA chelator (4) (Figure 6.1b). Importantly, 
signals assigned to unreacted acrylate groups on the dextrin backbone (δ = 6.0–6.6 ppm) 
can also be seen in Figure 6.1a and 6.1c. The unreacted acrylate groups allow further 
functionalization of the nanogel with thiol-functionalized PEG molecule (Figure 6.1d). 
PEG grafting was confirmed by disappearance of the signals assigned to unreacted 
acrylate ester groups and the appearance of a new intense signal (δ = 3.6 ppm) assigned 
to the methylene groups of the grafted PEG molecule. The 1H NMR spectrum of the 
DOTAdexC16PEG material (Figure 6.1d) displays new signals assigned to the PEG 
moiety (δ = 3.4 and 3.6 ppm) confirming the PEGylation of the nanoparticles. 
Figure 6.1. 1H NMR spectra of (a) dexC16, (b) DOTA-butyroamide, (c) DOTAdexC16 and (d) 
DOTAdexC16PEG. 
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6.3.3 Characterization of the nanoparticles 
The DOTA coupling to the dextrin nanoparticles was used as a tool to obtain a Ln3+ 
chelate which could be used as (radioactive) label for biodistribution studies. The high 
detection sensitivity of γ-emitting radioisotopes, e.g., 153Sm3+, ensures that a low degree 
of substitution on metal chelate allows sensitive detection, as required for biodistribution 
studies. Moreover, the formation of neutral Ln3+-DOTA-monoamide complexes ensures 
that the labelling procedure does not substantially changes the structure and/or the 
overall (neutral) charge of the original (unlabelled) nanoparticles, and therefore is not 
expected to interfere in the biodistribution studies. 
The size distribution and the zeta potential of the nanoparticles from different materials 
were determined by dynamic light scattering measurements (Table 6.1).  
 
Table 6.1. DLS analysis of the nanoparticles from different materials in aqueous dispersion (1.0 
mg/mL), pH 7.0. 
Material z-avg (nm) PdI 
Zeta Potential 
(mV) 
dexC16 23.9 0.388 -4.02 
dexC16PEG 32.4 0.442 -8.59 
DOTAdexC16 25.3 0.341 -17.8 
[Eu(DOTAdexC16)]  -- -- -1.35 
DOTAdexC16PEG 37.1 0.275 -- 
 
As can be seen from Table 6.1, the functionalization of the nanoparticles with the 
DOTA metal chelator does not have a substantial effect on the mean diameter of the 
nanoparticles. For dexC16 the nanoparticles size increased from 23.9 nm to 25.3 nm, after 
coupling of the metal chelator. For dexC16PEG a similar increase was observed, from 
32.4 nm to 37.1 nm. In contrast, the PEG functionalization increases substantially the 
hydrodynamic diameter of the nanoparticles. Figure 6.2 shows the size distribution 
obtained by DLS for the nanoparticles from the dexC16 and dexC16PEG materials. PEG 
decoration does not change the nanoparticle population distribution, only a shift to larger 
sizes is observed, suggesting that PEGylation does not change the nanoparticles 
structure. This is consistent with the formation of an exterior hydrophilic PEG corona 
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projecting into the aqueous media. The observed increase in nanoparticle´s size is similar 
to that observed for other types of nanoparticles (e.g. gold nanoparticles) following 
grafting with PEG 5,000 (Zhang, et al., 2009).  
The surface functionalization of the dexC16 nanoparticles with PEG is expected to 
affect its interaction with proteins and cells, and thus its fate in vivo. The PEG hydrophilic 
corona may avoid the recognition and uptake of the nanoparticles by the organs of the 
MPS increasing the blood circulation half-live, as reported by other authors working on 
different nanoparticulate materials (Shan, et al., 2009). 
 
 
 
 
 
 
Figure 6.2. Size distribution in intensity (%) of (  ) dexC16 or (---) dexC16PEG in aqueous 
dispersion (1.0 mg/mL).  
 
Zeta potential measurements were carried out to evaluate the nanoparticles surface 
charge. The change of the zeta potential of the dexC16 nanoparticles, from a near neutral 
value (-4.02 mV) to a negative value (-17.8 mV) at pH 7.0, following functionalization with 
the metal chelator, confirms the grafting of the metal chelator. The grafted DOTA-
monoamide macrocycle is expected to bear an overall negative charge at pH 7.0. 
Moreover, after complexation of the DOTAdexC16 nanoparticles with Eu3+, the zeta 
potential value returns to a near neutral value, similar to that of the original dexC16 
nanoparticles (Gonçalves, et al., 2008), consistent with the formation of neutral 
[Eu(DOTAdexC16)] complexes. 
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Figure 6.3. 1H NMR spectra of (a) Eu(DOTA) and (b) [Eu(DOTAdexC16)]. 
The 1H NMR spectrum of the [Eu(DOTAdexC16)] material (Figure 6.3b) confirms that 
the Eu3+ complexation effectively occurred. In the NMR spectra of the Eu(DOTA-
butyroamide) chelate (5) and [Eu(DOTAdexC16)] material (Figure 6.3) the CH2 
ressonances within the macrocycle and pendant acetate display strong paramagnetic 
shifts as reported before for glycoconjugates of Eu(DOTA-monoamide) chelates (André, 
et al., 2004). The amount of metal chelator grafted to the dexC16 material was estimated 
by back titration of excess Eu3+ with EDTA in the presence of the complexometric 
indicator xylenol orange: circa 0.152 µmol of DOTA-butyroamide per mg of DOTAdexC16 
material. The Eu3+ complexation was used as model system for the labelling of the 
nanoparticles with the radioisotope 153Sm3+ for biodistribution studies. These studies 
confirm that nanoparticles features (size and surface potential) are conserved after 
labelling. Consequently, the biodistribution of the labelled nanoparticles is expected to be 
representative of the original (unlabelled) nanoparticles  
6.3.4 Blood clearance and biodistribution studies 
We have attempted previously to perform biodistribution studies of the dexC16 
nanoparticles, using fluorescein-labelled dextrin nanoparticles (Gonçalves, et al., 2010). 
Although succeeding in evaluating the nanoparticles blood clearance, we failed in the 
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attempts to characterize the organ accumulation. In the present work, labelling the 
nanoparticles with 153Sm3+ effectively allowed to study the nanoparticles blood clearance 
and to obtain the biodistribution profile in vivo.  
The blood clearance profile of 153Sm3+-labelled nanoparticles in Wistar rats, after 
intravenous injection, is shown in figure 6.4. The clearance of the nanoparticles from the 
systemic circulation is relatively fast in the first hour, proceeding afterwards at a lower 
rate. In the first 15 min, about 23% of the nanoparticles were removed from the 
bloodstream. At 1 h after injection, 47% of the injected dose is still detected in the 
bloodstream, followed by a further reduction 2 h later to about 30%. The blood clearance 
profile obtained is very similar to the one previously reported, using fluorescein-labelled 
dextrin nanoparticles (Gonçalves, et al., 2010).  
 
Figure 6.4. Blood clearance profile of radio-labelled nanoparticles. The error bars correspond to 
the standard deviation (N=4). 
The organ biodistribution of the [153Sm(DOTAdexC16)] in Wistar rats was evaluated at 
different time points. Figure 6.5 shows representative data stated as percentage of the 
injected dose per gram of tissue (%ID/g). 
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Figure 6.5. Biodistribution in () liver, () kidney and () spleen of Wistar rats 5 min, 30 min, 2 h, 
3 h, 24 h after i.v. injection of [153Sm(DOTAdexC16)]  stated as percentage of injected dose per 
gram of organ (%ID/g). Results are the mean of four animals. 
The radioactivity was located mainly in the liver, spleen and kidneys (Figure 6.5), with 
low %ID/g found in the other organs (data not shown), in the time frame analysed in the 
experiment. These results suggest that the removal of nanoparticles occur by 
phagocytosis, since liver and spleen are macrophage-rich organs, consistently with the 
previous observation of in vitro internalization of nanoparticles by macrophages 
(Gonçalves, et al., 2010). The maximum activity detected in the liver and spleen gradually 
increases from the first data obtained (5 minutes), reaching its maximum 2 h after 
injection, paralleling the decreasing profile of the blood activity (see above). The 
reduction of activity observed after 2 h suggests that the material does not accumulate in 
the organs, presumably being metabolized and excreted. As can be seen in Figure 6.5 
there is some renal uptake of nanoparticles, and excretion in the urine was detected (data 
not shown), thus reinforcing the hypothesis of kidney filtration of the smallest 
nanoparticles. Zhang, et al., reported that 20 nm pegylated gold nanoparticles are also 
excreted through renal filtration (Zhang, et al., 2009). They assumed that the samples of 
gold nanoparticles contained a small fraction of nanoparticles with diameters < 5 nm, 
which could be excreted via the urinary system. In the current case, small dextrin 
nanoparticles are also likely to be present in the fairly polydisperse materials. 
Furthermore, it may be hypothesized that the self-assembled material is flexible enough 
to cross the renal filtration system, which would be expected to exclude rigid 
nanoparticles of the same size range. It must be remarked that only few studies are 
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available reporting the biodistribution of self-assembled polymeric nanoparticles; 
furthermore, the existing studies do not include nanoparticles in the size range used in 
this study. 
To avoid a rapid blood clearance, the nanoparticles should retard opsonization and 
macrophage recognition, which results in sequestration by the MPS organs. The 
decoration with PEG was tested in this work with the purpose of improving the circulation 
time. Figure 6.6 compares the 2 h organ distribution of labelled nanoparticles, coated or 
not with PEG. 
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Figure 6.6. Comparison of the biodistribution in Wistar rats 2 h after i.v. injection of () 
[153Sm(DOTAdexC16)] or () [153Sm(DOTAdexC16PEG)]. Results are the mean of four animals. 
The results obtained confirm the well documented stealth effect: PEG reduces 
opsonisation, presumably by steric and hydration effects, improving blood circulation time 
and reducing the accumulation in the liver and spleen (Shan, et al., 2009). 
The decoration with PEG increases significantly the hydrodynamic diameter of the 
nanoparticles. Although larger particles have been reported as being taken up faster by 
the MPS (Gaumet, et al., 2008), the increased size is, in the current case, effectively 
counterbalanced by the the PEG steric and hydration effects, overall resulting in 
reduction of the uptake rate. In general, pegylated nanoparticles were found to have 
longer circulation time than the non-pegylated ones. 
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6.4 Conclusions 
Functionalization of dextrin nanoparticles with a metal chelator allows the radioactive 
labelling of the nanoparticles. The labelling process has no significant effect on the 
nanoparticles size and surface charge; hence the biodistribution profile obtained in Wistar 
rats following intravenous administration is considered representative of the unmodified 
nanoparticles. This strategy is appropriate for in vivo studies, combining a high sensitive 
detection technique with minor nanoparticle modifications. The dexC16 nanoparticles 
display a characteristic biodistribution profile, being mainly taken up by the organs of the 
MPS- liver and spleen. The blood circulation time extends to several hours, although the 
concentration is halved in about 1 hour. The functionalization of the nanoparticles with 
PEG 5,000 in this formulation improves their circulation time in the bloodstream and 
reduces the accumulation in the liver and spleen.  
 
Acknowledgments. The authors wish to acknowledge funding through the FCT/POCTI 
program (project PTDC/QUI/70063/2006). 
 
Studies on the biodistribution of dextrin nanoparticles | Chapter 6 
Gonçalves, C. | 2010 151 
6.5 References 
André, J.P.; Geraldes, C.F.G.C.; Martins, J.A.; Merbach, A.E.; Prata, M.I.M.; Santos, A.C.; de Lima, J.J.P.; 
Toth, E. Lanthanide(III) complexes of DOTA-glycoconjugates: A potential new class of lectin-mediated 
medical imaging agents. Chemistry- A European Journal 2004, 10, 5804-5816. 
Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A. Polymeric nanoparticle-encapsulated 
curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. Journal of Nanobiotechnology 
2007, 5, 3. 
Brunisholz, G.; Randin, M. Sur la séparation des terres rares à l'aide de l'acide éthylènediamine-
tétraacétique. IX. Procédé en cycle pour le fractionnement des terres yttriques. Helvetica Chimica Acta 
1959, 42, 1927-1938. 
Carvalho, J.; Goncalves, C.; Gil, A.M.; Gama, F.M. Production and characterization of a new dextrin based 
hydrogel. European Polymer Journal 2007, 43, 3050-3059. 
Farokhzad, O.C.; Langer, R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. 
Advanced Drug Delivery Review 2006, 58, 1456-1459. 
Fernandez-Montesinos, R.; Castillo, P.M.; Klippstein, R.; Gonzalez-Rey, E.; Mejias, J.A.; Zaderenko, A.P.; 
Pozo, D. Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide 
nanoparticles. Nanomedicine (Lond) 2009, 4, 919-930. 
Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: the need for precision in 
reporting particle size parameters. European Journal of Pharmaceutics and Biopharmaceutics 2008, 69, 
1-9. 
Gonçalves, C.; Gama, F.M. Characterization of the self-assembly process of hydrophobically modified 
dextrin. European Polymer Journal 2008, 44, 3529-3534. 
Gonçalves, C.; Martins, J.A.; Gama, F.M. Self-assembled nanoparticles of dextrin substituted with 
hexadecanethiol. Biomacromolecules 2007, 8, 392-398. 
Gonçalves, C.; Torrado, E.; Martins, T.; Pereira, P.; Pedrosa, J.; Gama, M. Dextrin nanoparticles: studies on 
the interaction with murine macrophages and blood clearance. Colloids and Surfaces B: Biointerfaces 
2010, 75, 483-489. 
Gref, R.; Luck, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Muller, R.H. 'Stealth' 
corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG 
chain length and surface density) and of the core composition on phagocytic uptake and plasma protein 
adsorption. Colloids and Surfaces B: Biointerfaces 2000, 18, 301-313. 
Hiemstra, C.; van der Aa, L.J.; Zhong, Z.Y.; Dijkstra, P.J.; Feijen, J. Novel in situ forming, degradable dextran 
hydrogels by Michael addition chemistry: Synthesis, rheology, and degradation. Macromolecules 2007, 
40, 1165-1173. 
Studies on the biodistribution of dextrin nanoparticles | Chapter 6 
Gonçalves, C. | 2010 152 
Hunter, R.J. Zeta Potential in Colloid Science; Academic Press: New York, 1981. 
Leary, S.P.; Liu, C.Y.; Apuzzo, M.L. Toward the emergence of nanoneurosurgery: part II--nanomedicine: 
diagnostics and imaging at the nanoscale level. Neurosurgery 2006, 58, 805-823. 
Li, S.D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Molecular Pharmacology 2008, 5, 
496-504. 
Owens, D.E., 3rd; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric 
nanoparticles. International Journal of Pharmaceutics 2006, 307, 93-102. 
Peracchia, M.T.; Fattal, E.; Desmaele, D.; Besnard, M.; Noel, J.P.; Gomis, J.M.; Appel, M.; d'Angelo, J.; 
Couvreur, P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and 
splenic targeting. Journal of Controlled Release 1999a, 60, 121-128. 
Peracchia, M.T.; Harnisch, S.; Pinto-Alphandary, H.; Gulik, A.; Dedieu, J.C.; Desmaele, D.; d'Angelo, J.; 
Muller, R.H.; Couvreur, P. Visualization of in vitro protein-rejecting properties of PEGylated stealth 
polycyanoacrylate nanoparticles. Biomaterials 1999b, 20, 1269-1275. 
Port, M.; Idee, J.M.; Medina, C.; Robic, C.; Sabatou, M.; Corot, C. Efficiency, thermodynamic and kinetic 
stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. 
Biometals 2008, 21, 469-490. 
Pressly, E.D.; Rossin, R.; Hagooly, A.; Fukukawa, K.; Messmore, B.W.; Welch, M.J.; Wooley, K.L.; Lamm, 
M.S.; Hule, R.A.; Pochan, D.J.; Hawker, C.J. Structural effects on the biodistribution and positron 
emission tomography (PET) imaging of well-defined (64)Cu-labeled nanoparticles comprised of 
amphiphilic block graft copolymers. Biomacromolecules 2007, 8, 3126-3134. 
Shaikh, J.; Ankola, D.D.; Beniwal, V.; Singh, D.; Kumar, M.N. Nanoparticle encapsulation improves oral 
bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as 
absorption enhancer. European Journal of Pharmaceutical Science 2009, 37, 223-230. 
Shan, X.; Liu, C.; Yuan, Y.; Xu, F.; Tao, X.; Sheng, Y.; Zhou, H. In vitro macrophage uptake and in vivo 
biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock 
copolymer. Colloids and Surfaces B: Biointerfaces 2009, 72, 303-311. 
Shubayev, V.I.; Pisanic, T.R.; Jin, S.H. Magnetic nanoparticles for theragnostics. Advanced Drug Delivery 
Reviews 2009, 61, 467-477. 
van Dijk, M.; Rijkers, D.T.; Liskamp, R.M.; van Nostrum, C.F.; Hennink, W.E. Synthesis and applications of 
biomedical and pharmaceutical polymers via click chemistry methodologies. Bioconjugate Chemistry 
2009, 20, 2001-2016. 
Weinstein, J.S.; Varallyay, C.G.; Dosa, E.; Gahramanov, S.; Hamilton, B.; Rooney, W.D.; Muldoon, L.L.; 
Neuwelt, E.A. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and 
potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, 
a review. Journal of Cerebral Blood Flow and Metabolism 2010, 30, 15-35. 
Studies on the biodistribution of dextrin nanoparticles | Chapter 6 
Gonçalves, C. | 2010 153 
Zhang, G.; Yang, Z.; Lu, W.; Zhang, R.; Huang, Q.; Tian, M.; Li, L.; Liang, D.; Li, C. Influence of anchoring 
ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated 
gold nanoparticles in tumor-xenografted mice. Biomaterials 2009, 30, 1928-1936. 
 
 
Conclusions and Perspectives | Chapter 7 
Gonçalves, C. | 2010 155 
7. Conclusions and Perspectives 
The main purpose of the present work has been the development and characterization 
of self-assembled dextrin nanogels. Its potencial for biomedical applications was also 
accessed. The results obtained lead to the following main conclusions: 
Dextrin can be modified by grafting long alkyl chains (16 carbons), an amphiphilic 
polymer (dexC16) being obtained; the degree of substitution with hydrophobic chains can 
be controlled. DexC16 with DSC16 7% has a critical micelle concentration around 0.01 
mg/mL. A DSC16 in the range of 6.0-8.0% was assumed as ideal, since a lower DSC16 
corresponds to a high CMC and a higher DSC16 does not facilitate the material 
manipulation, due to the low solubility. The aqueous dispersion of dexC16 results in 
spontaneous formation of nanoparticles colloidally stable (over 2 months), when the 
concentration of the polymer is higher than its critical micelle concentration. Nanoparticles 
have about 85–90 wt% of water and may thus be considered hydrogel-like structures: 
nanogels. The size distribution of self-assembled nanoparticles was evaluated by 
dynamic light scattering, after filtration through a 0.22 µm membrane. A general 
conclusion is achieved: two populations exist after self-assembly, with diameters of 
roughly 20 and 100 nm. Depending on which is the predominant one, the average 
diameter obtained vary between 20-60 nm.  
The hydrophobic domains within dextrin nanoparticles, dispersed in water, allow 
curcumin dissolution with high entrapment efficiency and stability, using the appropriate 
polymer/curcumin ratio. Nanoparticles served as an effective ‘‘nanocarrier’’, by controlling 
curcumin release profile. Incorporation of curcumin into nanoparticles did not compromise 
its cytotoxicity in HeLa cell line. Therefore, dextrin nanoparticles hold promise as delivery 
system for the development of an injectable formulation of curcumin for the treatment of 
human cancers.  
The study of interactions between macrophages and dextrin nanoparticles revealed 
that nanoparticles are non-cytotoxic and do not elicit a reactive response when in contact 
with macrophages. Otherwise nanoparticles are internalized by macrophages being 
concentrated in cellular organelles.   
The blood clearance of dextrin nanoparticles studied after intravenous injection of 
fluorescein-labelled nanoparticles in BALB/c mice or radioactively labelled nanoparticles 
in Wistar rats showed that a relatively fast removal of the nanoparticles occurs in the first 
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3 h, then continuing slowly up to 24 h. For fluorescein-labelled nanoparticles, although 
the blood clearance of dextrin nanoparticles could be readily followed by fluorescence 
measurements, its organ distribution profile could not be evaluated, possibly due to 
quenching effects of the fluorescent probe in the organ´s homogenates. Functionalization 
of dextrin nanoparticles with a metal chelator allows the radioactive labelling of the 
nanoparticles. The labelling process has no significant effect on the nanoparticles size 
and surface charge; hence the biodistribution profile obtained is considered 
representative of the unmodified nanoparticles. This strategy combines a high sensitive 
detection technique with minor nanoparticle modifications. The dexC16 nanoparticles 
display a characteristic biodistribution profile, being mainly taken up by the organs of the 
mononuclear phagocytic system- liver and spleen. The surface coating of the 
nanoparticles with PEG 5,000 improves the circulation time in the blood and reduces the 
accumulation in the liver and spleen.  
Therefore, dexC16 nanoparticles may be used to target phagocytic cells or antigen 
presenting cells for the treatment of macrophage-associated pathologies or vaccination 
purposes. Otherwise, when other targets are envisaged, dexC16 nanoparticles coated 
with PEG avoid phagocytic activity, improving the circulation time in the bloodstream 
therefore the probability to reach the target. 
 
The following goals are proposed for future work: 
- Subcutaneous injection of dextrin nanoparticles to evaluate accumulation in 
lymph nodes for vaccination purposes; 
- Chemical crosslinking of dextrin nanoparticles using PEG dithiol to improve 
the mechanical stability; 
- Explore the small size of dextrin nanoparticles for passive targeting of tumor 
tissues by the enhanced permeability and retention effect in xenografs rats;  
- Incorporation of therapeutic proteins; it has been demonstrated that proteins 
are stabilized in the interior of the nanogels, therefore a comprehensive study 
of the interaction protein/nanogel is required; 
- Analysis of the intracellular trafficking of nanoparticles, which will determine 
the kind of applications in the field of drug delivery. 
 
